Form 10-Q BIOCEPT INC For: Mar 31

 

UNITED STATES  

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

For the quarterly period ended March 31, 2016

OR

For the transition period from                      to                     .

Commission file number: 001-36284

 

Biocept, Inc.

(Exact name of registrant as specified in its charter)

 

 

5810 Nancy Ridge Drive, San Diego, California

(Address of principal executive offices)

92121

(Zip Code)

(858) 320-8200

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of May 6, 2016, there were 24,969,975 shares of the Registrant’s common stock outstanding.

 

 

 

 

 

---

BIOCEPT, INC.

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED

March 31, 2016

INDEX

 

 

 

 

2

---

IMPORTANT NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included or incorporated by reference in this Quarterly Report other than statements of historical fact, are forward-looking statements. You can identify these and other forward-looking statements by the use of words such as “may,” “will,” “could,” “anticipate,” “expect,” “intend,” “believe,” “continue” or the negative of such terms, or other comparable terminology. Forward-looking statements also include the assumptions underlying or relating to such statements.

Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in our other filings with the Securities and Exchange Commission, or the SEC. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements speak only as of the date on which they are made and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they are made except as required by law. Readers should, however, review the factors and risks we describe in the reports and registration statements we file from time to time with the SEC.

 

 

 

3

---

PART I. FINANCIAL INFORMATION

 

Item 1. Financial Statements

Biocept, Inc.

Condensed Balance Sheets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

4

---

Biocept, Inc.

Condensed Statements of Operations and Comprehensive Loss

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

5

---

Biocept, Inc.

Condensed Statements of Cash Flows

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

6

---

Non-cash Investing and Financing Activities:

A public offering of the Company’s common stock and warrants to purchase its common stock was effected on February 9, 2015, the closing of which occurred on February 13, 2015 (see Note 3). In connection with the closing of this offering, (i) warrants were issued to buy (in the aggregate) up to 8,000,000 shares of common stock at a price of $1.56 per share with a term of five years and an estimated grant date fair value of $7,690,395, which was recorded as an offset to additional paid-in capital within common stock issuance costs, (ii) the underwriters were granted a 45 day option from the closing date of this offering to purchase up to 1,200,000 additional shares of common stock at a price of $1.25 per share and/or additional warrants to purchase up to 1,200,000 shares of common stock at a price of $0.0001 per warrant, less underwriting discounts and commissions, to cover over-allotments, if any, with an aggregate estimated grant date fair value of $1,627,396 that was recorded to common stock issuance costs, and (iii) costs of $63,111 directly associated with this offering that were included in prepaid expenses and other current assets at December 31, 2014 were reclassified to common stock issuance costs. Proceeds from warrant exercises associated with this offering of $17,472 had not yet been received as of March 31, 2015, and are excluded from cash proceeds and changes in prepaid expenses and other current assets in the Company’s unaudited condensed statement of cash flows.

During the three months ended March 31, 2016, the Company financed insurance premiums of $434,475 through third party financings.

The amount of unpaid fixed asset purchases excluded from cash purchases in the Company’s unaudited condensed statement of cash flows decreased from $19,546 and $64,300 at December 31, 2014 and 2015, respectively, to $12,205 and $18,937 at March 31, 2015 and 2016, respectively.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

7

---

BIOCEPT, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 

1. Basis of Presentation

Basis of Presentation

The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America.

The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by U.S. Generally Accepted Accounting Principles, or GAAP, to be included in a full set of financial statements. The balance sheet at December 31, 2015 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2015, filed with the SEC with our Annual Report on Form 10-K on March 10, 2016 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year.

Certain prior period amounts have been reclassified to conform to the current period presentation. Additionally, a total of $290,709 of revenue-generating costs previously allocated to research and development expenses during the three months ended March 31, 2015 were reclassified to cost of revenues in the current period presentation of the unaudited condensed statement of operations and comprehensive loss.  

The Company and Business Activities

Biocept, Inc., or the Company, was founded in California in May 1997 and is an early stage cancer diagnostics company developing and commercializing proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample to improve the treatment that oncologists provide to their patients by providing better, more detailed information on the characteristics of their tumor.

The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations.

In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013.

Recent Accounting Pronouncements

In May 2014, and as subsequently updated and amended from time to time, the Financial Accounting Standards Board, or FASB, issued authoritative guidance that requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. This proposed guidance has been deferred and would be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.

In June 2014, the FASB issued authoritative guidance requiring share-based payments with a performance target which affects vesting and that could be achieved after the requisite service period be treated as a performance condition. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The Company adopted this guidance for the interim reporting period ended March 31, 2016. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures.

8

---

In August 2014, the FASB issued authoritative guidance requiring management to evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Certain additional financial statement disclosures are required if such conditions or events are identified. This guidance is effective for the annual reporting period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.

In July 2015, the FASB issued authoritative guidance requiring entities that do not measure inventory using the retail inventory method or on a last-in, first-out basis to record inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This guidance is effective on a prospective basis for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures.

In January 2016, the FASB issued authoritative guidance requiring, among other things, that certain equity investments be measured at fair value with changes in fair value recognized in net income, that financial assets and financial liabilities be presented separately by measurement category and form of financial asset on the balance sheet or the accompanying notes to the financial statements, that the prior requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet be eliminated, and that a reporting organization is to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the organization has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption of the instrument-specific credit risk amendment is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures.

In February 2016, the FASB issued authoritative guidance requiring, among other things, that entities recognize the assets and liabilities arising from leases on the balance sheet under revised criteria, while the classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria in the previous leases guidance. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.

In March 2016, the FASB issued authoritative guidance clarifying that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument does not necessarily require dedesignation of that hedging relationship, provided that all other applicable hedge accounting criteria continue to be met. This guidance is effective on either a prospective basis or modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.

In March 2016, the FASB issued authoritative guidance requiring entities to assess whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts, and clarifies what steps are required when assessing whether the economic characteristics and risks of call (put) options are clearly and closely related to the economic characteristics and risks of their debt hosts. This guidance is effective on a modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.

In March 2016, the FASB issued authoritative guidance simplifying the accounting for stock compensation. This guidance, among other things, amends existing accounting and classification requirements primarily around income taxes, forfeitures, and cash payments associated with share-based payment awards to employees. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.

 

2. Liquidity and Going Concern Uncertainty

As of March 31, 2016, cash and cash equivalents totaled $4.6 million and the Company had an accumulated deficit of $160.1 million. For the year and three month periods ended December 31, 2015 and March 31, 2016, the Company incurred net losses of $16.9 million and $4.9 million, respectively. At March 31, 2016, the Company had aggregate gross interest-bearing indebtedness of approximately $5.0 million, of which approximately $2.1 million was due within one year in the absence of subjective acceleration of amounts due under a credit facility entered into in April 2014 with Oxford Finance LLC, or the April 2014 Credit Facility, in addition to approximately $2.5 million of other non-interest bearing liabilities. Additionally, in February 2016, the Company signed a firm,

9

---

noncancelable, and unconditional commitment in an aggregate amount of $1,062,500 with a vendor to purchase certain inventory items, payable in quarterly installments of $62,500 through May 2020 (see Note 10). These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying unaudited condensed financial statements have been prepared assuming that the Company will continue as a going concern. The unaudited condensed financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

While the Company is currently in the commercialization stage of operations, the Company has not yet achieved profitability and anticipates that it will continue to incur net losses for the foreseeable future. Historically, the Company’s principal sources of cash have included proceeds from the issuance of common and preferred stock, proceeds from the exercise of warrants to purchase common stock, proceeds from the issuance of debt, and revenues from laboratory services. The Company’s principal uses of cash have included cash used in operations, payments relating to purchases of property and equipment and repayments of borrowings. The Company expects that the principal uses of cash in the future will be for continuing operations, hiring of sales and marketing personnel and increased sales and marketing activities, funding of research and development, capital expenditures, and general working capital requirements. The Company expects that, as revenues grow, sales and marketing and research and development expenses will continue to grow, albeit at a slower rate and, as a result, the Company will need to generate significant growth in net revenues to achieve and sustain income from operations.

Subsequent to the closing of a follow-on public offering on February 13, 2015, cash proceeds of approximately $9.8 million have been received by the Company from the exercise of warrants sold in such offering, while approximately $2.7 million in gross warrant proceeds remain outstanding and available to be exercised at $1.56 per share until their expiration in February 2020. On December 21, 2015, the Company entered into a common stock purchase agreement with Aspire Capital Fund LLC, or Aspire Capital, whereby approximately $13.6 million, or up to 2,684,122 shares, are available to be issued to Aspire Capital under this agreement as of May 13, 2016, subject to certain contractual limitations that prohibit the Company’s ability to sell its common stock to Aspire Capital. In May 2015, the SEC declared effective a shelf registration statement filed by the Company. The shelf registration statement allows the Company to issue any combination of its common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as the Company’s public float is less than $75 million. As of March 31, 2016, the Company had not sold any securities under this shelf registration statement. A public offering of the Company’s common stock and warrants to purchase its common stock was effected under this shelf registration statement on April 29, 2016, the closing of which occurred on May 4, 2016, pursuant to which the Company received net cash proceeds of approximately $4.4 million (see Note 12). Subsequent to the closing of this public offering on May 4, 2016, no warrants sold in such offering have been exercised, with approximately $4.5 million in gross warrant proceeds remaining outstanding and available to be exercised at $1.30 per share until their expiration in May 2021. Following this offering, and subject to certain limitations for so long as the Company’s public float is less than $75 million, an aggregate initial offering price of up to approximately $39.2 million of the Company’s common stock, preferred stock, debt securities and warrants remains available to be sold under this shelf registration statement. In connection with its May 2016 public offering, the Company has agreed to certain contractual terms that limit its ability to issue, or enter into any agreement to issue, shares of its common stock or common stock equivalents for a period of 75 days, and limit its ability to issue variable rate securities for a period of one year. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings.

Management’s Plan to Continue as a Going Concern

In order to continue as a going concern, the Company will need, among other things, additional capital resources. Until the Company can generate significant cash from operations, including assay revenues, management’s plans to obtain such resources for the Company include proceeds from offerings of the Company’s equity securities or debt, or transactions involving product development, technology licensing or collaboration. Management can provide no assurances that any sources of a sufficient amount of financing will be available to the Company on favorable terms, if at all.

 

3. Sales of Equity Securities

Pursuant to an underwriting agreement dated February 9, 2015 between the Company, Aegis Capital Corp. and Feltl and Company, as underwriters named therein, a public offering of 8,000,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 8,000,000 shares of common stock was effected at a combined offering price of $1.25. The estimated grant date fair value of these warrants of $7.7 million was recorded as an offset to additional paid-in capital within common stock issuance upon the closing of this offering. Each of the members of the Company’s Board of Directors participated in this offering, purchasing an aggregate 142,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 142,000 shares of its common stock for a total purchase price of $177,500. All warrants sold in this offering have a per share exercise price of $1.56, are exercisable immediately and expire five years from the date of issuance. The closing of the sale of these securities to the underwriters occurred on February 13, 2015, when the Company received, after deducting underwriting discounts and additional costs paid to the underwriters, $9.1 million of net cash proceeds. The total increase in capital as a result of the sale of these shares and warrants was $8.8 million after deducting $0.3 million of additional non-underwriter costs incurred. Additionally, the underwriters were granted a

10

---

45-day option to purchase up to 1,200,000 additional shares of common stock at a price of $1.25 per share and/or additional warrants to purchase up to 1,200,000 shares of common stock at a price of $0.0001 per warrant, less underwriting discounts and commissions, to cover over-allotments, if any, which was not exercised. The estimated grant date fair value of the over-allotment options and warrants of $1.6 million was recorded as an offset to additional paid-in capital within common stock issuance costs upon the closing of this offering. Underwriter costs and discounts of $0.2 million and $0.7 million, respectively, as well as additional non-underwriter costs associated with this offering of $0.3 million, were also recorded to common stock issuance costs upon closing. Subsequent to the closing of this offering on February 13, 2015, additional cash proceeds of $9.8 million have been received from the exercise of warrants sold in such offering. As such, the aggregate total increase in capital related to this offering has been $18.6 million, after deducting $0.9 million of underwriter costs and discounts and $0.3 million of additional non-underwriter costs incurred, which were netted against these proceeds under applicable accounting guidance.

In May 2015, the SEC declared effective a shelf registration statement filed by the Company. The shelf registration statement allows the Company to issue any combination of its common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as the Company’s public float is less than $75 million. As of March 31, 2016, the Company had not sold any securities under this shelf registration statement. In May 2016, the Company received net proceeds of approximately $4.4 million from the sale of common stock and warrants to purchase common stock under this shelf registration statement (see Note 12). Following this offering, and subject to certain limitations for so long as the Company’s public float is less than $75 million, an aggregate initial offering price of up to approximately $39.2 million of the Company’s common stock, preferred stock, debt securities and warrants remains available to be sold under this shelf registration statement. In connection with its May 2016 public offering, the Company has agreed to certain contractual terms that limit its ability to issue, or enter into any agreement to issue, shares of its common stock or common stock equivalents for a period of 75 days, and limit its ability to issue variable rate securities for a period of one year. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings.

On December 21, 2015, the Company entered into a common stock purchase agreement with Aspire Capital, which committed to purchase up to an aggregate of $15.0 million of shares of the Company’s common stock over the 30-month term of the common stock purchase agreement. Upon execution of the common stock purchase agreement, the Company sold to Aspire Capital 625,000 shares of common stock at $1.60 per share for proceeds of $1,000,000, and concurrently also entered into a registration rights agreement with Aspire Capital, pursuant to which the Company filed a registration statement registering the sale of the shares of the Company’s common stock that have been and may be issued to Aspire Capital under the common stock purchase agreement. Under the common stock purchase agreement, on any trading day selected by the Company, the Company has the right, in its sole discretion, to present a purchase notice directing Aspire Capital to purchase up to 100,000 shares of the Company’s common stock per business day, up to $15.0 million of common stock in the aggregate at a per share price equal to the lesser of either i) the lowest sale price of the Company’s common stock on the purchase date, or ii) the arithmetic average of the three lowest closing sale prices for the Company’s common stock during the 10 consecutive trading days ending on the trading day immediately preceding the purchase date. In addition, on any date on which the Company submits a purchase notice to Aspire Capital in an amount equal to 100,000 shares and the Company’s stock price is not less than $0.50 per share, the Company also has the right, in its sole discretion, to present Aspire Capital with a volume-weighted average price purchase notice directing Aspire Capital to purchase an amount of stock equal to up to 30% of the aggregate shares of the Company’s common stock traded on the its principal market on the next trading day, subject to a maximum number of shares the Company may determine. The purchase price per share pursuant to such volume-weighted average price purchase notice is generally 97% of the volume-weighted average price for the Company’s common stock traded on its principal market on the volume-weighted average purchase date. The purchase price will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, or other similar transaction occurring during the period(s) used to compute the purchase price. The Company may deliver multiple purchase notices and volume-weighted average price purchase notices to Aspire Capital from time to time during the term of the common stock purchase agreement, so long as the most recent purchase has been completed. The common stock purchase agreement provides that the Company and Aspire Capital shall not effect any sales on any purchase date where the closing sale price of the Company’s common stock is less than $0.50. There are no trading volume requirements or restrictions under the common stock purchase agreement, and the Company will control the timing and amount of sales of its common stock to Aspire Capital. Aspire Capital has no right to require any sales by the Company, but is obligated to make purchases from the Company as directed by the Company in accordance with the common stock purchase agreement. There are no limitations on use of proceeds, financial or business covenants, restrictions on future fundings, rights of first refusal, participation rights, penalties or liquidated damages in the common stock purchase agreement. In consideration for entering into, and concurrently with the execution of, the common stock purchase agreement, the Company issued to Aspire Capital 165,000 shares of its common stock. The common stock purchase agreement may be terminated by the Company at any time, at its discretion, without any cost to the Company. Aspire Capital has agreed that neither it nor any of its agents, representatives and affiliates shall engage in any direct or indirect short-selling or hedging of the Company’s common stock during any time prior to the termination of the common stock purchase agreement. Any proceeds the Company receives under the common stock purchase agreement are expected to be used for working capital and general corporate purposes. During the three months ended March 31, 2016, the Company submitted purchase notices to Aspire Capital for an aggregate of 300,000 shares of common stock for gross proceeds of $403,000. Costs associated with this offering of approximately $42,000 and $79,000 during the year ended December 31, 2015 and March 31, 2016, respectively, were also recorded to common stock issuance costs under applicable accounting guidance, and as such, the aggregate total increase in capital related to this

11

---

transaction has been approximately $1.3 million. Approximately $13.6 million, or up to 2,684,122 shares, remains available to be issued to Aspire Capital under this agreement as of May 13, 2016, subject to certain contractual limitations that prohibit the Company’s ability to sell its common stock to Aspire Capital.

 

4. Fair Value Measurement

The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company believes the carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate their estimated fair values due to the short-term maturities of these financial instruments.

Other Fair Value Measurements

The estimated fair value of the Company’s credit facility at March 31, 2016 approximated carrying value, which was determined using a discounted cash flow analysis. The analysis considered interest rates of instruments with similar maturity dates, which involved the use of significant unobservable Level 3 inputs.

In connection with the closing of the Company’s public offering on May 4, 2016, warrants were issued to buy (in the aggregate) up to 3,490,601 shares of common stock with an estimated grant date fair value of $1,997,667, which was recorded as an offset to additional paid-in capital within common stock issuance costs (see Note 12).

 

5. Balance Sheet Details

The following provides certain balance sheet details:

 

 

 

6. April 2014 Credit Facility

On April 30, 2014, the Company received net cash proceeds of approximately $4,898,000 pursuant to the execution of its April 2014 Credit Facility with Oxford Finance LLC. Upon the entry into the April 2014 Credit Facility, the Company was required to pay the lenders a facility fee of $50,000 in conjunction with the funding of the term loan. The April 2014 Credit Facility is secured by substantially all of the Company’s personal property other than its intellectual property. Amounts due to Oxford Finance LLC under the April 2014 Credit Facility are callable before maturity by the lender under certain subjective acceleration clauses of the underlying agreement, including changes deemed to be materially adverse by the lender. The term loan under the April 2014 Credit Facility bears interest at an annual rate equal to the greater of (i) 7.95% or (ii) the sum of (a) the three-month U.S. LIBOR rate reported in the Wall Street Journal three business days prior to the funding date of the term loan, plus (b) 7.71%. The term loan bears interest at an annual

12

---

rate of 7.95%. The Company was required to make interest-only payments on the term loan through August 1, 2015. The outstanding term loan under the April 2014 Credit Facility began amortizing at the end of the applicable interest-only period, with monthly payments of principal and interest being made by the Company to the lenders in consecutive monthly installments following such interest-only period. The term loan under the April 2014 Credit Facility matures on July 1, 2018. Upon repayment, the Company is also required to make a final payment to the lenders equal to 5.5% of the original principal amount of the term loan funded. At its option, the Company may prepay the outstanding principal balance of the term loan in whole but not in part, subject to a prepayment fee of 1% of any amount prepaid after April 30, 2016. The April 2014 Credit Facility includes affirmative and negative covenants applicable to the Company and any subsidiaries created in the future. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal existence and governmental approvals, deliver certain financial reports and maintain insurance coverage. The negative covenants include, among others, restrictions on transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets, and suffering a change in control, in each case subject to certain exceptions. The April 2014 Credit Facility also includes events of default, the occurrence and continuation of which provide Oxford Finance LLC, as collateral agent, with the right to exercise remedies against the Company and the collateral securing the term loan under the April 2014 Credit Facility, including foreclosure against the Company’s properties securing the April 2014 Credit Facility, including its cash. These events of default include, among other things, the Company’s failure to pay any amounts due under the April 2014 Credit Facility, a breach of covenants under the April 2014 Credit Facility, insolvency, a material adverse change, the occurrence of any default under certain other indebtedness in an amount greater than $250,000, and a final judgment against the Company in an amount greater than $250,000.

A warrant to purchase up to 52,966 shares of the Company’s common stock at an exercise price of $4.72 per share with a term of 10 years was issued to Oxford Finance LLC on April 30, 2014. Issuance costs of $102,498 associated with the term loan under the April 2014 Credit Facility were recorded as a discount to outstanding debt as of the closing date, resulting in net proceeds of $4,897,502. The estimated fair value of the warrant issued of $233,107 was recorded as a discount to outstanding debt as of the closing date. The discounts and other issuance costs are amortized to interest expense utilizing the effective interest method over the underlying term of the loan. The effective annual interest rate associated with the April 2014 Credit Facility was 11.50% at both December 31, 2015 and March 31, 2016.

 

7. Stock-based Compensation

Equity Incentive Plans

The Company maintains two equity incentive plans: the Amended and Restated 2013 Equity Incentive Plan, or the 2013 Plan, and the 2007 Equity Incentive Plan, or the 2007 Plan. The 2013 Plan includes a provision that shares available for grant under the Company’s 2007 Plan become available for issuance under the 2013 Plan and are no longer available for issuance under the 2007 Plan. As of March 31, 2016, under all plans, a total of 3,068,865 shares were authorized for issuance, 2,297,168 stock options and restricted stock units, or RSUs, had been issued and were outstanding, and 647,263 shares were available for grant.

Stock Options

A summary of stock option activity for option awards granted under the 2013 Plan and 2007 Plan for the three months ended March 31, 2016 is as follows:

 

 

The intrinsic values of options outstanding and options vested and unvested expected to vest at March 31, 2016 were both zero. The intrinsic value of options exercisable at March 31, 2016 was zero.

13

---

The fair values of option awards granted during the three months ended March 31, 2016 were estimated using a Black-Scholes pricing model with the following assumptions:

 

Using the assumptions described above, with stock and exercise prices being equal on date of grant, the weighted-average estimated fair value of options granted in the three months ended March 31, 2016 was $0.98 per share.

On August 31, 2015, the Company’s Board of Directors approved the issuance of 100,000 stock options with an estimated grant date fair value of $1.47 per share to its Chief Executive Officer pursuant to the 2013 Plan. On February 29, 2016, the Company’s Board of Directors approved the issuance of 100,000 stock options with an estimated grant date fair value of $0.96 per share to its Chief Executive Officer pursuant to the 2013 Plan. Vesting of these stock options may occur based on the Company’s achievement of specified objectives by December 31, 2016 as determined by the Company’s Board of Directors, or a committee of the Company’s Board of Directors, in its sole discretion, as follows:

 

Restricted Stock

On June 12, 2014, the Company’s Board of Directors granted an RSU award for 44,496 shares with a grant date fair value of $5.35 per share to its Chief Executive Officer pursuant to the 2013 Plan. Vesting of these RSUs was based on the Company’s achievement of specified objectives by December 31, 2015 as determined by the Company’s Board of Directors or the Compensation Committee of the Board of Directors, as follows:

 

During the three months ended March 31, 2016, a total of 13,348 RSUs were declared vested by the Company’s Board of Directors and issued to its Chief Executive Officer in satisfaction of this award and the remaining 31,148 shares underlying this RSU were forfeited. At March 31, 2016, 32,769 RSUs with an intrinsic value of $42,272 were outstanding and vested.

14

---

Stock-based Compensation Expense

The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statement of operations and comprehensive loss during the periods presented:

 

 

Stock-based compensation expense was recorded net of estimated forfeitures of 0% - 4% per annum during the three months ended March 31, 2015 and 2016. As of March 31, 2016 total unrecognized stock-based compensation expense related to unvested stock option, adjusted for estimated forfeitures, was approximately $2,476,000 and is expected to be recognized over a weighted-average period of 2.4 years.

 

8. Common Stock Warrants Outstanding

A summary of equity-classified common stock warrant activity for the three months ended March 31, 2016 is as follows:

 

 

The intrinsic value of equity-classified common stock warrants outstanding and exercisable at March 31, 2016 was $0.

In connection with the closing of the Company’s public offering on May 4, 2016, warrants were issued to buy (in the aggregate) up to 3,490,601 shares of common stock at an exercise price of $1.30 per share with a term of five years (see Note 12).

 

9. Net Loss per Common Share

Basic and diluted net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted-average common shares outstanding during the period. Because there is a net loss attributable to common shareholders for the three months ended March 31, 2015 and 2016, the outstanding RSUs, warrants, and common stock options have been excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive. Therefore, the weighted-average shares used to calculate both basic and diluted loss per share are the same.

15

---

The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive:

 

 

 

10. Commitments and Contingencies

In the normal course of business, the Company may be involved in legal proceedings or threatened legal proceedings. The Company is not party to any legal proceedings or aware of any threatened legal proceedings that are expected to have a material adverse effect on its financial condition, results of operations or liquidity.

In February 2016, the Company signed a firm, noncancelable, and unconditional commitment in an aggregate amount of $1,062,500 with a vendor to purchase certain inventory items, payable in quarterly installments of $62,500 through May 2020.

 

11. Related Party Transactions

All of the members of the Company’s Board of Directors participated in its public offering in February 2015, purchasing an aggregate of 142,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 142,000 shares of its common stock for total proceeds of $177,500.

A member of the Company’s management is the controlling person of Aegea Biotechnologies, Inc., or Aegea. On September 2, 2012, the Company entered into an Assignment and Exclusive Cross-License Agreement, or the Cross-License Agreement, with Aegea. The Company received a payment of $19,047 during the three months ended March 31, 2016 from Aegea as reimbursement for shared patent costs under the Cross-License Agreement.

Pursuant to a sublease agreement dated March 30, 2015, the Company subleased 9,849 square feet, plus free use of an additional area, of its San Diego facility to an entity affiliated with the Company’s non-executive Chairman for $12,804 per month, with a refundable security deposit of $12,804 due from the subtenant. The initial term of the sublease expired on July 31, 2015, and is subject to renewal on a month-to-month basis thereafter. A total of $38,412 in rental income was recorded to other income/(expense) in the Company’s statement of operations and comprehensive loss during the three months ended March 31, 2016.

Three members of the Company’s Board of Directors participated in its public offering in May 2016, purchasing an aggregate of 175,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 122,500 shares of its common stock for total proceeds to the Company of $175,000 (see Note 12).

The Company believes that these transactions were on terms at least as favorable to the Company as could have been obtained from unrelated third parties.

 

12. Subsequent Events

In May 2015, the SEC declared effective a shelf registration statement filed by the Company. The shelf registration statement allows the Company to issue any combination of its common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as the Company’s public float is less than $75 million. As of March 31, 2016, the Company had not sold any securities under this shelf registration statement. Pursuant to an exclusive placement agent agreement dated April 25, 2016 between the Company and H.C. Wainwright & Co., LLC, or Wainwright, and a securities purchase agreement dated April 29, 2016 between the Company and the purchasers signatory thereto, a public offering of 4,986,573 shares of the Company’s common stock and warrants to purchase up to an aggregate of 3,490,601 shares of common stock was effected under this registration statement at a combined offering price of $1.00. Three members of the Company’s Board of Directors participated in this offering, purchasing an aggregate 175,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 122,500 shares of its common stock for a total purchase price of $175,000. All warrants sold in this offering have a per share exercise price of $1.30, are exercisable immediately and expire five years from the date of issuance. The closing of the sale of these securities to the purchasers occurred on May 4, 2016, pursuant to which the Company received, after

16

---

deducting the placement agent’s fees and non-accountable expense reimbursements paid to Wainwright, as well as advisory service fees paid to ROTH Capital Partners, LLC and certain other transactional fees paid to third parties, approximately $4.6 million of net cash proceeds. The total increase in capital as a result of the sale of these shares and warrants was approximately $4.4 million after deducting an estimated $0.2 million of additional third party costs incurred in connection with this offering. The aggregate balance of approximately $0.6 million related to placement agent’s fees, advisory service expenses and non-placement agent costs associated with this offering was recorded to common stock issuance costs upon closing under applicable accounting guidance. The estimated aggregate grant date fair value of $1,997,667 associated with the warrants to purchase 3,490,601 shares of common stock was recorded as an offset to additional paid-in capital within common stock issuance costs, and was estimated using Black-Scholes valuation model with the following assumptions:

 

Subsequent to the closing of this public offering on May 4, 2016, no warrants sold in such offering have been exercised, with approximately $4.5 million in gross warrant proceeds remaining outstanding and available to be exercised at $1.30 per share until their expiration in May 2021. Following this offering, and subject to certain limitations for so long as the Company’s public float is less than $75 million, an aggregate initial offering price of up to approximately $39.2 million of the Company’s common stock, preferred stock, debt securities and warrants remains available to be sold under this shelf registration statement. In connection with its May 2016 public offering, the Company has agreed to certain contractual terms that limit its ability to issue, or enter into any agreement to issue, shares of its common stock or common stock equivalents for a period of 75 days, and limit its ability to issue variable rate securities for a period of one year. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings.

 

17

---

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed financial statements and related notes included in this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto as of and for the year ended December 31, 2015 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the Securities and Exchange Commission on March 10, 2016. Past operating results are not necessarily indicative of results that may occur in future periods.

We are an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or “liquid biopsy.” Our assays provide, and our planned future assays would provide, information to oncologists and other physicians that enable them to select appropriate personalized treatment for their patients who have been diagnosed with cancer based on timelier and more-detailed data on the characteristics of their patients’ tumors.

Our current assays and our planned future assays focus on key solid tumor indications utilizing our Target-Selector^TM CTC offering for the biomarker analysis of CTCs and ctDNA from a standard blood sample. The Target-Selector CTC offering is based on an internally developed and patented, microfluidics-based capture and analysis platform, with enabling features that change how CTC testing is used by clinicians. The Target-Selector platforms provide both biomarker detection as well as monitoring, and require only a blood sample. Our patent pending Target-Selector ctDNA technology enables mutation detection with enhanced sensitivity and specificity and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. We believe the Target-Selector technology can someday be used as a stand-alone test for molecular biomarker screening.

At our corporate headquarters facility located in San Diego, California, we operate a clinical laboratory that is certified under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, and accredited by the College of American Pathologists. We manufacture our microfluidic channels, related equipment and certain reagents to perform our current assays and our planned future assays at this facility. CLIA certification is required before any clinical laboratory, including ours, may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, or treatment of disease or the assessment of health. The assays we offer and intend to offer are classified as laboratory developed tests, or LDTs, under CLIA regulations.

We are commercializing our Target-Selector assays for a number of solid tumor indications such as: breast cancer, non-small cell lung cancer, or NSCLC, small cell lung cancer, or SCLC, gastric cancer, colorectal cancer, prostate cancer, and melanoma. These assays utilize our dual CTC and ctDNA technology platform and provide biomarker analysis from a standard blood sample.

In the case of our breast and gastric cancer offering, biomarker analysis involves fluorescence in situ hybridization, or FISH, for the detection and quantitation of the human epidermal growth factor receptor 2, or HER2, gene copy number as well as immunocytochemical analysis of estrogen receptor, or ER, protein, as well as androgen receptor, or AR, protein, which are currently commercially available. We plan to include immunocytochemical analysis of progesterone receptor, or PR, proteins as part of the Target-Selector CTC menu in 2016. A patient’s HER2 status provides the physician with information about the appropriateness of therapies such as Herceptin® or Tykerb®. ER and PR status provides the physician with information about the appropriateness of endocrine therapies such as tamoxifen and aromatase inhibitors.

The lung cancer biomarker analyses currently includes FISH testing for ALK and ROS1, gene rearrangements and mutation analysis of the T790M, Deletion 19, and L858R mutations of the epidermal growth factor receptor, or EGFR, gene as well as B-RAF using our Target-Selector CTC platform. The L858R mutation of the EGFR gene and Exon 19 deletions as activators of EGFR kinase activity are associated with the drugs Tarceva®, Gilotrif® and Iressa®. For lung cancer, we also offer a resistance panel assay consisting of the biomarkers MET, HER2 (both of which we perform using our technology for CTCs), K-RAS, and T790M (both of which are performed using ctDNA in plasma). This assay could be used by physicians to identify the mechanism causing disease progression for patients with NSCLC who are being treated with TKI therapy and therefore could qualify for inclusion in a clinical trial. In November 2015, Tagrisso® was approved by the U.S. Food and Drug Administration, providing another biomarker based therapy for the treatment of patients with EGFR related lung cancer.  Tagrisso® is indicated for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, who have progressed on or after EGFR tyrosine kinase inhibitor therapy.

Fibroblast growth receptor 1, or FGFR1, amplification is offered using our CTC technology. FGFR1 is present in several tumor types, including both NSCLC and SCLC and has been shown to be a prognostic indicator of progression. FGFR1 is also a key target for many drugs which are in clinical development.

Mutations of the B-RAF gene are associated with Zelboraf® and Tafinlar®, which are both approved for treating patients with melanoma and are in clinical trials for lung cancer. We offer testing for B-RAF on blood using our ctDNA offering.

18

---

We plan to add other biomarker analyses, such as RET and PDL1, on blood samples to our current assays and our planned future Target-Selector CTC assays as their relevance is demonstrated in clinical trials and/or included in guidelines used by physicians to make treatment decisions.

Our revenue generating efforts are focused in three areas:

We accessioned 723 commercial cases during the three months ended March 31, 2016 as compared to 247 commercial cases for the same period in 2015, an increase of 476 cases, or 193%. Revenues from commercial cases are recognized as collected, and the expected collection period for a commercial case often extends beyond the end of the quarter in which accessioned, with multiple payments received per case. For commercial accessions received from January 1, 2016 through March 31, 2016, the expected price to be collected at 2016 Medicare schedule rates ranged from less than $200 per accession to over $3,400 per accession, and the weighted-average expected price to be collected is approximately $1,100 per accession, although such reimbursement experience has not yet been achieved. Relatively higher reimbursement rates are expected to be achieved for cases billed to certain private payors where we have contracts. Approximately 31% of the number of commercial accessions billed from January 1, 2016 through March 31, 2016 were subject to Medicare reimbursement rates, and approximately 41% and 35% of commercial revenues and total revenues, respectively, during the three months ended March 31, 2016 were associated with Medicare reimbursement. We have not historically been reimbursed at these average rates for a variety of reasons, including billing challenges related to changes in Medicare CPT codes for our FISH assays in early 2015, and because we were establishing our associated internal processes and also managing an external “out-sourced” billing company. Additionally, a significant amount of our non-Medicare business (private payors) has historically not been contracted, and reimbursement for this business has historically not been at “in network” rates and has therefore been inconsistent. We did begin to contract private payor networks in 2015 and continue to do so in 2016, and our number of accessions treated as “in network” increased and reimbursement is improving. We are currently contracted with eight Preferred Provider Organization networks and one large health plan and expect to continue to gain contracts in order to be considered as an “in-network” provider with additional plans.

Results of Operations

Three Months Ended March 31, 2015 and 2016

The following table sets forth certain information concerning our results of operations for the periods shown:

 

 

Revenues

Revenues were approximately $221,000 for the three months ended March 31, 2016, compared with approximately $150,000 for the same period in 2015, an increase of $71,000, or 47%. The increase was due to an increase of approximately $52,000 in commercial assay revenues resulting primarily from increases in both commercial accession volume and collections made thereon, as well as an increase of approximately $19,000 in development services revenues with 87 development services accessions performed during the three months ended March 31, 2016 as compared to 42 accessions performed during the same period in 2015.

19

---

Costs and Expenses

Cost of Revenues. Cost of revenues was approximately $1,475,000 for the three months ended March 31, 2016, compared with approximately $1,148,000 for the three months ended March 31, 2015, an increase of $327,000, or 28%. The increase was primarily attributable to an increase of approximately $393,000 in personnel, materials and other direct costs mainly related to higher assay volume, partially offset by decreases of approximately $49,000 in allocated facilities costs and approximately $21,000 in laboratory costs charged to research and development.

Research and Development Expenses. Research and development expenses were approximately $728,000 for the three months ended March 31, 2016, compared with approximately $651,000 for the three months ended March 31, 2015, an increase of $77,000, or 12%. The increase was primarily attributable to an increase of $58,000 in personnel costs due to an increase in the average number of employees in the research and development function from 7 employees during the three months ended March 31, 2015 to 10 employees during the same period in 2016, as well as an increase of approximately $21,000 in laboratory costs charged to research and development.

General and Administrative Expenses. General and administrative expenses were approximately $1,487,000 for the three months ended March 31, 2016, compared with approximately $1,292,000 for the three months ended March 31, 2015, an increase of $195,000, or 15%. The increase was primarily due to an increase of approximately $112,000 in consulting, billing, and other third party service provider costs mainly associated with expanded commercial activities, as well as an increase of approximately $73,000 in allocated facilities costs.

Sales and Marketing Expenses. Sales and marketing expenses were approximately $1,305,000 for the three months ended March 31, 2016, compared with approximately $709,000 for the three months ended March 31, 2015, an increase of $596,000, or 84%. The increase was primarily due to an increase of approximately $435,000 in personnel costs and travel expenses associated with an increase in the average number of employees included in the sales and marketing function from 11 employees during the three months ended March 31, 2015 to 15 employees during the same period in 2016, as well as an increase of approximately $158,000 in consulting and other third party service provider costs associated with expanded commercial activities.

Income Taxes

Over the past several years we have generated operating losses in all jurisdictions in which we may be subject to income taxes. As a result, we have accumulated significant net operating losses and other deferred tax assets. Because of our history of losses and the uncertainty as to the realization of those deferred tax assets, a full valuation allowance has been recognized. We do not expect to report a provision for income taxes until we have a history of earnings, if ever, that would support the realization of our deferred tax assets.

We have not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since our formation, due to the complexity and cost associated with such a study, and the fact that there may be additional ownership changes in the future, however, we believe an ownership change likely occurred during 2015. As a result, we have estimated that the use of our net operating loss is limited and the remaining net operating loss carryforwards and research and development credits we estimate can be used in the future remain fully offset by a valuation allowance to reduce the net asset to zero.

Liquidity and Capital Resources

Cash Flows

Our net cash flow from operating, investing and financing activities for the periods below were as follows:

 

 

20

---

Cash Used in Operating Activities. Net cash used in operating activities was $4.0 million for the three months ended March 31, 2016, compared to net cash used in operating activities of $3.3 million for the three months ended March 31, 2015. In all periods the primary use of cash was to fund our net loss. The increase of $0.7 million in cash used in operating activities for the three months ended March 31, 2016 as compared to the same period in 2015 also includes a decrease of $0.4 million in cash used to fund operating assets and liabilities.

Cash Used in Investing Activities. Cash used in investing activities of approximately $90,000 and $25,000 during the three months ended March 31, 2016 and 2015, respectively, was related to the acquisition of fixed assets.

Cash Provided by (Used in) Financing Activities. Net cash used in financing activities was $0.2 million for the three months ended March 31, 2016, compared to net cash provided by financing activities of $17.3 million for the three months ended March 31, 2015. Our primary sources of cash from financing during the three months ended March 31, 2015 consisted of proceeds from our follow-on public offering and the exercise of common stock warrants sold in that offering. Our primary use of cash in financing during the three months ended March 31, 2016 related to $0.5 million of principal payments made on indebtedness, which was partially offset by $0.3 million in net proceeds received from the sale of common stock to Aspire Capital.

Capital Resources and Expenditure Requirements

We expect to continue to incur substantial operating losses in the future. It may take several years to achieve positive operational cash flow or we may not ever achieve positive operational cash flow. We expect that we will use a portion of the net proceeds from our follow-on public offerings, the proceeds from our common stock purchase agreement with Aspire Capital, and our revenues from operations to hire sales and marketing personnel, support increased sales and marketing activities, fund further research and development, clinical utility studies and future enhancements of our assays, acquire equipment, implement automation and scale our capabilities to prepare for significant assay volume, for general corporate purposes and to fund ongoing operations and the expansion of our business, including the increased costs associated with expanded commercial activities. We may also use a portion of the net proceeds from our follow-on public offerings and the proceeds from our common stock purchase agreement with Aspire Capital to acquire or invest in businesses, technologies, services or products, although we do not have any current plans to do so.

As of March 31, 2016, our cash and cash equivalents totaled $4.6 million, and our outstanding indebtedness totaled $5.0 million (including $0.2 million of interest accrued thereon, and excluding $0.2 million of associated debt discounts). While we currently are in the commercialization stage of operations, we have not yet achieved profitability and anticipate that we will continue to incur net losses for the foreseeable future. Management expects that the Company will need additional financing in the future to execute on its current or future business strategies beyond September 2016.

On February 13, 2015, we received net cash proceeds of $9.1 million as a result of the closing of a follow-on public offering, before deducting $0.3 million of additional non-underwriting costs incurred. Subsequent to the closing of this follow-on public offering on February 13, 2015, additional cash proceeds of approximately $9.8 million have been received from the exercise of warrants sold in such offering, while approximately $2.7 million in gross warrant proceeds remain outstanding and available to be exercised at $1.56 per share until their expiration in February 2020.

In May 2015, the SEC declared effective a shelf registration statement filed by us. The shelf registration statement allows us to issue any combination of our common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as our public float is less than $75 million. As of March 31, 2016, we had not sold any securities under this shelf registration statement. A public offering of our common stock and warrants to purchase our common stock was effected under this shelf registration statement on April 29, 2016, the closing of which occurred on May 4, 2016, pursuant to which net cash proceeds of approximately $4.6 million were received, before deducting $0.2 million of additional associated costs incurred by third parties. Subsequent to the closing of this public offering on May 4, 2016, no warrants sold in such offering have been exercised, with approximately $4.5 million in gross warrant proceeds remaining outstanding and available to be exercised at $1.30 per share until their expiration in May 2021. Following this offering, and subject to certain limitations for so long as the Company’s public float is less than $75 million, an aggregate initial offering price of up to approximately $39.2 million of the Company’s common stock, preferred stock, debt securities and warrants remains available to be sold under this shelf registration statement. In connection with our May 2016 public offering, we have agreed to certain contractual terms that limit our ability to issue, or enter into any agreement to issue, shares of our common stock or common stock equivalents for a period of 75 days, and limit our ability to issue variable rate securities for a period of one year. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings.

On December 21, 2015, we entered into a common stock purchase agreement with Aspire Capital, which committed to purchase up to an aggregate of $15.0 million of shares of our common stock over the 30-month term of the common stock purchase agreement. Upon execution of the common stock purchase agreement, we sold to Aspire Capital 625,000 shares of common stock at $1.60 per share for gross proceeds of $1,000,000, before deducting approximately $0.1 million of associated costs incurred by third parties, and we concurrently also entered into a registration rights agreement with Aspire Capital, pursuant to which we filed a registration statement

21

---

registering the sale of the shares of our common stock that have been and may be issued to Aspire Capital under the common stock purchase agreement. In consideration for entering into, and concurrently with the execution of, the common stock purchase agreement, we issued to Aspire Capital 165,000 shares of our common stock. During the three months ended March 31, 2016, we submitted purchase notices to Aspire Capital for an aggregate of 300,000 shares of common stock for gross proceeds of $403,000. Approximately $13.6 million, or up to 2,684,122 shares, remains available to be issued to Aspire Capital under this agreement as of May 13, 2016, subject to certain contractual limitations that prohibit our ability to sell our common stock to Aspire Capital.

We expect that we will need additional financing in the future to execute on our current or future business strategies. Until we can generate significant cash from operations, including assay revenues, we expect to continue to fund operations with the proceeds from offerings of our equity securities or debt, or transactions involving product development, technology licensing or collaboration. For example, we have an effective shelf registration statement on file with the SEC which allows us to issue any combination of our common stock, preferred stock, debt securities and warrants from time to time with an available remaining aggregate initial offering price of up to approximately $39.2 million, subject to certain limitations for so long as our public float is less than $75.0 million. In connection with our May 2016 public offering, we have agreed to certain contractual terms that limit our ability to issue, or enter into any agreement to issue, shares of our common stock or common stock equivalents for a period of 75 days, and limit our ability to issue variable rate securities for a period of one year. We also have entered into a common stock purchase agreement with Aspire Capital pursuant to which we can sell up to $15.0 million of shares of our common stock to Aspire Capital over the 30-month term of the common stock purchase agreement. Approximately $13.6 million, or up to 2,684,122 shares, remains available to be issued to Aspire Capital under this agreement as of May 13, 2016, subject to certain contractual limitations that prohibit our ability to sell our common stock to Aspire Capital. We can provide no assurances that any sources of a sufficient amount of financing will be available to us on favorable terms, if at all. If we are unable to raise a sufficient amount of financing in a timely manner, we would likely need to scale back our general and administrative activities and certain of our research and development activities. Our forecast pertaining to our current financial resources and the costs to support our general and administrative and research and development activities are forward-looking statements and involve risks and uncertainties. Actual results could vary materially and negatively as a result of a number of factors, including:

 

 

 

 

 

 

 

 

 

 

We may raise additional capital to fund our current operations and to fund expansion of our business to meet our long-term business objectives through public or private equity offerings, our common stock purchase agreement with Aspire Capital, debt financings, borrowings or strategic partnerships coupled with an investment in our company or a combination thereof. If we raise additional funds through the issuance of convertible debt securities, or other debt securities, these securities could be secured and could have rights senior to those of our common stock. In addition, any new debt incurred by us could impose covenants that restrict our operations. The issuance of any new equity securities will also dilute the interest of our current stockholders. Given the risks associated with our business, including our unprofitable operating history and our ability or inability to develop additional assays, additional capital may not be available when needed on acceptable terms, or at all. If adequate funds are not available, we will need to curb our expansion plans or limit our research and development activities, which would have a material adverse impact on our business prospects and results of operations.

Off-Balance Sheet Arrangements

We have not engaged in any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K.

22

---

Critical Accounting Policies and Significant Judgments and Estimates

For a discussion of accounting policies that we consider critical to our business operations and understanding of our results of operations, and that affect the more significant judgments and estimates used in the preparation of our financial statements, see Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Significant Judgments and Estimates” contained in our Annual Report on Form 10-K for the year ended December 31, 2015. There have been no material changes to our critical accounting policies and estimates from the information provided in our Annual Report on Form 10-K for the year ended December 31, 2015.

 

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not applicable.

 

Item 4. Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

As of March 31, 2016, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2016. There were no changes in our internal control over financial reporting that occurred during the three months ended March 31, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

23

---

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

None.

 

Item 1A. Risk Factors

For a discussion of our potential risks and uncertainties, please see the information listed below, along with the information listed in the item captioned “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015. Except as provided below, there have been no material changes to the risk factors as disclosed in the Form 10-K. You should carefully consider the risk factors discussed below and in our Annual Report on Form 10-K for the year ended December 31, 2015, which could materially affect our business, financial position and results of operations.

We need to raise additional capital to continue as a going concern.

We expect to continue to incur losses for the foreseeable future and will have to raise additional capital to fund our planned operations and to meet our long-term business objectives. As a result, there is substantial doubt about our ability to continue as a going concern unless we are able to successfully raise additional capital. Until we can generate significant cash from operations, including assay revenues, we expect to continue to fund our operations with the proceeds from offerings of our equity securities or debt, or transactions involving product development, technology licensing or collaboration. We can provide no assurances that any sources of a sufficient amount of financing will be available to us on favorable terms, if at all. Failure to raise additional capital in sufficient amounts would significantly impact our ability to continue as a going concern. The actual amount of funds that we will need and the timing of any such investment will be determined by many factors, some of which are beyond our control. For further discussion of our liquidity requirements as they relate to our ability to continue as a going concern and our long-term plans, see the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources.”

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Unregistered Sales of Equity Securities

None.

Use of Proceeds

Not applicable.

 

Item 3. Defaults Upon Senior Securities

Not applicable.

 

Item 4. Mine Safety Disclosures

Not applicable.

 

Item 5. Other Information

Not applicable.

 

Item 6. Exhibits

The exhibits listed on the accompanying index to exhibits immediately preceding the exhibits are filed as part of, or hereby incorporated by reference into, this Quarterly Report.

 

 

 

24

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

25

---

Exhibit Index

The exhibits listed below are hereby filed with the SEC as part of this Quarterly Report on Form 10-Q.

EXHIBITS

 

26

---

 

 

27

 

EXHIBIT 31.1

CERTIFICATION

I, Michael W. Nall, certify that:

Date: May 13, 2016

 

 

 

 

EXHIBIT 31.2

CERTIFICATION

I, Mark G. Foletta, certify that:

Date: May 13, 2016

 

 

 

 

EXHIBIT 32.1

CERTIFICATION

I, Michael W. Nall, hereby certify pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that, to my knowledge, the Quarterly Report on Form 10-Q of Biocept, Inc. for the period ended March 31, 2016 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Biocept, Inc.

 

This certification accompanies the Report pursuant to Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934.

 

 

EXHIBIT 32.2

CERTIFICATION

I, Mark G. Foletta, hereby certify pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that, to my knowledge, the Quarterly Report on Form 10-Q of Biocept, Inc. for the period ended March 31, 2016 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Biocept, Inc.

 

This certification accompanies the Report pursuant to Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934.

 

v3.4.0.3

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May. 06, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q1
Trading Symbol	BIOC
Entity Registrant Name	BIOCEPT INC
Entity Central Index Key	0001044378
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		24,969,975

v3.4.0.3

Condensed Balance Sheets - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 4,572,750	$ 8,821,329
Accounts receivable	43,421	34,200
Inventories, net	366,957	349,271
Prepaid expenses and other current assets	877,903	435,938
Total current assets	5,861,031	9,640,738
Fixed assets, net	919,799	946,180
Total assets	6,780,830	10,586,918
Current liabilities:
Accounts payable	853,329	632,538
Accrued liabilities	1,182,861	966,899
Supplier financings	360,285	42,369
Current portion of equipment financings	121,384	110,924
Current portion of credit facility	1,619,830	1,588,058
Total current liabilities	4,137,689	3,340,788
Non-current portion of equipment financings, net	259,392	291,189
Non-current portion of credit facility, net	2,246,260	2,638,487
Non-current portion of interest payable	173,930	153,547
Non-current portion of deferred rent	452,790	470,172
Total liabilities	$ 7,270,061	$ 6,894,183
Commitments and contingencies (see Note 10)
Shareholders’ equity/(deficit):
Common stock, $0.0001 par value, 40,000,000 authorized; 19,670,054 issued and outstanding at December 31, 2015; 19,983,402 issued and outstanding at March 31, 2016	$ 1,998	$ 1,967
Additional paid-in capital	159,620,517	158,927,316
Accumulated deficit	(160,111,746)	(155,236,548)
Total shareholders’ equity/(deficit)	(489,231)	3,692,735
Total liabilities and shareholders’ equity/(deficit)	$ 6,780,830	$ 10,586,918

v3.4.0.3

Condensed Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	19,983,402	19,670,054
Common stock, shares outstanding	19,983,402	19,670,054

v3.4.0.3

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Revenues:	$ 221,369	$ 150,002
Costs and expenses:
Cost of revenues	1,474,790	1,147,682
Research and development expenses	728,076	651,420
General and administrative expenses	1,487,224	1,292,049
Sales and marketing expenses	1,304,899	709,456
Total costs and expenses	4,994,989	3,800,607
Loss from operations	(4,773,620)	(3,650,605)
Other income/(expense):
Interest expense, net	(138,440)	(149,199)
Other income	38,412
Total other income/(expense):	(100,028)	(149,199)
Loss before income taxes	(4,873,648)	(3,799,804)
Income tax expense	(1,550)	(924)
Net loss & comprehensive loss	$ (4,875,198)	$ (3,800,728)
Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders:
Basic	19,700,975	10,372,667
Diluted	19,700,975	10,372,667
Net loss per common share:
Basic	$ (0.25)	$ (0.37)
Diluted	$ (0.25)	$ (0.37)

v3.4.0.3

Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash Flows From Operating Activities:
Net loss	$ (4,875,198)	$ (3,800,728)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	77,352	52,983
Inventory reserve	(13,840)	1,440
Stock-based compensation	368,990	334,065
Non-cash interest expense related to credit facility and other financing activities	24,799	28,575
Increase/(decrease) in cash resulting from changes in:
Accounts receivable	(9,221)	(5,000)
Inventory	(3,846)	(26,272)
Prepaid expenses and other current assets	(7,490)	(455,884)
Accounts payable	264,500	336,956
Accrued liabilities	208,789	181,380
Accrued interest	15,548	20,830
Deferred rent	(7,614)	1,871
Net cash used in operating activities	(3,957,231)	(3,329,784)
Cash Flows From Investing Activities:
Purchases of fixed assets	(90,337)	(25,096)
Net cash used in investing activities	(90,337)	(25,096)
Cash Flows From Financing Activities:
Net proceeds from issuance of common stock	324,242	8,833,558
Proceeds from exercise of common stock warrants		8,482,108
Payments on equipment financings	(23,427)	(13,950)
Payments on supplier and other third party financings	(116,529)	(16,712)
Payments on line of credit	(385,297)
Net cash provided (used) by financing activities	(201,011)	17,285,004
Net increase (decrease) in Cash and Cash Equivalents	(4,248,579)	13,930,124
Cash and Cash Equivalents at Beginning of Period	8,821,329	5,364,582
Cash and Cash Equivalents at End of Period	4,572,750	19,294,706
Cash paid during the period for:
Interest	97,627	103,386
Taxes	$ 1,550	$ 1,630

v3.4.0.3

Condensed Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Warrants to purchase common stock, period	5 years
Purchase of common stock by underwriters to cover overallotments, grant date fair value	$ 7,690,395
Overallotment issued to underwriter to purchase common stock, period	45 days
Common shares issuable to underwriters under granted option	1,200,000
Common Shares issuable to underwriters under warrants granted	1,200,000
Common stock, par value	$ 0.0001		$ 0.0001
Issuance of warrants to purchase shares of common stock, grant date fair value	$ 1,627,396
Offering costs recorded in prepaid expenses and other current assets reclassified to common stock issuance costs	63,111
Proceeds from warrants not yet received		$ 17,472
Financed insurance premium through third party financing	434,475
Purchases of fixed assets	$ 18,937	$ 12,205	$ 64,300	$ 19,546

v3.4.0.3

Basis of Presentation	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Basis of Presentation	1. Basis of Presentation Basis of Presentation The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by U.S. Generally Accepted Accounting Principles, or GAAP, to be included in a full set of financial statements. The balance sheet at December 31, 2015 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2015, filed with the SEC with our Annual Report on Form 10-K on March 10, 2016 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. Certain prior period amounts have been reclassified to conform to the current period presentation. Additionally, a total of $290,709 of revenue-generating costs previously allocated to research and development expenses during the three months ended March 31, 2015 were reclassified to cost of revenues in the current period presentation of the unaudited condensed statement of operations and comprehensive loss.   The Company and Business Activities Biocept, Inc., or the Company, was founded in California in May 1997 and is an early stage cancer diagnostics company developing and commercializing proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample to improve the treatment that oncologists provide to their patients by providing better, more detailed information on the characteristics of their tumor. The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations. In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013. Recent Accounting Pronouncements In May 2014, and as subsequently updated and amended from time to time, the Financial Accounting Standards Board, or FASB, issued authoritative guidance that requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. This proposed guidance has been deferred and would be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In June 2014, the FASB issued authoritative guidance requiring share-based payments with a performance target which affects vesting and that could be achieved after the requisite service period be treated as a performance condition. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The Company adopted this guidance for the interim reporting period ended March 31, 2016. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures. In August 2014, the FASB issued authoritative guidance requiring management to evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Certain additional financial statement disclosures are required if such conditions or events are identified. This guidance is effective for the annual reporting period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In July 2015, the FASB issued authoritative guidance requiring entities that do not measure inventory using the retail inventory method or on a last-in, first-out basis to record inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This guidance is effective on a prospective basis for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures. In January 2016, the FASB issued authoritative guidance requiring, among other things, that certain equity investments be measured at fair value with changes in fair value recognized in net income, that financial assets and financial liabilities be presented separately by measurement category and form of financial asset on the balance sheet or the accompanying notes to the financial statements, that the prior requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet be eliminated, and that a reporting organization is to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the organization has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption of the instrument-specific credit risk amendment is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures. In February 2016, the FASB issued authoritative guidance requiring, among other things, that entities recognize the assets and liabilities arising from leases on the balance sheet under revised criteria, while the classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria in the previous leases guidance. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance clarifying that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument does not necessarily require dedesignation of that hedging relationship, provided that all other applicable hedge accounting criteria continue to be met. This guidance is effective on either a prospective basis or modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance requiring entities to assess whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts, and clarifies what steps are required when assessing whether the economic characteristics and risks of call (put) options are clearly and closely related to the economic characteristics and risks of their debt hosts. This guidance is effective on a modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance simplifying the accounting for stock compensation. This guidance, among other things, amends existing accounting and classification requirements primarily around income taxes, forfeitures, and cash payments associated with share-based payment awards to employees. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.

v3.4.0.3

Liquidity and Going Concern Uncertainty	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Liquidity and Going Concern Uncertainty	2. Liquidity and Going Concern Uncertainty As of March 31, 2016, cash and cash equivalents totaled $4.6 million and the Company had an accumulated deficit of $160.1 million. For the year and three month periods ended December 31, 2015 and March 31, 2016, the Company incurred net losses of $16.9 million and $4.9 million, respectively. At March 31, 2016, the Company had aggregate gross interest-bearing indebtedness of approximately $5.0 million, of which approximately $2.1 million was due within one year in the absence of subjective acceleration of amounts due under a credit facility entered into in April 2014 with Oxford Finance LLC, or the April 2014 Credit Facility, in addition to approximately $2.5 million of other non-interest bearing liabilities. Additionally, in February 2016, the Company signed a firm, noncancelable, and unconditional commitment in an aggregate amount of $1,062,500 with a vendor to purchase certain inventory items, payable in quarterly installments of $62,500 through May 2020 (see Note 10). These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying unaudited condensed financial statements have been prepared assuming that the Company will continue as a going concern. The unaudited condensed financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. While the Company is currently in the commercialization stage of operations, the Company has not yet achieved profitability and anticipates that it will continue to incur net losses for the foreseeable future. Historically, the Company’s principal sources of cash have included proceeds from the issuance of common and preferred stock, proceeds from the exercise of warrants to purchase common stock, proceeds from the issuance of debt, and revenues from laboratory services. The Company’s principal uses of cash have included cash used in operations, payments relating to purchases of property and equipment and repayments of borrowings. The Company expects that the principal uses of cash in the future will be for continuing operations, hiring of sales and marketing personnel and increased sales and marketing activities, funding of research and development, capital expenditures, and general working capital requirements. The Company expects that, as revenues grow, sales and marketing and research and development expenses will continue to grow, albeit at a slower rate and, as a result, the Company will need to generate significant growth in net revenues to achieve and sustain income from operations. Subsequent to the closing of a follow-on public offering on February 13, 2015, cash proceeds of approximately $9.8 million have been received by the Company from the exercise of warrants sold in such offering, while approximately $2.7 million in gross warrant proceeds remain outstanding and available to be exercised at $1.56 per share until their expiration in February 2020. On December 21, 2015, the Company entered into a common stock purchase agreement with Aspire Capital Fund LLC, or Aspire Capital, whereby approximately $13.6 million, or up to 2,684,122 shares, are available to be issued to Aspire Capital under this agreement as of May 13, 2016, subject to certain contractual limitations that prohibit the Company’s ability to sell its common stock to Aspire Capital. In May 2015, the SEC declared effective a shelf registration statement filed by the Company. The shelf registration statement allows the Company to issue any combination of its common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as the Company’s public float is less than $75 million. As of March 31, 2016, the Company had not sold any securities under this shelf registration statement. A public offering of the Company’s common stock and warrants to purchase its common stock was effected under this shelf registration statement on April 29, 2016, the closing of which occurred on May 4, 2016, pursuant to which the Company received net cash proceeds of approximately $4.4 million (see Note 12). Subsequent to the closing of this public offering on May 4, 2016, no warrants sold in such offering have been exercised, with approximately $4.5 million in gross warrant proceeds remaining outstanding and available to be exercised at $1.30 per share until their expiration in May 2021. Following this offering, and subject to certain limitations for so long as the Company’s public float is less than $75 million, an aggregate initial offering price of up to approximately $39.2 million of the Company’s common stock, preferred stock, debt securities and warrants remains available to be sold under this shelf registration statement. In connection with its May 2016 public offering, the Company has agreed to certain contractual terms that limit its ability to issue, or enter into any agreement to issue, shares of its common stock or common stock equivalents for a period of 75 days, and limit its ability to issue variable rate securities for a period of one year. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings. Management’s Plan to Continue as a Going Concern In order to continue as a going concern, the Company will need, among other things, additional capital resources. Until the Company can generate significant cash from operations, including assay revenues, management’s plans to obtain such resources for the Company include proceeds from offerings of the Company’s equity securities or debt, or transactions involving product development, technology licensing or collaboration. Management can provide no assurances that any sources of a sufficient amount of financing will be available to the Company on favorable terms, if at all.

v3.4.0.3

Sales of Equity Securities	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Sales of Equity Securities	3. Sales of Equity Securities Pursuant to an underwriting agreement dated February 9, 2015 between the Company, Aegis Capital Corp. and Feltl and Company, as underwriters named therein, a public offering of 8,000,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 8,000,000 shares of common stock was effected at a combined offering price of $1.25. The estimated grant date fair value of these warrants of $7.7 million was recorded as an offset to additional paid-in capital within common stock issuance upon the closing of this offering. Each of the members of the Company’s Board of Directors participated in this offering, purchasing an aggregate 142,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 142,000 shares of its common stock for a total purchase price of $177,500. All warrants sold in this offering have a per share exercise price of $1.56, are exercisable immediately and expire five years from the date of issuance. The closing of the sale of these securities to the underwriters occurred on February 13, 2015, when the Company received, after deducting underwriting discounts and additional costs paid to the underwriters, $9.1 million of net cash proceeds. The total increase in capital as a result of the sale of these shares and warrants was $8.8 million after deducting $0.3 million of additional non-underwriter costs incurred. Additionally, the underwriters were granted a 45-day option to purchase up to 1,200,000 additional shares of common stock at a price of $1.25 per share and/or additional warrants to purchase up to 1,200,000 shares of common stock at a price of $0.0001 per warrant, less underwriting discounts and commissions, to cover over-allotments, if any, which was not exercised. The estimated grant date fair value of the over-allotment options and warrants of $1.6 million was recorded as an offset to additional paid-in capital within common stock issuance costs upon the closing of this offering. Underwriter costs and discounts of $0.2 million and $0.7 million, respectively, as well as additional non-underwriter costs associated with this offering of $0.3 million, were also recorded to common stock issuance costs upon closing. Subsequent to the closing of this offering on February 13, 2015, additional cash proceeds of $9.8 million have been received from the exercise of warrants sold in such offering. As such, the aggregate total increase in capital related to this offering has been $18.6 million, after deducting $0.9 million of underwriter costs and discounts and $0.3 million of additional non-underwriter costs incurred, which were netted against these proceeds under applicable accounting guidance. In May 2015, the SEC declared effective a shelf registration statement filed by the Company. The shelf registration statement allows the Company to issue any combination of its common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as the Company’s public float is less than $75 million. As of March 31, 2016, the Company had not sold any securities under this shelf registration statement. In May 2016, the Company received net proceeds of approximately $4.4 million from the sale of common stock and warrants to purchase common stock under this shelf registration statement (see Note 12). Following this offering, and subject to certain limitations for so long as the Company’s public float is less than $75 million, an aggregate initial offering price of up to approximately $39.2 million of the Company’s common stock, preferred stock, debt securities and warrants remains available to be sold under this shelf registration statement. In connection with its May 2016 public offering, the Company has agreed to certain contractual terms that limit its ability to issue, or enter into any agreement to issue, shares of its common stock or common stock equivalents for a period of 75 days, and limit its ability to issue variable rate securities for a period of one year. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings. On December 21, 2015, the Company entered into a common stock purchase agreement with Aspire Capital, which committed to purchase up to an aggregate of $15.0 million of shares of the Company’s common stock over the 30-month term of the common stock purchase agreement. Upon execution of the common stock purchase agreement, the Company sold to Aspire Capital 625,000 shares of common stock at $1.60 per share for proceeds of $1,000,000, and concurrently also entered into a registration rights agreement with Aspire Capital, pursuant to which the Company filed a registration statement registering the sale of the shares of the Company’s common stock that have been and may be issued to Aspire Capital under the common stock purchase agreement. Under the common stock purchase agreement, on any trading day selected by the Company, the Company has the right, in its sole discretion, to present a purchase notice directing Aspire Capital to purchase up to 100,000 shares of the Company’s common stock per business day, up to $15.0 million of common stock in the aggregate at a per share price equal to the lesser of either i) the lowest sale price of the Company’s common stock on the purchase date, or ii) the arithmetic average of the three lowest closing sale prices for the Company’s common stock during the 10 consecutive trading days ending on the trading day immediately preceding the purchase date. In addition, on any date on which the Company submits a purchase notice to Aspire Capital in an amount equal to 100,000 shares and the Company’s stock price is not less than $0.50 per share, the Company also has the right, in its sole discretion, to present Aspire Capital with a volume-weighted average price purchase notice directing Aspire Capital to purchase an amount of stock equal to up to 30% of the aggregate shares of the Company’s common stock traded on the its principal market on the next trading day, subject to a maximum number of shares the Company may determine. The purchase price per share pursuant to such volume-weighted average price purchase notice is generally 97% of the volume-weighted average price for the Company’s common stock traded on its principal market on the volume-weighted average purchase date. The purchase price will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, or other similar transaction occurring during the period(s) used to compute the purchase price. The Company may deliver multiple purchase notices and volume-weighted average price purchase notices to Aspire Capital from time to time during the term of the common stock purchase agreement, so long as the most recent purchase has been completed. The common stock purchase agreement provides that the Company and Aspire Capital shall not effect any sales on any purchase date where the closing sale price of the Company’s common stock is less than $0.50. There are no trading volume requirements or restrictions under the common stock purchase agreement, and the Company will control the timing and amount of sales of its common stock to Aspire Capital. Aspire Capital has no right to require any sales by the Company, but is obligated to make purchases from the Company as directed by the Company in accordance with the common stock purchase agreement. There are no limitations on use of proceeds, financial or business covenants, restrictions on future fundings, rights of first refusal, participation rights, penalties or liquidated damages in the common stock purchase agreement. In consideration for entering into, and concurrently with the execution of, the common stock purchase agreement, the Company issued to Aspire Capital 165,000 shares of its common stock. The common stock purchase agreement may be terminated by the Company at any time, at its discretion, without any cost to the Company. Aspire Capital has agreed that neither it nor any of its agents, representatives and affiliates shall engage in any direct or indirect short-selling or hedging of the Company’s common stock during any time prior to the termination of the common stock purchase agreement. Any proceeds the Company receives under the common stock purchase agreement are expected to be used for working capital and general corporate purposes. During the three months ended March 31, 2016, the Company submitted purchase notices to Aspire Capital for an aggregate of 300,000 shares of common stock for gross proceeds of $403,000. Costs associated with this offering of approximately $42,000 and $79,000 during the year ended December 31, 2015 and March 31, 2016, respectively, were also recorded to common stock issuance costs under applicable accounting guidance, and as such, the aggregate total increase in capital related to this transaction has been approximately $1.3 million. Approximately $13.6 million, or up to 2,684,122 shares, remains available to be issued to Aspire Capital under this agreement as of May 13, 2016, subject to certain contractual limitations that prohibit the Company’s ability to sell its common stock to Aspire Capital.

v3.4.0.3

Fair Value Measurement	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurement	4. Fair Value Measurement The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company believes the carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate their estimated fair values due to the short-term maturities of these financial instruments. Other Fair Value Measurements The estimated fair value of the Company’s credit facility at March 31, 2016 approximated carrying value, which was determined using a discounted cash flow analysis. The analysis considered interest rates of instruments with similar maturity dates, which involved the use of significant unobservable Level 3 inputs. In connection with the closing of the Company’s public offering on May 4, 2016, warrants were issued to buy (in the aggregate) up to 3,490,601 shares of common stock with an estimated grant date fair value of $1,997,667, which was recorded as an offset to additional paid-in capital within common stock issuance costs (see Note 12).

v3.4.0.3

Balance Sheet Details	3 Months Ended
	Mar. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Balance Sheet Details	5. Balance Sheet Details The following provides certain balance sheet details:     December 31,     March 31,     2015     2016   Fixed Assets     Machinery and equipment $ 2,518,158     $ 2,540,587   Furniture and office equipment   143,726       143,726   Computer equipment and software   577,898       602,097   Leasehold improvements   514,614       514,614   Financed equipment   914,179       976,599   Construction in process   70,815       12,738       4,739,390       4,790,361   Less accumulated depreciation and amortization   3,793,210       3,870,562   Total fixed assets, net $ 946,180     $ 919,799   Accrued Liabilities               Accrued interest $ 28,981     $ 26,429   Accrued payroll   128,753       235,685   Accrued vacation   307,845       322,974   Accrued bonuses   376,100       471,035   Accrued sales commissions   76,574       73,010   Current portion of deferred rent   31,170       40,938   Accrued other   17,476       12,790   Total accrued liabilities $ 966,899     $ 1,182,861

v3.4.0.3

April 2014 Credit Facility	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
April 2014 Credit Facility	6. April 2014 Credit Facility On April 30, 2014, the Company received net cash proceeds of approximately $4,898,000 pursuant to the execution of its April 2014 Credit Facility with Oxford Finance LLC. Upon the entry into the April 2014 Credit Facility, the Company was required to pay the lenders a facility fee of $50,000 in conjunction with the funding of the term loan. The April 2014 Credit Facility is secured by substantially all of the Company’s personal property other than its intellectual property. Amounts due to Oxford Finance LLC under the April 2014 Credit Facility are callable before maturity by the lender under certain subjective acceleration clauses of the underlying agreement, including changes deemed to be materially adverse by the lender. The term loan under the April 2014 Credit Facility bears interest at an annual rate equal to the greater of (i) 7.95% or (ii) the sum of (a) the three-month U.S. LIBOR rate reported in the Wall Street Journal three business days prior to the funding date of the term loan, plus (b) 7.71%. The term loan bears interest at an annual rate of 7.95%. The Company was required to make interest-only payments on the term loan through August 1, 2015. The outstanding term loan under the April 2014 Credit Facility began amortizing at the end of the applicable interest-only period, with monthly payments of principal and interest being made by the Company to the lenders in consecutive monthly installments following such interest-only period. The term loan under the April 2014 Credit Facility matures on July 1, 2018. Upon repayment, the Company is also required to make a final payment to the lenders equal to 5.5% of the original principal amount of the term loan funded. At its option, the Company may prepay the outstanding principal balance of the term loan in whole but not in part, subject to a prepayment fee of 1% of any amount prepaid after April 30, 2016. The April 2014 Credit Facility includes affirmative and negative covenants applicable to the Company and any subsidiaries created in the future. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal existence and governmental approvals, deliver certain financial reports and maintain insurance coverage. The negative covenants include, among others, restrictions on transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets, and suffering a change in control, in each case subject to certain exceptions. The April 2014 Credit Facility also includes events of default, the occurrence and continuation of which provide Oxford Finance LLC, as collateral agent, with the right to exercise remedies against the Company and the collateral securing the term loan under the April 2014 Credit Facility, including foreclosure against the Company’s properties securing the April 2014 Credit Facility, including its cash. These events of default include, among other things, the Company’s failure to pay any amounts due under the April 2014 Credit Facility, a breach of covenants under the April 2014 Credit Facility, insolvency, a material adverse change, the occurrence of any default under certain other indebtedness in an amount greater than $250,000, and a final judgment against the Company in an amount greater than $250,000. A warrant to purchase up to 52,966 shares of the Company’s common stock at an exercise price of $4.72 per share with a term of 10 years was issued to Oxford Finance LLC on April 30, 2014. Issuance costs of $102,498 associated with the term loan under the April 2014 Credit Facility were recorded as a discount to outstanding debt as of the closing date, resulting in net proceeds of $4,897,502. The estimated fair value of the warrant issued of $233,107 was recorded as a discount to outstanding debt as of the closing date. The discounts and other issuance costs are amortized to interest expense utilizing the effective interest method over the underlying term of the loan. The effective annual interest rate associated with the April 2014 Credit Facility was 11.50% at both December 31, 2015 and March 31, 2016.

v3.4.0.3

Stock-based Compensation	3 Months Ended
	Mar. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based Compensation	7. Stock-based Compensation Equity Incentive Plans The Company maintains two equity incentive plans: the Amended and Restated 2013 Equity Incentive Plan, or the 2013 Plan, and the 2007 Equity Incentive Plan, or the 2007 Plan. The 2013 Plan includes a provision that shares available for grant under the Company’s 2007 Plan become available for issuance under the 2013 Plan and are no longer available for issuance under the 2007 Plan. As of March 31, 2016, under all plans, a total of 3,068,865 shares were authorized for issuance, 2,297,168 stock options and restricted stock units, or RSUs, had been issued and were outstanding, and 647,263 shares were available for grant. Stock Options A summary of stock option activity for option awards granted under the 2013 Plan and 2007 Plan for the three months ended March 31, 2016 is as follows:                     Average             Weighted     Remaining     Number of     Average Exercise     Contractual     Shares     Price Per Share     Term in Years   Vested and unvested expected to vest, December 31, 2015   1,940,701     $ 5.16       9.0   Outstanding at December 31, 2015   2,141,141     $ 3.71     9.1   Granted   264,000     $ 1.34           Exercised   —                   Cancelled/forfeited/expired   (140,742 )   $ 2.56           Outstanding at March 31, 2016   2,264,399     $ 3.51       8.9   Vested and unvested expected to vest, March 31, 2016   2,136,107     $ 3.60       8.8     The intrinsic values of options outstanding and options vested and unvested expected to vest at March 31, 2016 were both zero. The intrinsic value of options exercisable at March 31, 2016 was zero. The fair values of option awards granted during the three months ended March 31, 2016 were estimated using a Black-Scholes pricing model with the following assumptions:   Stock and exercise prices $ 1.34   Expected dividend yield   0.00 % Discount rate-bond equivalent yield 1.24% – 1.39%   Expected life (in years) 5.42 – 6.08   Expected volatility   90.0 % Using the assumptions described above, with stock and exercise prices being equal on date of grant, the weighted-average estimated fair value of options granted in the three months ended March 31, 2016 was $0.98 per share. On August 31, 2015, the Company’s Board of Directors approved the issuance of 100,000 stock options with an estimated grant date fair value of $1.47 per share to its Chief Executive Officer pursuant to the 2013 Plan. On February 29, 2016, the Company’s Board of Directors approved the issuance of 100,000 stock options with an estimated grant date fair value of $0.96 per share to its Chief Executive Officer pursuant to the 2013 Plan. Vesting of these stock options may occur based on the Company’s achievement of specified objectives by December 31, 2016 as determined by the Company’s Board of Directors, or a committee of the Company’s Board of Directors, in its sole discretion, as follows:     Percentage of     Overall Stock     Option Grants     Subject to Vesting   Target       Minimum number of accessions processed, billed and collected   13 % Minimum revenues from contracts with pharmaceutical    companies   10 % Attainment of a sustainable positive GAAP gross  margin   12 % Minimum operating cash on-hand with no more than one interim    dilutive equity financing event   15 % Achievement of the Company's 2016 corporate goals   25 % Completion of a Board-approved strategic transaction   25 % Total   100 % Restricted Stock On June 12, 2014, the Company’s Board of Directors granted an RSU award for 44,496 shares with a grant date fair value of $5.35 per share to its Chief Executive Officer pursuant to the 2013 Plan. Vesting of these RSUs was based on the Company’s achievement of specified objectives by December 31, 2015 as determined by the Company’s Board of Directors or the Compensation Committee of the Board of Directors, as follows:     Percentage of     Overall RSU     Grant Subject to     Vesting   Target       Minimum revenue   25 % Maximum EBITDA loss   15 % Attainment of financial plan for fiscal 2015   20 % Minimum value of strategic agreements   20 % Implementation of four new diagnostic test panels   20 % Total   100 % During the three months ended March 31, 2016, a total of 13,348 RSUs were declared vested by the Company’s Board of Directors and issued to its Chief Executive Officer in satisfaction of this award and the remaining 31,148 shares underlying this RSU were forfeited. At March 31, 2016, 32,769 RSUs with an intrinsic value of $42,272 were outstanding and vested. Stock-based Compensation Expense The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statement of operations and comprehensive loss during the periods presented:     For the three months ended     March 31,     2015     2016   Stock Options               Cost of revenues $ 16,136     $ 26,075   Research and development expenses   20,420       33,003   General and administrative expenses   219,061       272,569   Sales and marketing expenses   31,012       37,343   Total expenses related to stock options   286,629       368,990   RSUs               Research and development expenses   7,500       —   General and administrative expenses   39,936       —   Total stock-based compensation $ 334,065     $ 368,990     Stock-based compensation expense was recorded net of estimated forfeitures of 0% - 4% per annum during the three months ended March 31, 2015 and 2016. As of March 31, 2016 total unrecognized stock-based compensation expense related to unvested stock option, adjusted for estimated forfeitures, was approximately $2,476,000 and is expected to be recognized over a weighted-average period of 2.4 years.

v3.4.0.3

Common Stock Warrants Outstanding	3 Months Ended
	Mar. 31, 2016
Other Liabilities Disclosure [Abstract]
Common Stock Warrants Outstanding	8. Common Stock Warrants Outstanding A summary of equity-classified common stock warrant activity for the three months ended March 31, 2016 is as follows:                     Average             Weighted     Remaining     Number of     Average Exercise     Contractual     Shares     Price Per Share     Term in Years   Outstanding at December 31, 2015   2,352,738     $ 3.73       3.8   Issued   —                   Exercised   —                   Expired   (152,712 )   $ 10.00           Outstanding at March 31, 2016   2,200,026     $ 3.29       3.8     The intrinsic value of equity-classified common stock warrants outstanding and exercisable at March 31, 2016 was $0. In connection with the closing of the Company’s public offering on May 4, 2016, warrants were issued to buy (in the aggregate) up to 3,490,601 shares of common stock at an exercise price of $1.30 per share with a term of five years (see Note 12).

v3.4.0.3

Net Loss per Common Share	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Net Loss per Common Share	9. Net Loss per Common Share Basic and diluted net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted-average common shares outstanding during the period. Because there is a net loss attributable to common shareholders for the three months ended March 31, 2015 and 2016, the outstanding RSUs, warrants, and common stock options have been excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive. Therefore, the weighted-average shares used to calculate both basic and diluted loss per share are the same. The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive:       For the three months ended     March 31,     2015     2016   Preferred warrants outstanding (number of common stock      equivalents)   1,587       1,587   Preferred share RSUs (number of common stock equivalents)   73,151       —   Common warrants outstanding   3,160,738       2,200,026   Common share RSUs   178,467       32,769   Common options outstanding   916,239       2,264,399   Total anti-dilutive common share equivalents   4,330,182       4,498,781

v3.4.0.3

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies In the normal course of business, the Company may be involved in legal proceedings or threatened legal proceedings. The Company is not party to any legal proceedings or aware of any threatened legal proceedings that are expected to have a material adverse effect on its financial condition, results of operations or liquidity. In February 2016, the Company signed a firm, noncancelable, and unconditional commitment in an aggregate amount of $1,062,500 with a vendor to purchase certain inventory items, payable in quarterly installments of $62,500 through May 2020.

v3.4.0.3

Related Party Transactions	3 Months Ended
	Mar. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	11. Related Party Transactions All of the members of the Company’s Board of Directors participated in its public offering in February 2015, purchasing an aggregate of 142,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 142,000 shares of its common stock for total proceeds of $177,500. A member of the Company’s management is the controlling person of Aegea Biotechnologies, Inc., or Aegea. On September 2, 2012, the Company entered into an Assignment and Exclusive Cross-License Agreement, or the Cross-License Agreement, with Aegea. The Company received a payment of $19,047 during the three months ended March 31, 2016 from Aegea as reimbursement for shared patent costs under the Cross-License Agreement. Pursuant to a sublease agreement dated March 30, 2015, the Company subleased 9,849 square feet, plus free use of an additional area, of its San Diego facility to an entity affiliated with the Company’s non-executive Chairman for $12,804 per month, with a refundable security deposit of $12,804 due from the subtenant. The initial term of the sublease expired on July 31, 2015, and is subject to renewal on a month-to-month basis thereafter. A total of $38,412 in rental income was recorded to other income/(expense) in the Company’s statement of operations and comprehensive loss during the three months ended March 31, 2016. Three members of the Company’s Board of Directors participated in its public offering in May 2016, purchasing an aggregate of 175,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 122,500 shares of its common stock for total proceeds to the Company of $175,000 (see Note 12). The Company believes that these transactions were on terms at least as favorable to the Company as could have been obtained from unrelated third parties.

v3.4.0.3

Subsequent Events	3 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events In May 2015, the SEC declared effective a shelf registration statement filed by the Company. The shelf registration statement allows the Company to issue any combination of its common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as the Company’s public float is less than $75 million. As of March 31, 2016, the Company had not sold any securities under this shelf registration statement. Pursuant to an exclusive placement agent agreement dated April 25, 2016 between the Company and H.C. Wainwright & Co., LLC, or Wainwright, and a securities purchase agreement dated April 29, 2016 between the Company and the purchasers signatory thereto, a public offering of 4,986,573 shares of the Company’s common stock and warrants to purchase up to an aggregate of 3,490,601 shares of common stock was effected under this registration statement at a combined offering price of $1.00. Three members of the Company’s Board of Directors participated in this offering, purchasing an aggregate 175,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 122,500 shares of its common stock for a total purchase price of $175,000. All warrants sold in this offering have a per share exercise price of $1.30, are exercisable immediately and expire five years from the date of issuance. The closing of the sale of these securities to the purchasers occurred on May 4, 2016, pursuant to which the Company received, after deducting the placement agent’s fees and non-accountable expense reimbursements paid to Wainwright, as well as advisory service fees paid to ROTH Capital Partners, LLC and certain other transactional fees paid to third parties, approximately $4.6 million of net cash proceeds. The total increase in capital as a result of the sale of these shares and warrants was approximately $4.4 million after deducting an estimated $0.2 million of additional third party costs incurred in connection with this offering. The aggregate balance of approximately $0.6 million related to placement agent’s fees, advisory service expenses and non-placement agent costs associated with this offering was recorded to common stock issuance costs upon closing under applicable accounting guidance. The estimated aggregate grant date fair value of $1,997,667 associated with the warrants to purchase 3,490,601 shares of common stock was recorded as an offset to additional paid-in capital within common stock issuance costs, and was estimated using Black-Scholes valuation model with the following assumptions:   Stock price $ 0.90   Exercise price $ 1.30   Expected dividend yield   0.00 % Discount rate-bond equivalent yield   1.23 % Expected life (in years)   5.00   Expected volatility   90.0 % Subsequent to the closing of this public offering on May 4, 2016, no warrants sold in such offering have been exercised, with approximately $4.5 million in gross warrant proceeds remaining outstanding and available to be exercised at $1.30 per share until their expiration in May 2021. Following this offering, and subject to certain limitations for so long as the Company’s public float is less than $75 million, an aggregate initial offering price of up to approximately $39.2 million of the Company’s common stock, preferred stock, debt securities and warrants remains available to be sold under this shelf registration statement. In connection with its May 2016 public offering, the Company has agreed to certain contractual terms that limit its ability to issue, or enter into any agreement to issue, shares of its common stock or common stock equivalents for a period of 75 days, and limit its ability to issue variable rate securities for a period of one year. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings.

v3.4.0.3

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by U.S. Generally Accepted Accounting Principles, or GAAP, to be included in a full set of financial statements. The balance sheet at December 31, 2015 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2015, filed with the SEC with our Annual Report on Form 10-K on March 10, 2016 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. Certain prior period amounts have been reclassified to conform to the current period presentation. Additionally, a total of $290,709 of revenue-generating costs previously allocated to research and development expenses during the three months ended March 31, 2015 were reclassified to cost of revenues in the current period presentation of the unaudited condensed statement of operations and comprehensive loss.
The Company and Business Activities	The Company and Business Activities Biocept, Inc., or the Company, was founded in California in May 1997 and is an early stage cancer diagnostics company developing and commercializing proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample to improve the treatment that oncologists provide to their patients by providing better, more detailed information on the characteristics of their tumor. The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations. In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, and as subsequently updated and amended from time to time, the Financial Accounting Standards Board, or FASB, issued authoritative guidance that requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. This proposed guidance has been deferred and would be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In June 2014, the FASB issued authoritative guidance requiring share-based payments with a performance target which affects vesting and that could be achieved after the requisite service period be treated as a performance condition. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The Company adopted this guidance for the interim reporting period ended March 31, 2016. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures. In August 2014, the FASB issued authoritative guidance requiring management to evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Certain additional financial statement disclosures are required if such conditions or events are identified. This guidance is effective for the annual reporting period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In July 2015, the FASB issued authoritative guidance requiring entities that do not measure inventory using the retail inventory method or on a last-in, first-out basis to record inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This guidance is effective on a prospective basis for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures. In January 2016, the FASB issued authoritative guidance requiring, among other things, that certain equity investments be measured at fair value with changes in fair value recognized in net income, that financial assets and financial liabilities be presented separately by measurement category and form of financial asset on the balance sheet or the accompanying notes to the financial statements, that the prior requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet be eliminated, and that a reporting organization is to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the organization has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption of the instrument-specific credit risk amendment is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures. In February 2016, the FASB issued authoritative guidance requiring, among other things, that entities recognize the assets and liabilities arising from leases on the balance sheet under revised criteria, while the classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria in the previous leases guidance. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance clarifying that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument does not necessarily require dedesignation of that hedging relationship, provided that all other applicable hedge accounting criteria continue to be met. This guidance is effective on either a prospective basis or modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance requiring entities to assess whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts, and clarifies what steps are required when assessing whether the economic characteristics and risks of call (put) options are clearly and closely related to the economic characteristics and risks of their debt hosts. This guidance is effective on a modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance simplifying the accounting for stock compensation. This guidance, among other things, amends existing accounting and classification requirements primarily around income taxes, forfeitures, and cash payments associated with share-based payment awards to employees. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.
Fair Value Measurement	The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company believes the carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate their estimated fair values due to the short-term maturities of these financial instruments.

v3.4.0.3

Balance Sheet Details (Tables)	3 Months Ended
	Mar. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Fixed Assets and Accrued Liabilities	The following provides certain balance sheet details:     December 31,     March 31,     2015     2016   Fixed Assets     Machinery and equipment $ 2,518,158     $ 2,540,587   Furniture and office equipment   143,726       143,726   Computer equipment and software   577,898       602,097   Leasehold improvements   514,614       514,614   Financed equipment   914,179       976,599   Construction in process   70,815       12,738       4,739,390       4,790,361   Less accumulated depreciation and amortization   3,793,210       3,870,562   Total fixed assets, net $ 946,180     $ 919,799   Accrued Liabilities               Accrued interest $ 28,981     $ 26,429   Accrued payroll   128,753       235,685   Accrued vacation   307,845       322,974   Accrued bonuses   376,100       471,035   Accrued sales commissions   76,574       73,010   Current portion of deferred rent   31,170       40,938   Accrued other   17,476       12,790   Total accrued liabilities $ 966,899     $ 1,182,861

v3.4.0.3

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Option Activity for Option Awards Granted	A summary of stock option activity for option awards granted under the 2013 Plan and 2007 Plan for the three months ended March 31, 2016 is as follows:                     Average             Weighted     Remaining     Number of     Average Exercise     Contractual     Shares     Price Per Share     Term in Years   Vested and unvested expected to vest, December 31, 2015   1,940,701     $ 5.16       9.0   Outstanding at December 31, 2015   2,141,141     $ 3.71     9.1   Granted   264,000     $ 1.34           Exercised   —                   Cancelled/forfeited/expired   (140,742 )   $ 2.56           Outstanding at March 31, 2016   2,264,399     $ 3.51       8.9   Vested and unvested expected to vest, March 31, 2016   2,136,107     $ 3.60       8.8
Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model	The fair values of option awards granted during the three months ended March 31, 2016 were estimated using a Black-Scholes pricing model with the following assumptions:   Stock and exercise prices $ 1.34   Expected dividend yield   0.00 % Discount rate-bond equivalent yield 1.24% – 1.39%   Expected life (in years) 5.42 – 6.08   Expected volatility   90.0 %
Schedule of Performance Stock Options Vesting Percentage	Vesting of these stock options may occur based on the Company’s achievement of specified objectives by December 31, 2016 as determined by the Company’s Board of Directors, or a committee of the Company’s Board of Directors, in its sole discretion, as follows:     Percentage of     Overall Stock     Option Grants     Subject to Vesting   Target       Minimum number of accessions processed, billed and collected   13 % Minimum revenues from contracts with pharmaceutical    companies   10 % Attainment of a sustainable positive GAAP gross  margin   12 % Minimum operating cash on-hand with no more than one interim    dilutive equity financing event   15 % Achievement of the Company's 2016 corporate goals   25 % Completion of a Board-approved strategic transaction   25 % Total   100 % Vesting of these RSUs was based on the Company’s achievement of specified objectives by December 31, 2015 as determined by the Company’s Board of Directors or the Compensation Committee of the Board of Directors, as follows:     Percentage of     Overall RSU     Grant Subject to     Vesting   Target       Minimum revenue   25 % Maximum EBITDA loss   15 % Attainment of financial plan for fiscal 2015   20 % Minimum value of strategic agreements   20 % Implementation of four new diagnostic test panels   20 % Total   100 %
Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss	The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statement of operations and comprehensive loss during the periods presented:     For the three months ended     March 31,     2015     2016   Stock Options               Cost of revenues $ 16,136     $ 26,075   Research and development expenses   20,420       33,003   General and administrative expenses   219,061       272,569   Sales and marketing expenses   31,012       37,343   Total expenses related to stock options   286,629       368,990   RSUs               Research and development expenses   7,500       —   General and administrative expenses   39,936       —   Total stock-based compensation $ 334,065     $ 368,990

v3.4.0.3

Common Stock Warrants Outstanding (Tables)	3 Months Ended
	Mar. 31, 2016
Equity Classified Warrants [Abstract]
Summary of Equity-Classified Common Stock Warrant Activity	A summary of equity-classified common stock warrant activity for the three months ended March 31, 2016 is as follows:                     Average             Weighted     Remaining     Number of     Average Exercise     Contractual     Shares     Price Per Share     Term in Years   Outstanding at December 31, 2015   2,352,738     $ 3.73       3.8   Issued   —                   Exercised   —                   Expired   (152,712 )   $ 10.00           Outstanding at March 31, 2016   2,200,026     $ 3.29       3.8

v3.4.0.3

Net Loss per Common Share (Tables)	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares	The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive:       For the three months ended     March 31,     2015     2016   Preferred warrants outstanding (number of common stock      equivalents)   1,587       1,587   Preferred share RSUs (number of common stock equivalents)   73,151       —   Common warrants outstanding   3,160,738       2,200,026   Common share RSUs   178,467       32,769   Common options outstanding   916,239       2,264,399   Total anti-dilutive common share equivalents   4,330,182       4,498,781

v3.4.0.3

Subsequent Events (Tables)	3 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
Assumptions Used for Determining Fair Values of Common Stock Warrants	The estimated aggregate grant date fair value of $1,997,667 associated with the warrants to purchase 3,490,601 shares of common stock was recorded as an offset to additional paid-in capital within common stock issuance costs, and was estimated using Black-Scholes valuation model with the following assumptions:   Stock price $ 0.90   Exercise price $ 1.30   Expected dividend yield   0.00 % Discount rate-bond equivalent yield   1.23 % Expected life (in years)   5.00   Expected volatility   90.0 %

v3.4.0.3

Basis of Presentation - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015 USD ($)
Accounting Policies [Abstract]
Reclassification of revenue generation cost from research and development to cost of revenue	$ 290,709

v3.4.0.3

Liquidity and Going Concern Uncertainty- Additional Information (Detail) - USD ($)			1 Months Ended	3 Months Ended		12 Months Ended
	May. 04, 2016	Feb. 13, 2015	Feb. 29, 2016	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 21, 2015	May. 31, 2015	Dec. 31, 2014
Liquidity And Managements Plans [Line Items]
Cash and cash equivalents				$ 4,572,750	$ 19,294,706	$ 8,821,329			$ 5,364,582
Accumulated deficit				(160,111,746)		(155,236,548)
Net loss				(4,875,198)	(3,800,728)	$ (16,900,000)
Other non-interest bearing liabilities				$ 2,500,000
Unconditional purchase commitment aggregate amount			$ 1,062,500
Unconditional purchase commitment, quarterly payment amount			$ 62,500
Unconditional purchase commitment payment terms				Quarterly
Unconditional purchase commitment period				through May 2020
Proceeds from exercise of common stock warrants		$ 9,800,000			8,482,108
Proceeds from gross exercise of common stock warrants outstanding		$ 2,700,000
Exercisable warrant available price per share		$ 1.56
Exercisable warrant available price per share expiration period		2020-02
Net proceeds from issuance of common stock		$ 177,500		$ 324,242	$ 8,833,558
Shelf Registration Statement [Member]
Liquidity And Managements Plans [Line Items]
Minimum public float limit for offering								$ 75,000,000
Shelf Registration Statement [Member] | Subsequent Event [Member]
Liquidity And Managements Plans [Line Items]
Proceeds from exercise of common stock warrants	$ 0
Proceeds from gross exercise of common stock warrants outstanding	$ 4,500,000
Exercisable warrant available price per share	$ 1.30
Exercisable warrant available price per share expiration period	2021-05
Minimum public float limit for offering	$ 75,000,000
Net proceeds from issuance of common stock	$ 4,400,000
Period of limitation to issue common shares	75 days
Period of limitation to issue variable rate securities	1 year
Maximum [Member] | Shelf Registration Statement [Member]
Liquidity And Managements Plans [Line Items]
Aggregate offering price								$ 50,000,000
Maximum [Member] | Shelf Registration Statement [Member] | Subsequent Event [Member]
Liquidity And Managements Plans [Line Items]
Aggregate offering price	$ 39,200,000
Aspire Capital Fund, LLC [Member] | Common Stock Purchase Agreement [Member]
Liquidity And Managements Plans [Line Items]
Additional paid in capital available to be issued							$ 13,600,000
Additional paid in capital available to be issued, shares							2,684,122
April 2014 Credit Facility [Member]
Liquidity And Managements Plans [Line Items]
Aggregate gross interest-bearing indebtedness				5,000,000
Due within one year				$ 2,100,000

v3.4.0.3

Sales of Equity Securities - Additional Information (Detail) - USD ($)						1 Months Ended	3 Months Ended		12 Months Ended
	May. 13, 2016	May. 04, 2016	Dec. 21, 2015	Feb. 13, 2015	Feb. 09, 2015	May. 31, 2016	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	May. 31, 2015
Class Of Stock [Line Items]
Issuance of warrants to purchase shares of common stock				1,200,000
Stock price							$ 0.90
Purchase of common stock by underwriters to cover overallotments, grant date fair value				$ 7,700,000			$ 7,690,395
Proceeds from issuance of common stock				$ 177,500			324,242	$ 8,833,558
Exercise price of warrants				$ 1.56
Net cash proceeds from issue of initial public offering after deducting underwriting discounts and additional costs				$ 9,100,000
Increase in capital shares value					$ 8,800,000		$ 1,300,000
Additional costs incurred prior to, and associated with IPO, beginning of period				$ 300,000
Overallotment issued to underwriter to purchase common stock, period					45 days		45 days
Purchase of common stock by underwriters to cover overallotments, number of shares				1,200,000
Purchase of common stock by underwriters to cover overallotments, per share				$ 1.25
Common stock, par value				$ 0.0001			$ 0.0001		$ 0.0001
Issuance of warrants to purchase shares of common stock, grant date fair value				$ 1,627,396			$ 1,627,396
Underwriter cost				200,000
Underwriting discounts				700,000
Non-underwriter costs				300,000
Proceeds from exercise of common stock warrants				9,800,000				$ 8,482,108
Aggregate increase in capital from public offerings				18,600,000
Underwriting cost and discount				$ 900,000
Common stock, shares issued			165,000				19,983,402		19,670,054
Common stock issuance costs							$ 79,000		$ 42,000
Common Stock Purchase Agreement [Member]
Class Of Stock [Line Items]
Proceeds from issuance of common stock							$ 403,000
Aggregate common stock shares purchase							300,000
Aspire Capital Fund, LLC [Member]
Class Of Stock [Line Items]
Maximum number of shares of common stock to be purchase per business day			100,000
Aggregate amount of common stock			$ 15,000,000
Consecutive trading days threshold			10 days
Common stock shares trading volume percentage			30.00%
Percentage of volume weighted average price			97.00%
Subsequent Event [Member]
Class Of Stock [Line Items]
Issuance of warrants to purchase shares of common stock		3,490,601
Purchase of common stock by underwriters to cover overallotments, grant date fair value		$ 1,997,667
Exercise price of warrants		$ 1.30
Aggregate amount of common stock	$ 13,600,000
Common stock remains available to be issued	2,684,122
Common Stock [Member] | Aspire Capital Fund, LLC [Member]
Class Of Stock [Line Items]
Public offering, number of shares issued			625,000
Stock price			$ 1.60
Proceeds from issuance of common stock			$ 1,000,000
Increase in capital shares value			$ 15,000,000
Overallotment issued to underwriter to purchase common stock, period			30 months
Minimum [Member] | Aspire Capital Fund, LLC [Member]
Class Of Stock [Line Items]
Stock price			$ 0.50
Sale of common stock, closing price per share			$ 0.50
Shelf Registration Statement [Member]
Class Of Stock [Line Items]
Minimum public float limit for offering										$ 75,000,000
Shelf Registration Statement [Member] | Subsequent Event [Member]
Class Of Stock [Line Items]
Public offering, number of shares issued		4,986,573
Issuance of warrants to purchase shares of common stock		3,490,601
Stock price		$ 1.00
Proceeds from issuance of common stock		$ 4,400,000
Exercise price of warrants		$ 1.30
Net cash proceeds from issue of initial public offering after deducting underwriting discounts and additional costs		$ 4,600,000
Increase in capital shares value		4,400,000
Issuance of warrants to purchase shares of common stock, grant date fair value		1,997,667
Proceeds from exercise of common stock warrants		0
Minimum public float limit for offering		$ 75,000,000
Period of limitation to issue common shares		75 days
Period of limitation to issue variable rate securities		1 year
Common stock issuance costs		$ 600,000
Shelf Registration Statement [Member] | Maximum [Member]
Class Of Stock [Line Items]
Aggregate offering price										$ 50,000,000
Shelf Registration Statement [Member] | Maximum [Member] | Subsequent Event [Member]
Class Of Stock [Line Items]
Aggregate offering price		$ 39,200,000
Scenario Forecast [Member] | Shelf Registration Statement [Member]
Class Of Stock [Line Items]
Minimum public float limit for offering						$ 75,000,000
Proceeds from sale of common stock and warrants to purchase common stock						$ 4,400,000
Period of limitation to issue common shares						75 days
Period of limitation to issue variable rate securities						1 year
Scenario Forecast [Member] | Shelf Registration Statement [Member] | Maximum [Member]
Class Of Stock [Line Items]
Aggregate offering price						$ 39,200,000
Aegis Capital Corp. and Feltl [Member]
Class Of Stock [Line Items]
Public offering, number of shares issued					8,000,000
Issuance of warrants to purchase shares of common stock				8,000,000
Stock price				$ 1.25
Director [Member]
Class Of Stock [Line Items]
Public offering, number of shares issued				142,000
Issuance of warrants to purchase shares of common stock				142,000
Director [Member] | Shelf Registration Statement [Member] | Subsequent Event [Member]
Class Of Stock [Line Items]
Public offering, number of shares issued		175,000
Issuance of warrants to purchase shares of common stock		122,500
Proceeds from issuance of common stock		$ 175,000

v3.4.0.3

Fair Value Measurement - Other Fair Value Measurements - Additional Information (Detail) - USD ($)			3 Months Ended
	May. 04, 2016	Feb. 13, 2015	Mar. 31, 2016
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Issuance of warrants to purchase shares of common stock		1,200,000
Purchase of common stock by underwriters to cover overallotments, grant date fair value		$ 7,700,000	$ 7,690,395
Aegis Capital Corp [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Issuance of warrants to purchase shares of common stock		8,000,000
Subsequent Event [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Issuance of warrants to purchase shares of common stock	3,490,601
Purchase of common stock by underwriters to cover overallotments, grant date fair value	$ 1,997,667
Subsequent Event [Member] | Aegis Capital Corp [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Issuance of warrants to purchase shares of common stock	3,490,601

v3.4.0.3

Balance Sheet Details - Schedule of Fixed Assets and Accrued Liabilities (Detail) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Fixed Assets
Machinery and equipment	$ 2,540,587	$ 2,518,158
Furniture and office equipment	143,726	143,726
Computer equipment and software	602,097	577,898
Leasehold improvements	514,614	514,614
Financed equipment	976,599	914,179
Construction in process	12,738	70,815
Total fixed assets, gross	4,790,361	4,739,390
Less accumulated depreciation and amortization	3,870,562	3,793,210
Total fixed assets, net	919,799	946,180
Accrued Liabilities
Accrued interest	26,429	28,981
Accrued payroll	235,685	128,753
Accrued vacation	322,974	307,845
Accrued bonuses	471,035	376,100
Accrued sales commissions	73,010	76,574
Current portion of deferred rent	40,938	31,170
Accrued other	12,790	17,476
Total accrued liabilities	$ 1,182,861	$ 966,899

v3.4.0.3

April 2014 Credit Facility - Additional Information (Detail) - USD ($)			3 Months Ended	12 Months Ended
	Feb. 13, 2015	Apr. 30, 2014	Mar. 31, 2016	Dec. 31, 2014	Dec. 31, 2015
Line of Credit Facility [Line Items]
Exercise price of warrants	$ 1.56
Warrant term			5 years
Issuance of warrants to purchase shares of common stock, grant date fair value	$ 1,627,396		$ 1,627,396
Oxford Finance LLC [Member] | Common Stock [Member]
Line of Credit Facility [Line Items]
Warrant issued to lender		52,966
Exercise price of warrants		$ 4.72
Warrant term		10 years
Oxford Finance LLC [Member] | Minimum [Member]
Line of Credit Facility [Line Items]
Debt Default limit amount		$ 250,000
Debt default final judgment amount		250,000
Oxford Finance LLC [Member] | First Term Loan [Member]
Line of Credit Facility [Line Items]
Net cash proceeds on term loan		4,898,000
Line Of Credit Facility Fees Amount Payable		$ 50,000
Line of Credit Facility, Interest Rate During Period		7.95%
Percentage of final interest payment due at maturity		5.50%
Issuance costs				$ 102,498
Net proceeds from credit facility				4,897,502
Issuance of warrants to purchase shares of common stock, grant date fair value				$ 233,107
Effective annual interest rate			11.50%		11.50%
Oxford Finance LLC [Member] | Scenario One
Line of Credit Facility [Line Items]
Line of Credit Facility, Interest Rate During Period		7.95%
Oxford Finance LLC [Member] | Scenario Two
Line of Credit Facility [Line Items]
Line of Credit Facility, Interest Rate During Period		7.71%
Oxford Finance LLC [Member] | Two Years [Member]
Line of Credit Facility [Line Items]
Term Loan prepayment fee percentage		1.00%

v3.4.0.3

Stock-based Compensation - Additional Information (Detail) - USD ($)				3 Months Ended
	Feb. 29, 2016	Aug. 31, 2015	Jun. 12, 2014	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total Shares Outstanding				2,264,399		2,141,141
Number of Shares, Granted				264,000
Unrecognized stock-based compensation expense, stock options				$ 2,476,000
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Estimated forfeitures rate				0.00%	0.00%
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Estimated forfeitures rate				4.00%	4.00%
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic value of options outstanding				$ 0
Intrinsic value of options vested and unvested expected to vest				0
Intrinsic value of options exercisable				$ 0
Option awards assumptions, method used				Black-Scholes pricing model
Weighted-average estimated fair value of options granted				$ 0.98
Unrecognized stock-based compensation expense, weighted-average recognition period				2 years 4 months 24 days
RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average estimated fair value of options granted			$ 5.35
Issuance of restricted stock units			44,496
Total stock options and RSUs authorized				31,148
Intrinsic value shares, RSUs outstanding				$ 42,272
Intrinsic value amount, RSUs vested				$ 42,272
Total Shares Outstanding				32,769
RSUs [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of vested shares issued				13,348
2013 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares authorized				647,263
Total stock options and RSUs authorized				3,068,865
Stock options and RSUs issued				2,297,168
Total Shares Outstanding				2,297,168
2013 Equity Incentive Plan [Member] | Stock Options [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average estimated fair value of options granted	$ 0.96	$ 1.47
Number of Shares, Granted	100,000	100,000

v3.4.0.3

Stock-based Compensation - Summary of Stock Option Activity for Option Awards Granted (Detail) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Shares, Vested and unvested expected to vest, Beginning Balance	1,940,701
Number of Shares Outstanding, Beginning Balance	2,141,141
Number of Shares, Granted	264,000
Number of Shares, Cancelled/forfeited/expired	(140,742)
Number of Shares Outstanding, Ending Balance	2,264,399	2,141,141
Number of Shares, Vested and unvested expected to vest, Ending Balance	2,136,107	1,940,701
Weighted Average Exercise Price Per Share, Vested and unvested expected to vest, Beginning Balance	$ 5.16
Weighted Average Exercise Price Per Share, Outstanding, Beginning Balance	3.71
Weighted Average Exercise Price Per Share, Granted	1.34
Weighted Average Exercise Price Per Share, Cancelled/forfeited/expired	2.56
Weighted Average Exercise Price Per Share, Outstanding, Ending Balance	3.51	$ 3.71
Weighted Average Exercise Price Per Share, Vested and unvested expected to vest, Ending Balance	$ 3.60	$ 5.16
Average Remaining Contractual Term in Years, Vested and unvested expected to vest	8 years 9 months 18 days	9 years
Average Remaining Contractual Term in Years, Outstanding	8 years 10 months 24 days	9 years 1 month 6 days

v3.4.0.3

Stock-based Compensation - Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model (Detail)	3 Months Ended
	Mar. 31, 2016 $ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and exercise prices	$ 1.34
Expected dividend yield	0.00%
Expected volatility	90.00%
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Discount rate-bond equivalent yield	1.24%
Expected life (in years)	5 years 5 months 1 day
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Discount rate-bond equivalent yield	1.39%
Expected life (in years)	6 years 29 days

v3.4.0.3

Stock-based Compensation - Schedule of Performance Stock Units Vesting Percentage (Detail)	3 Months Ended
	Mar. 31, 2016
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	100.00%
Stock Options [Member] | Minimum Number of Accessions Processed, Billed and Collected [Member] | 2013 Equity Incentive Plan [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	13.00%
Stock Options [Member] | Minimum Revenues from Contracts with Pharmaceutical Companies [Member] | 2013 Equity Incentive Plan [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	10.00%
Stock Options [Member] | Attainment of a Sustainable Positive GAAP Gross Margin [Member] | 2013 Equity Incentive Plan [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	12.00%
Stock Options [Member] | Minimum Operating Cash on-Hand with no More than One Interim Dilutive Equity Financing Event [Member] | 2013 Equity Incentive Plan [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	15.00%
Stock Options [Member] | Achievement of the Company's 2016 Corporate Goals [Member] | 2013 Equity Incentive Plan [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	25.00%
Stock Options [Member] | Completion of a Board-approved Strategic Transaction [Member] | 2013 Equity Incentive Plan [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	25.00%
RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	100.00%
RSUs [Member] | Minimum Revenue [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	25.00%
RSUs [Member] | Maximum EBITDA Loss [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	15.00%
RSUs [Member] | Attainment of Financial Plan for Fiscal 2015 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	20.00%
RSUs [Member] | Minimum Value of Strategic Agreements [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	20.00%
RSUs [Member] | Implementation of Four New Diagnostic Test Panels [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	20.00%

v3.4.0.3

Stock-based Compensation - Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	$ 368,990	$ 286,629
Stock Options [Member] | Cost of revenues [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	26,075	16,136
Stock Options [Member] | Research and Development Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	33,003	20,420
Stock Options [Member] | General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	272,569	219,061
Stock Options [Member] | Sales and Marketing Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	37,343	31,012
RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	$ 368,990	334,065
RSUs [Member] | Research and Development Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation		7,500
RSUs [Member] | General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation		$ 39,936

v3.4.0.3

Common Stock Warrants Outstanding - Summary of Equity-Classified Common Stock Warrant Activity (Detail) - Warrants [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Class Of Warrant Or Right [Line Items]
Number of Shares, Outstanding, Beginning Balance	2,352,738
Number of Shares, Expired	(152,712)
Number of Shares, Outstanding, Ending Balance	2,200,026	2,352,738
Weighted Average Exercise Price Per Share, Outstanding, Beginning Balance	$ 3.73
Weighted Average Exercise Price Per Share, Expired	10.00
Weighted Average Exercise Price Per Share, Outstanding, Ending Balance	$ 3.29	$ 3.73
Average Remaining Contractual Term (in years)	3 years 9 months 18 days	3 years 9 months 18 days

v3.4.0.3

Common Stock Warrants Outstanding - Additional Information (Detail) - USD ($)		3 Months Ended
	May. 04, 2016	Mar. 31, 2016	Feb. 13, 2015
Class Of Warrant Or Right [Line Items]
Common stock warrants exercisable, intrinsic value		$ 0
Common stock warrants outstanding, intrinsic value		$ 0
Issuance of warrants to purchase shares of common stock			1,200,000
Exercise price of warrants			$ 1.56
Warrants to purchase common stock, period		5 years
Subsequent Event [Member]
Class Of Warrant Or Right [Line Items]
Issuance of warrants to purchase shares of common stock	3,490,601
Exercise price of warrants	$ 1.30
Warrants to purchase common stock, period	5 years

v3.4.0.3

Net Loss per Common Share - Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares (Detail) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	4,498,781	4,330,182
Warrants Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	2,200,026	3,160,738
Preferred Warrants Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	1,587	1,587
Preferred Share RSUs [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents		73,151
Common Share RSUs [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	32,769	178,467
Common Options Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	2,264,399	916,239

v3.4.0.3

Commitments and Contingencies - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended
	Feb. 29, 2016	Mar. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Unconditional purchase commitment aggregate amount	$ 1,062,500
Unconditional purchase commitment, quarterly payment amount	$ 62,500
Unconditional purchase commitment payment terms		Quarterly
Unconditional purchase commitment period		through May 2020

v3.4.0.3

Related Party Transactions - Additional Information (Detail)				3 Months Ended
	May. 04, 2016 USD ($) Director shares	Feb. 13, 2015 USD ($) shares	Feb. 09, 2015 USD ($) shares	Mar. 31, 2016 USD ($) ft²	Mar. 31, 2015 USD ($)
Related Party Transaction [Line Items]
Issuance of warrants to purchase shares of common stock | shares		1,200,000
Proceeds from issuance of common stock		$ 177,500		$ 324,242	$ 8,833,558
Rental income				38,412
Subsequent Event [Member]
Related Party Transaction [Line Items]
Issuance of warrants to purchase shares of common stock | shares	3,490,601
Director [Member]
Related Party Transaction [Line Items]
Initial public offering, number of shares issued | shares			142,000
Issuance of warrants to purchase shares of common stock | shares			142,000
Proceeds from issuance of common stock			$ 177,500
Director [Member] | Subsequent Event [Member]
Related Party Transaction [Line Items]
Initial public offering, number of shares issued | shares	175,000
Issuance of warrants to purchase shares of common stock | shares	122,500
Proceeds from issuance of common stock	$ 175,000
Number of members of board of directors | Director	3
Aegea Biotechnologies, Inc [Member]
Related Party Transaction [Line Items]
Reimbursement for shared patent costs				$ 19,047
Nonexecutive [Member]
Related Party Transaction [Line Items]
Lease agreement date of commencement				Mar. 30, 2015
Leased facility, rent expense per month				$ 12,804
Lease facility, refundable security deposit amount				$ 12,804
Lease expiration date				Jul. 31, 2015
Nonexecutive [Member] | San Diego California Facility [Member]
Related Party Transaction [Line Items]
Leased facility, expansion of original premises | ft²				9,849

v3.4.0.3

Subsequent Events - Additional Information (Detail)				3 Months Ended		12 Months Ended
	May. 04, 2016 USD ($) Director $ / shares shares	Feb. 13, 2015 USD ($) $ / shares shares	Feb. 09, 2015 USD ($)	Mar. 31, 2016 USD ($) $ / shares	Mar. 31, 2015 USD ($)	Dec. 31, 2015 USD ($)	May. 31, 2015 USD ($)
Subsequent Event [Line Items]
Issuance of warrants to purchase shares of common stock | shares		1,200,000
Stock price | $ / shares				$ 0.90
Proceeds from issuance of common stock		$ 177,500		$ 324,242	$ 8,833,558
Exercise price of warrants | $ / shares		$ 1.56
Net cash proceeds from issue of initial public offering after deducting underwriting discounts and additional costs		$ 9,100,000
Increase in capital shares value			$ 8,800,000	1,300,000
Common stock issuance costs				79,000		$ 42,000
Issuance of warrants to purchase shares of common stock, grant date fair value		1,627,396		$ 1,627,396
Proceeds from exercise of common stock warrants		9,800,000			$ 8,482,108
Proceeds from gross exercise of common stock warrants outstanding		$ 2,700,000
Exercisable warrant available price per share | $ / shares		$ 1.56
Exercisable warrant available price per share expiration period		2020-02
Director [Member]
Subsequent Event [Line Items]
Public offering, number of shares issued | shares		142,000
Issuance of warrants to purchase shares of common stock | shares		142,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Issuance of warrants to purchase shares of common stock | shares	3,490,601
Exercise price of warrants | $ / shares	$ 1.30
Shelf Registration Statement [Member]
Subsequent Event [Line Items]
Minimum public float limit for offering							$ 75,000,000
Shelf Registration Statement [Member] | Maximum [Member]
Subsequent Event [Line Items]
Aggregate offering price							$ 50,000,000
Shelf Registration Statement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Minimum public float limit for offering	$ 75,000,000
Placement agent agreement, effective date	Apr. 25, 2016
Securities purchase agreement, effective date	Apr. 29, 2016
Public offering, number of shares issued | shares	4,986,573
Issuance of warrants to purchase shares of common stock | shares	3,490,601
Stock price | $ / shares	$ 1.00
Number of members of board of directors | Director	3
Proceeds from issuance of common stock	$ 4,400,000
Exercise price of warrants | $ / shares	$ 1.30
Net cash proceeds from issue of initial public offering after deducting underwriting discounts and additional costs	$ 4,600,000
Increase in capital shares value	4,400,000
Third party costs incurred in connection with offering	200,000
Common stock issuance costs	600,000
Issuance of warrants to purchase shares of common stock, grant date fair value	1,997,667
Proceeds from exercise of common stock warrants	0
Proceeds from gross exercise of common stock warrants outstanding	$ 4,500,000
Exercisable warrant available price per share | $ / shares	$ 1.30
Exercisable warrant available price per share expiration period	2021-05
Period of limitation to issue common shares	75 days
Period of limitation to issue variable rate securities	1 year
Shelf Registration Statement [Member] | Subsequent Event [Member] | Maximum [Member]
Subsequent Event [Line Items]
Aggregate offering price	$ 39,200,000
Shelf Registration Statement [Member] | Subsequent Event [Member] | Director [Member]
Subsequent Event [Line Items]
Public offering, number of shares issued | shares	175,000
Issuance of warrants to purchase shares of common stock | shares	122,500
Proceeds from issuance of common stock	$ 175,000

v3.4.0.3

Subsequent Events - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail)	3 Months Ended
	Mar. 31, 2016 $ / shares
Subsequent Events [Abstract]
Stock price	$ 0.90
Exercise price	$ 1.30
Expected dividend yield	0.00%
Discount rate-bond equivalent yield	1.23%
Expected life (in years)	5 years
Expected volatility	90.00%

begin 644 Financial_Report.xlsx
M4$L#!!0    ( %2#K4B9D_GWS $  -,:   3    6T-O;G1E;G1?5'EP97-=
M+GAM;,V9RT[#,!!%?Z7*%C6N[?(494/9 A+\@$FFC=4XMFRWE+_'3@%!51"O
M2G>31^]X[DW&.9N>WS\Y"H.U:;LP*9H8W1ECH6K(J%!:1UU29M8;%=.MGS.G
MJH6:$Q.CT1&K;!>IB\.8>Q07YS;"/7X4C?)4WT6?YKO[VWA?
ML+\<>:[]]6=#[\7 ^M,>(?&C' (DAP3),0;)<0B2XP@DQS%(CA.0'*<@.?@(
M)0@*43D*4CD*4SD*5#D*53D*5CD*5SD*6#D*604*604*604*604*604*604*
M604*604*604*604*624*624*624*624*624*624*624*624*624*624*6<[%    *P(   L   !?
M.0Q(OW[
MCMB PD.MQ-*O>X^NO ZIK XTHO8<4M?'5$Q^#*G*_=ITJK$"2+8CCVG!D4*>
M-BP>-9?20D0[8$NP+,L5R*V.V:SGVL7.U49V[M,41Y26M#;3"&>6X9MY6&3I
M//B)]!=C;IK>TI;MR5/0!_ZS#0//>997'L=V+YRO+0O]C^AY%.!)T:'B1?4C
M9@,2[2F]@OIZ (4QOCLEFI2"(S>C@KN_V/P"4$L#!!0    ( %2#K4AYY7JT
ML0$  !L:   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/%V< 94 *S=LU1MH8* $^I/.&/7NK2P,_LP7%R3?IDT[R9EWT3QI
MVD4;R_EC.%7IT+6Q/O1Q\M:0D(:PY6@O@6CA>"P!;
M.&(+(%LX9@M 6SAJ"V!;.&X+@%LX<@N@6SAV"\!;.'HKT%LY>BO06TGOVNAE
MFZ.W KV5H[<"O96CMP*]E:.W KV5H[<"O96CMP*]E:.W KV5H[X[>'NCM.7K["[UC70UA^Y2&0[N/UZ[Y-AP67> =T_LI7#_E/!4V
M7&B=QIV".Q^O_M25_?4[)\"@)+3IPWARG/ONQW??'1DJVQM,C<[1.($6
M7C.I[( N+SH+Y_)!$%B^P(S94S)1]#;5)F..'LU3H--4<+S6O,A0N2#L]_;84;.XKW\@2
MH9ZF3!@;#9=NL$3NM%FW:>D^VZ5$<]]T.Y]1?K8#C\RB/UYTELP(IEP'K/A#
MCV&G"EO=EF>96V>B!VV>[0+1V6&PO2R/N[:[9]&/^F%I0:=]RV!;6;2F;:]N
M?S,33J*=I%-FW'^BHJQI0T1_S415Z,8%,)7 6#F2(_Q452AJWBXEV]-(TUPH
MBPE<,:*
M65$:30U: C33="M>"I%X0CVWWS7) "@B1Z/@7O%:3$SC7GH?$Y:0ZQ5!NZ?6
M_(9D!7,F"X0[9+8P90T->>^P#]?HF)#U3B]S(R2$O;,^C&@]" #W$Q%Z3#I9IA64&'A@QC!/^:1PUA%)]9W]1?G>:FN!N@\;!WYS
M-480KFJEYYT8=\0\*MY$XF^4U/P$_$"N8$8I6<9]!?7F^C ?
MEPEI7M,?0U,BM2V"DQE[)%%\:47^&M6^!V'8K@=5H(\1=;R4>L:Z<)F0!(5N
M/V)A_0 WCU@9K,6O>;<&B504=<6$Q=9UCJ.
MM47K.$1#6\PX33\AZ:_U.CB.^=9R#,J"VB\DZ+9<24=T<#!NV]E13-9KM!9#
MS0>%M8\Z'$4]=_3^9U+0,NO2'U4-=^'[^NDU*X0E@/3]XZ\*@@7!UT;4(A
MW"+9(KJ"L2"VH'F8Q H3DVOK-<<8^@US7.SX!M@TR^9, W+)D;,C,'4],:E*
M*0KA@:/U'5Z*'N_VOB:8% QJT& PL'R2LZ1Z,3MC&U.R05^5T7'- RZM5&L%
M\K8=RGZG8F<$K\-)#K)O3U__]$ 9EG25AZ#ZJJ9I)LV,ZN+ .7M;/C[3OTF5
M"[\#<8UMT0
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M?+&A T%116F]?
M(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D
M3EJ(X53"Q,!J9S]6:\?1TDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*
MVG0T;1K@X_%X.+;+THMP' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3
M]WW?ZYMHG J-6T_3:W?=TXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H
M0D;CZWH2%;7E0-,@ %AP=M;,[email protected]=90:V1V[W4%<\%CN.8D1_L;%!-9I
MTAF6-$9RG9 %#@ WQ-%,4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]
M]9>[R:0S>IU].LYKE']IJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N
M(]>IP+,BUY1&)$6?R"VZY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3
M?;>^",C?C8CWJV^:/5>A6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SCFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0
MKH)[ ?_1VC?"J_B"P#E_+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO J
MQ GH9%LE"0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-
M"S-#MW)+ZK:4OK4F.$KTL@'37[]EUVY".E,%.70[@:
M0KX#;;J=W#HXGIB1N0K34I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\
MEAW'B/*B(>ZAAIC/PT.'>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#
MKU$"\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@3
M9ZO*WF6QP54=SU5;\K"^:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?!8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!
M=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_
M6-8>^3+?.7#;.MX#7N83+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND
M]MW@#'S4JUJE9"L1/TL'?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?
MAT6:&C/5BZPYC0IO0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.
MX>V+OP%02P,$%     @ 5(.M2&L4^I=' @  ? H   T   !X;"]S='EL97,N
M>&ULS59;:]LP%/XK0AFCA1';"4WI:AM&(3#8RJ!YZ%N1;=D6Z.+)&VNM+%(>YX&.E%M !<5@_@RVBVC\P[JF@0@*ECT)KL A'##N/
M.T1)(HD!<\0([1R\,( ]O=Z/$2ZDS>TR'.:9^V,F6201]/OG]'3)R&X'LSU"
MZ?[V-!"'%5(*2[[6$]#;FZ[2F^."8R?2^KW@74C4!8NK28 ==-Y$R S+(7, 
M=U <4IPK'2!)49I1BXI[=MX09L/"70TJBK:?:*DX P[L0Y:BW[V
M$GUPA#X.T8X5E$*29^UO+D*J 2PAV&*I2#I%?DA4;7"K^AOLM?DQA6_=\M_4
M].>K-JK15_!?E^>_)I^>C7T-X8&>$X[BOF$)EFO[;7Z]L.7UN2HSK>ULI:W.
M5]K9'NCRYC>5>7UCF'2?O=XSH"!I"%6$[R0@\[=P;V33O;8P]AW-F;5CR[&K
M"B7Z5W OBR;+<(X:JKZ1K5!V,8*C_<7(#U:#UV:@B.!H?\49:=B-53#^;\8_
M 5!+ P04    " !4@ZU(1>MT0A $  !>#@  #P   'AL+W=ON]FCL? ]B,^'D]'%I3PTFBWEJU+GFGN)3376A"56P/X
M1@VP1DB=?'CO9K54< ?6(9B)MOTB&I@G3RIA2CB_K*2':I[D>&L>8>N![=JS
M3JIP,QE/DE& ;;IZ8UEI*AA@MVOIOCW_D; *:M$I?XO!;KX[3U*>V%*DIKE.I;A3_Z1O@%]^<)QNAEN?6B%ZNO(1/S
M9#I&X(-T@'53L3"BA2V!]7QPA<$+@+R>P-S?" @TE
M(Z#L&*CPF)K0/<=,S:Y;L-@K LH)*'\Y:"'[H,*
MH:"/8XE Q!50=E9Z"33?[PCCW3[C0DC+[H3J@'T&X3K;CPLU;DR5&\=&@WC"
MSL$+J6@ Z9:S$6D_ME8JQL=ISA86<A2C[J40IU-LT(F[A37E_LA(AOPO3
M8/US>Y.'*IM&G6T:K( ]BGT3UHJ@R'7GG<=446=3*FT:L?8+7ET9YQCJSC;<
M-4XA"J'"IE%CFT;Z0=3@"EKBT1;0Y7:.4RIL&C'V:U@U<&!P#J,GM]@O%^HH
M+B.40KU-(^(6WHK1(<[email protected]%$6-YA&C]U(6
M'28J,X_(',_="?M8X6R5AJ*HTCRB]-'BQVD1YE1J'I'ZLXCGA\NC+L=S*CHV6M$'Y)(453T
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M965T&ULC95=CZ,@%(;_BO$'C()?M;$F;3>3V8M-)G.Q>TU;
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M P  41$  !@   !X;"]W;W)K%+756TG^N+._M?#G53%9V_;=ZR]M*X
M8C\$566&C*FL*D[G]78S//O:;#?U>U>>SNYKLVK?JZIH_MNYLKX^KV$]/_AV
M>CMV_8-LN\EN_!E>ZUZU,4_NO#Y:XL^TR^Y7^GI#_;[ /I]9S]]Z&[WOY+T;J\+O\Y
M[;NC=\O6J[T[%.]E]ZV^_N&F/L@^X6M=ML/GZO6][>IJ#EFOJN+'^'TZ#]_7
M\1?#IK!T $X!> L \#['BS&>TW@=6M1C)T;)>9 (J5%+EM+E5&<, D?[V(^(_ CJQX3MJ-&/H'ZX
M0$BI>Y&1%TF]V*0725M1RDJ=-!/(A$4-C]VHR(TB;CA+NE%T!K2V
MC"?=J&  I>7FL1L=N='437(&=IHT(XT"EM;E5&>58'J)'Q/Y,=0/)OT8V@Y8
M;9-3F@H&GF+1 42O2J(6 H9K;>\44Z"278H$C9)$CI*05R96TFS3SG@K]
MJSKI*-1I!AH7.(K)C93<(H+-M,E#2F2_Q_,G%D@)\T#HEX  PQ=XBMF-E-TB
M8K>8/ 4:G=+D]S3WG=R0/>^@*;+%@I6*,6.1,E;8]/@&[+36I ND92XS>O'!8<-#!F+%+&RC3/D*+S$R@& #JNCME8
MJ)72OR'EHOF+28N4M#+--:0$_23\,-S9S09"_\[VP[7D6!>S%BEK)4_7%$5H
M<@\YEQ45WME$9N3P>RG>W%]%\W8ZMZN7NO/GZ.'0>ZCKSOE\[+.OB:,K]K>;
MTAVZ_E+[ZV8\\8\W77V9_\"X_8NR_1]02P,$%     @ 5(.M2(H&6@OA 0  
M: 4  !@   !X;"]W;W)K)<-
M(0I\,MK)?= HU>\@E,>&,"Q7O">=?E)SP;#22W&"LA<$5];$*(P0RB##;1<4
MN=U[%47.SXJV'7D50)X9P^+/,Z%\V =A,&V\M:=&F0U8Y'#V52TCG6QY!P2I
M]\%3N"LSH[""7RT9I#<'AOW ^;M9_*CV 3((A)*C,@E8#Q=2$DI-D"[\,6;^
M*VF,_GQ*?['=:OH#EJ3D]'=;J4;#H@!4I,9GJM[X\)V,+:0F\,BIM-_@>):*
ML\D2 (8_W=AV=AS%.RX4)T(&]>$DW16@E8(H7!)5CZ0W:5);F@2GV9]729S
M-(E7)D'NLR0L'PKO$J4W1*E/M%DD2KU"X7:[B1,4+1)="[,U0MYK#_=:_/E6OP%4$L#!!0    ( %2#K4CK-"7,>0,  $H.   8
M    >&PO=V]R:W-H965T&ULG9=;CYL\$(;_"N*^BT_XL,I&
MVE!5[46EJA?M-9LX"2K@?$ V[;^O.20[MKR-]=T$<-Z9><:8%[RZF.Y7?]1Z
M2'XW==L_I<=A.#UF6;\]ZJ;L'\Q)M_:?O>F:4IQ>AWX7AV.PSB0K5?9+6Y7
M-;KM*],FG=X_I<_XL2!LE$R*'Y6^]. \&>%?C/DU7GS9/:5H9-"UW@YCBM(>
M7G6AZWK,9"O_MR1]JSD&PO-K]D]3NQ;_I>QU8>J?U6XX6EJ4)CN]+\_U\-U<
M/NNEAWQ,N#5U/_TFVW,_F.8:DB9-^7L^5NUTO,S_2+2$A0/($D!N ;OFZ;*=]7;T=ZR2$-NQ_/O6XXC,]=3#YWPR$F
M$TPH%-(5CLX*N8SH1W@\ O+P((\ =0212 1E!93Q'#."[M-(CT9"&A&DD<[L
M2$$("^(X.J((8NH^C_)X%.2101X%ZU#$I%)!'J@32+&\-*%AH
MLVCF2DPIIF28R!%2:5\@2$0P89\).I (+M7-HIE+?6!"4$["B]I54IY;JCR"
MBGC/*8:V)2)L"U._+VA<@H3[HI 64\G8.VVY0J:PBEB.V/="#,U0T# 3AR^L22V^2
M1WSO(]#[9-C["(ZFPO^/RO<^ KU/QGP4^MY'Z#]F6RU].9:&'D@>DA6^C,9T
MY/L>8?^8YRL/B^-A=W@R\(G>Z.XP;5WZ9&O.[3!_/]]&;]NC9S)^XGOC&[MM
MFCC^,I\*>
M=_-69[X8S.FZ<[MM']=_ 5!+ P04    " !4@ZU(F@IZAU\$  !_$P  &   
M 'AL+W=O[8G]\U+VS75X&Z[U[P_=[;:3T%-G0-C
M1=Y4Q]-JLYZ>?>LVZ_9MJ(\G^ZW+^K>FJ;I_MK9N+X\KOKH^^'Y\/0SC@WRS
MSF]Q^V-C3_VQ/66=?7ELOY^>OF\TK//WL9U% I-D2R7\ILA=X]$,L/+#@81'$Y14421DP&N&^?8)
M:0WX>;RXQHLY7M!XX5M4FIM%0)7C@+
MAMR(O)L;D]"WG ?E< H*B/?NHEE>M0'@T8)\F60LQ0^$?BA73#31=M'64
MDUQ*$1W]I2=SQC'%3\A33H%J,.['(ZHJN(C[\8BJ5<+:RT.D)K%$CO7:& .^_4TW$WS1+P B'N
MH/ LQ7D'A9>*%VYO&/?D"PO%$Q9.")$'RO,49QYXS$/M+*F$7"'/0'NYXD #
M#U/ W*N+\\P3"3R#<*L(QG,57ZF![@._N'GBMH)W7@M5NI&"C$."
M+0PAB L<[@\432G1;#9TP6C#D)'H_6%DE4*<4%;(2/5;RH >7
MW\Y(6>DV1U%5Z:N*_VR-U?1G&
M2^6NN_E\:+X9VO/UN.MVYK;Y%U!+ P04    " !4@ZU(@=EHCJ\"  !V"0  
M&    'AL+W=OS8/CYR?9E'$MD?28?9$3Z07=_9TZ# 7E\,A8J>!X)T*ZMH(QG$6=;CI
MP[I28R]#7=$S;YN>O P!.W<='OXN2$NO\Q"$MX'7YG#D7YS_Z;*%>EO,"-+VOYN=OPHLHW#8$?V^-SR5WK]3L8:4FFX
MI2U3_\'VS#CM;B%AT.%W?6QZ=;SJ.T4\AOD#X!@ IX")XP](QH#D'H ^#4!C
M +H'9)\&I&- ZA B7;N:N17FN*X&>@W8"-&!H(Z!A 'V(I:G(_%E8)JE/LH96
MHLGC1)-;HDC/5V(9(!NB-0M;DSZ&( >"+(/,AN0:HC6]TN19&2?E%T"I THM
M4.ZMQM84CR&9 \DL@]*&9!J2&=4 T@T#LD&3C-5#0.\.C
M2+.RQ&PJ'Y. 2[(Z"DQ\12U'T5A5CO(O-!X 79+5$B#RUP0-$DH0RK_PL0&W
M=P"S,93^SWK4C#4599+[2[=D$,:I3[:R9!E*XM@G6]MN98KU
MG+-@2\\]USUR&IVV#,]0+DK.^ +,EL SOI);#+6(W>WKZH0/Y"<>#DW/@@WE
M8BE4Z]:>4DY$WO&3F.BCV 1-%RW9@MP7Z@M/3;96CG-"\V![ D3U#Y_OC-B BX+> R5[$)'@_(;Z$Y&=SH%FP !)J%Q2X
M7\[P %(&(=_X==9\;QF(E_&B_ABG]>Y/W,(#RC^B<;TWFU'20,M'Z9YQ^@'S
M"+L@6*.T\4OJT3I4"X42Q=_2*G1PTT0\J[S8E>P?5/6Q3T
MFEY+5L:3&
M4;NTI6MUO9WW13R3=WA5#KR#7]QT0EMR0N=/-AY#B^C F\AN=I3T_OVLB836
MA?#.QR9=J90X')8'LK[2ZA]02P,$%     @ 5(.M2 3=@:6B 0  L0,  !@ 
M  !X;"]W;W)K_#B!QVM,-70I/HNM=*+"J9"NO$0JT%:B)@79/[S:[0Q$0$? L
M8+)G,0G>CX@O(?G=[&D6+("$V@4%[I<3W(.40<@W_CMK?K0,Q/-X4?\9I_7N
MC]S"/.7U*-UJ!8*)8J_IE7HN$[I
M3Y'-M,\)^4S(5\)M)+#4*-K\P1VO2H,3L0,/9[?9>;@)(EZ9V*AFTO3>J/75
M4[7);TMV"D(S)E$.%Y@5P;SZIRUR>DG/S^CYU_3M0M\FA]L+AS=?"Q2+0)$$
MBO^-F#"'2\SW?YJPLSU58+IX=2RI<=0N;>E:76_G71[/Y ->E0/OX(&;3FA+
MCNC\R<9C:!$=>!/9U34EO7\_:R*A=2'\YF.3KE1*' [+ UE?:?4.4$L#!!0 
M   ( %2#K4C "/W$H0$  +$#   8    >&PO=V]R:W-H965T&ULC5/;3N,P$/T5RQ^ T[0LJRJ-1$&KW0#3$#DIQ\[$'B>..KNA<>!)MYT*!
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M>&PO=V]R:W-H965TVFV=$ ;R-)299GV2>FN-"TKF+MT=053DX*
M#8^&V$DI;OZ>0.)\I#NZ%IY$/[A08'7%-EXK%&@K4!,#W9'>[PZG,B BX)> 
MV5[%)'@_(SZ'Y$=[I%FP !(:%Q2X7R[P %(&(=_XSZ+YVC(0K^-5_5N;$9)"QV?I'O"^3LL(^R#8(/2QB]I)NM0K11*%'])J]!QG=.?
MHEQH[Q/RA9!OA"]9-)X:19M?N>-U97 F=N3A['8'#S=!Q"L3&]5,FMX;M;YZ
MJ7=%4;%+$%HPB7*ZP6P(YM7?;9'36WI^1<\_IA":O\+H:>0\_N>F%MN2,
MSI]L/(8.T8$WD=WM*1G\^]D2"9T+X67)+0(
M+2_QS.2<,V=\*48TK[8#<.1-26WWM'.NWS%FJPX4MU?8@_9_&C2*.Y^:EMG>
M *\C24F69]D-4UQH6A:Q]F3* @<7R :83K
M(%BAM/%+JL$Z5#.%$L7?TBIT7,?T9_MCHGU-R"="OA!NLV@\-8HV?W+'R\+@
M2&S/P]FM=AYN@HA7)C:JF32]-VI]]52NUC<%.P6A"9,HAPO,@F!>_J:OD\/UA8VT]-V-F>*C!MO#J65#AH
ME[9TJ2ZW\RZ/9_(!+XN>M_";FU9H2X[H_,G&8V@0'7@3V=4U)9U_/TLBH7$A
MW/K8I"N5$H?]_$"65UJ^ U!+ P04    " !4@ZU(27,*G*,!  "Q P  &0  
M 'AL+W=O1I"3+L^P34UQH6I6Q]FBJ$D'4Q$0$?!+
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M    " !4@ZU(O)D[6:$!  "Q P  &0   'AL+W=O&<,V=\*21->[
M4&!5R59>(Q1H*U 3 ^V>WFUVAR(@(N!9P&3/8A*\'Q%?0_*[V=,L6  )M0L*
MW"\GN F\TH::#EHW1/./V"
M>83K(%BCM/%+ZM$Z5 N%$L7?TRIT7*?TYR:?:5\3\IF0KX3;+!I/C:+-!^YX
M51JG]'S[^G;A;Y-#K<7#K??"Q2+0)$$BO^-F#"'2TSQ3Q-VMJ<*3!>OCB4U
MCMJE+5VKZ^V\BX?(/N%5.? ._G#3"6W)$9T_V7@,+:(#;R*[NJ:D]^]G322T
M+H0W/C;I2J7$X; \D/655A]02P,$%     @ 5(.M2/2C*9"B 0  L0,  !D 
M  !X;"]W;W)K&ULA5/+;MLP$/P5@A\0RK*<%(8L
M($X1M(<"00[MF996$A&2JY"4E?Y]^9 4.PB:B[B[FIF=Y:.N6'/F*U[4-S>X #:_VG1*.Y\:CIF!P.\B20E69YEMTQQH6E5QMJ3J4H<
MG10:G@RQHU+<_#V"Q.E -W0I/(NN=Z' JI*MO$8HT%:@)@;: [W?[(]%0$3 
M;P&3O8A)\'Y"? G)S^9 LV !)-0N*'"_G.$!I Q"OO'KK/G>,A OXT7],4[K
MW9^XA0>4?T3C>F\VHZ2!EH_2/>/T ^81=D&P1FGCE]2C=:@6"B6*OZ55Z+A.
MZ4^1S;3/"?E,R%?"MTA@J5&T^9T[7I4&)V(''LYNL_=P$T2\,K%1S:3IO5'K
MJ^=J4^Q*=@Y",R91CE>8%<&\^JW7PL4BT"1
M!(K_C9@PQVO,W89_',WF'5^7 ._C%32>T
M)2=T_F3C,;2(#KR)[&9'2>_?SYI(:%T([WQLTI5*B<-A>2#K*ZW^ 5!+ P04
M    " !4@ZU($PAV6:,!  "Q P  &0   'AL+W=OP)%7);4]T-ZY8<^8K7M0W-[@ -K_:=$H[GQJ
M.F8' [R))"59GF5?F.)"TZJ,M4=3E3@Z*30\&F)'I;CY>P2)TX%NZ%)X$EWO
M0H%5)5MYC5"@K4!-#+0'>K?9'XN B(#? B9[$9/@_83X')*?S8%FP0)(J%U0
MX'XYPSU(&81\XY=9\ZUE(%[&B_I#G-:[/W$+]RC_B,;UWFQ&20,M'Z5[PND'
MS"/L@F"-TL8OJ4?K4"T42A1_3:O0<9W2GVTVTSXFY#,A7PFWD\
M*@U.Q X\G-UF[^$FB'AE8J.:2=-[H]97S]6FN"W9.0C-F$0Y7F%6!//J'[;(
MZ34]OZ#GG].W"WV;'&ZO''[[7*!8!(HD4/QOQ(0Y7F%VV;LF[&)/%9@N7AU+
M:ARU2UNZ5M?;>9?',WF#5^7 ._C%32>T)2=T_F3C,;2(#KR)[&9'2>_?SYI(
M:%T(O_K8I"N5$H?#\D#65UK] U!+ P04    " !4@ZU(%TGCAZ(!  "Q P  
M&0   'AL+W=OQ-W5S.PL'^6$YM7V (Z\
M*:GM@?;.#7O&;-V#XO8&!]#^3XM&<>=3TS$[&.!-)"G)BBR[98H+3:LRUIY-
M5>+HI-#P;(@=E>+F]Q$D3@>:TZ7P(KK>A0*K2K;R&J% 6X&:&&@/]"[?'[[,9)0VT?)3N!:<'F$?8!<$:I8U?4H_6H5HHE"C^EE:A
MXSJE/[MBIGU.*&9"L1*^9M%X:A1M?N..5Z7!B=B!A[/+]QYN@HA7)C:JF32]
M-VI]]5SEN[QDYR T8Q+E>(59$_)N^6>B;Y'!SY? _!+:+
MP#8);/\V8L(X=7Y< [>.*F
M$]J2$SI_LO$86D0'WD1VLZ.D]^]G322T+H1??&S2E4J)PV%Y(.LKK?X 4$L#
M!!0    ( %2#K4AVCTJ;H@$  +$#   9    >&PO=V]R:W-H965T6CG-"\V![ D3U#9;=,<:%I5<;:DZE*')T4&IX,L:-2W/P]@L3I0#=T*3R+
MKG>AP*J2K;Q&*-!6H"8&V@.]W^R/14!$P&\!D[V(2?!^0GP)R<_F0+-@ 234
M+BAPOYSA :0,0K[QZZSYWC(0+^-%_3%.Z]V?N(4'E']$XWIO-J.D@9:/TCWC
M] /F$79!L$9IXY?4HW6H%@HEBK^E5>BX3NG/]FZF?4[(9T*^$NZR:#PUBC:_
M<\>KTN!$[,##V6WV'FZ"B%U0+$(%$F@^-^("7.\QMQ^:,(N]E2!Z>+5
ML:3&4;NTI6MUO9WW>3R3=WA5#KR#7]QT0EMR0N=/-AY#B^C F\AN=I3T_OVL
MB836A?";CTVZ4BEQ."P/9'VEU3]02P,$%     @ 5(.M2"TOI->B 0  L0, 
M !D   !X;"]W;W)K&ULA5/;;J,P$/T5RQ]0$Y+T
M$A&DIJM5]V&EJ@^[SPX,8-7VL+8)[=_7%Z!)56U?\,QPSIDSOA0CFA?; 3CR
MJJ2V>]HYU^\8LU4'BMLK[$'[/PT:Q9U/3?"LV@[%PJL+-C"JX4";05J8J#9T_O5[K )
MB CX(V"T9S$)WH^(+R'Y5>]I%BR A,H%!>Z7$SR E$'(-_XW:7ZT#,3S>%;_
M&:?U[H_;45)#PP?IGG%\A&F$;1"L4-KX)=5@':J90HGBKVD5
M.JYC^I/?3;2O"?E$R!?";1:-IT;1Y@_N>%D8'(GM>3B[U<[#31#QRL1&-9.F
M]T:MKY[*U?:F8*<@-&$2Y7"!61#,JW_9(J>7]/R,GG]/7\_T=7*XOG!X^[W 
M9A;8)('-_T9,F,,EYNY3$W:VIPI,&Z^.)14.VJ4M7:K+[;S/XYE\P,NBYRW\
MYJ85VI(C.G^R\1@:1 ?>1':UI:3S[V=))#0NA#<^-NE*I<1A/S^0Y966[U!+
M P04    " !4@ZU(ME*,+LX!  #@!   &0   'AL+W=OX857M@PZV?(.":A.P=/N>#X8A 6\M3#*U1R9[!?./\SB=WD*0A,!
M*!3**! ]7.$9*#5"VOCOI/EM:8CK^:S^TW:KTU^(A&=.W]M2-3IL&* 2*C)0
M] QM<&=D
M8_X@BN29X".2/3'_;G?4<&%$M#*25DVX[G50J:O7?)>&&;X:H0GC*&NT?I?8']++!W GM/(/%;=)BSATG_H\GDQB3Q
M!*)-$Q\3WS=);TQ23V"_:>)CDOLFAQN3PUH@CC=-/$QZ^T_P:@LR$+4]:1(5
M?.B4VX%+=3G,3Y'=PM_P/.M)#7^(J-M.H@M7^B#875MQKD"'"!_T]VST=;,L
M*%3*3 ]Z+MP)= O%^_D^62ZU_ M02P,$%     @ 5(.M2!Z"*IVF 0  L0, 
M !D   !X;"]W;W)K&ULA5/;;J,P$/T5RQ]0$Y(V
M;420FJY6NP\K57UHGQT8P*K-L+8)[=_7%Z!05>H+GAG..7/&EVQ _6H: $O>
ME&S-D3;6=@?&3-& XN8*.VC=GPJUXM:ENF:FT\#+0%*2I4ERPQ07+8:]E:*%1TU,KQ37[R>0.!SIADZ%)U$WUA=8GK&95PH%K1'8$@W5D=YO#J>=
M1P3 LX#!+&+BO9\17WWRMSS2Q%L "87U"MPM%W@ *;V0:_Q_U/QLZ8G+>%+_
M':9U[L_
6%03A1+%W^(J
MVK .\<_^;J1]3TA'0CH3;I-@/#8*-G]QR_-,XT!,Q_W9;0X.KKV(4R8FJ.DX
MO3-J7/62;V[V&;MXH1$3*:<59D8PI_YMBY2NZ>F"GOY,WT[T;72X77;?[G\6
MV$T"NRBP6XUXNQXQ8DYKS-V7)FRQIPIT':Z.(07VK8U;.E?GVWF?AC/YA.=9
MQVOXQW4M6D/.:-W)AF.H$"TX$\G5-26->S]S(J&R/MR[6,:
M?P!02P,$%     @ 5(.M2'!"<0O* 0  X 0  !D   !X;"]W;W)K&ULC539;J,P%/T5BP^HV1*JB" U'56=AY&J/LP\.\EE46W,
MV"9T_GZ\ ,4(*7W!]N5L%VSG Q,]*T09';VILH&4&80%_&Y@D(LY,MG/G'^8Q<_K
M,0A-!*!P44:!Z.$&ST"I$=+&?T?-+TM#7,XG]1?;K4Y_)A*>.?W37%6MPX8!
MND))>JK>^? *8PL[(WCA5-HGNO12<391 L3(IQN;UHZ#>_,8CK1M0CP2XA4!
M.R,;\P=1I,@%'Y#LB/EWT4'#A1'1RDA:->&ZUT&EKMZ** MS?#-"(\913AYF
M1F"MOFD1!SX]7M#C^_1DHB;$$&HK(G3:(+
M[UOE=N!\R#M2P2\BJJ:5Z,R5/@AVUY:<*] AP@?]/6M]W&ULA5/;;IPP$/T5RQ\0 [O;
M)"L6*9LJ:A\J17EHG[TP@!6;(;99TK^O+T"@BI07/#.<<^:,+_F(^M6T ):\
M*]F9$VVM[8^,F;(%Q!?138;P32[8@1<]YB_G?)5GNJ0#?AZAA2XM#9N*5+=;F=#UDXDP]XD?>\
M@5]<-Z(SY([email protected]!PH:=W[61()M?7AK8MUO%(QL=C/#V1YI<4_
M4$L#!!0    ( %2#K4BGV&PO=V]R:W-H965TV/C)FR!<7-#?;0N3\U
M:L6M2W7#3*^!5X&D)$N3Y!M37'2TR$/M21
M D@HK5?@;KG"/4CIA5SCUTGSO:4GKN-9_3%,Z]Q?N(%[E']%95MG-J&D@IH/
MTC[C^!.F$0Y>L$1IPI>4@[&H9@HEBK_%571A'>.?VV2B?4Y()T+Z@Y!I'8GKNSVYW='#M19PR,4%-Q^F=4>.JUV)WN\_9U0M-F$@Y;S +@CGU
M3UND=$M/5_3T:_I^IN^CP_VZ>_;C:X%L%LBB0+89,=N.&#'G+>;PH0E;[:D"
MW82K8TB)0V?CEB[5Y7;>I>%,WN%%WO,&?G/=B,Z0"UIWLN$8:D0+SD1R]G2234UH??7:SCE8J)Q7Y^(,LK+?X#4$L#!!0    ( %2#K4@=2+HQI $ 
M +$#   9    >&PO=V]R:W-H965T5>R-6?:6-N=&#-% XJ;.^R@=7\JU(I;E^J:F4X#+P-)298FR3U37+0T
MST+M6><9]E:*%IXU,;U27/^[@,3A3#=T*KR(NK&^P/*,S;Q2*&B-P)9HJ,[T
M87.Z[#PB /X(&,PB)M[[%?'5)[_*,TV\!9!06*_ W7*#1Y#2"[G&;Z/F1TM/
M7,:3^H\PK7-_Y08>4?X5I6V2_N"PT\81]A[P0*E"5]2],:BFBB4
M*/X>5]&&=8A_#LE(^YJ0CH1T)AP#@<5&P>83MSS/- [$=-R?W>;DX-J+.&5B
[email protected]^>9XG[&;%QHQD7)9868$<^I?MDCIFIXNZ.GW].U$WT:'VV7W
M_?%[@=TDL(L"N]6(A_6($7-98SXW88L]5:#K<'4,*;!O;=S2N3K?SH *LC20I"L^R.2,85+HM8>S9EH0,[email protected]<*)"R( NOYA*4Y5HA \T1/^2'TS8@(N /A]&N8A2\G[5^#-/F$:X#8*5%C9^4358I^5,P4BR][1R%=S >\+'K6PF]F6JXL.FOG
MCS>>1:.U ^\CN[G%J/./:$D$-"Z$.Q^;=*]2XG0_OY+EJ9;_ 5!+ P04    
M" !4@ZU(';U(%T@$  #1%0  &0   'AL+W=OVV!_W=JO.M9'_QS5?WL;QXW-_.XC\$5[J7M7>3=Q[M;N:+H/77,_TQ./SE[0__Z
M[/UN2+<+_SEOW*HJ_MYOVET7;3R?;=PV?RO:[]7IP4TYZ-[A2U4TP]_9RUO3
M5N799#XK\U_CY_XP?)[&_R3Q9!8V@,D /@R$^JV!G PDUT!-!HIKH"<#_6E@
M?VM@)@/#9;"3@>4:))-!PC5()X.4:]#7?*Q<3$RBL>1#P]SF;;Y4(8\?ENHN[EARL YPK(L0* 
M6!*&!WGVH$8/TD^7A&G'USI"#@-$:0M6QR'A#^?P@I?
M"7^<"&MUN/AKA).@NM_@ H)P22*EUJS:T^DD_/'4-1#'Q\?*'>-96D5%]GG4G_>X%,
M@9TUU:5$N@3!\6%HUN;RK*F*)!((!!?L!XEVWM*PLZ92DD@E0(X)S,3FKY1@
M$B6 L\A)*B>)Y 2*X4-1.:G+Y:2HG!22$SUK.'\U#O^T,R>J[:MRN%H:%M5K>OH'Z>XR_\ 4$L#!!0    ( %2#K4@QK 8X$0<  !0L   9
M    >&PO=V]R:W-H965T(+&DU5<'
MF+DX0*!S9SK]T?O;@(%,DY@;F]+[]M>.%:K=B&2=,M.0<%:[DO:<7Z\V
M/^N7LFQ&OU?+=7T^?FF:UR_3:?WP4JZ*>E*]ENOV+T_59E4T[=O-\[1^W93%
MX]9HM9S*+#/35;%8CR_.MI]]VUR<56_-+0J?O>OB_7V];W_B\N"6=I !@/Y82#@H($*!HIK ,$ N 8Z&&BN@0D&AFM@
M@X'E&KA@X+@&/AAXKD&WY_W.96R3C\T6Q&3:9\DVQV9%4UR<;:KW4?U:=,P3
M7SK\IANG'7Q4;P?<]+G;IEG=?OKK0DI[-OW5C10PG,#<(H[(49HXP*<1MC# B!;E#@^@4Y"N>TY\UGK8;E-XE
MN=LEU>^21+,1C!'4;@3H1U!H!#);TZ]]CUGW<;;:V_YC> +B"9 GD@F^7WF(
M/&43S_"BB1<=KZD@N63[^>C(B[5X/A%NCG#&9\IK1D2&1&30O"$9D8E7V%I-
M ^HW8A[#E(3V)S7:;0QS3BFM'2-N2^*V*&Z=VJ\K&\<]T8;AQA$W#KE);YB+
MW'C!34!//'GDR:8\77NT=)^G1HP3BAN1R$A(G;Y',;GD[ ,H;#O;EZ"^D-P(
M,G\($HI!+@6:?PHZ$(VDT6#I\DGA":"ARB.HR FDR"(ZQR[9Q$"C=GXNX.X0Z$3I53(.F4(IV+L28*(ZVB]3H0Y"#P0%14
M/0623Q#I/(D5CY\F5/$$DCPJKCM?L>99MB\J>P+I'JBT+W<2\ZGPB5CY1+JV
M7(E8TOSGTG>+@ Z<%!E' 235/HFT#R 9E8RU3SC#70-)U4^B?@QT,KL#**P!
MVQ?5-AEKFW:IB4>0ILU-#9SPJ5I*K)9I?LM8
M+:W_)%GN$ PD#6E'&,3I=!3EI$*_.B,)JK/!":HI*[5@)(V.69E-. 5*4T9JS$A(.Y+#'=&2
MJQ%M!2<---"5A>$KNW?UB>@HDNKZ5:-+37[B:LI)C3@I.#FI+9VU'3YK2B#M
MC@M>KN-*"=X9;5D$H"32N%*F>P =5TI^#V!HM339(::$'L"@:LEQ0PEIQ'%Q
MS4U,2 !NUAA*2H.O_=*MAD$G65:K82@I#:ZEZ0;*H-,IN],PM.@:.%0R0EH8
M.&T)*!&S_).KH]S$E9WB=XXPB+--EDJ%Q7=IZ6RWL52PD]U2O;!(+PQG
M82Q];FF'/[BTE.$6EUV?+'%'KVC;C=>P:(>,F2$.OHK-WP65,B67]<'VZL/TT?'&630VPRR:=R-RX[
M2#SM:*)T^
M3I4;IT^CBJ/$=(B8EC4&[8?=\'[8[3U/9_3#UR[NAQV?*927CM$/7SE_DC-/
M:>D/]L/A*:Y'_3#O*:ZGG/2(;I:S#YZ6.#^\Q'G*)*^.[^651\^MN<]8/"UP
M'AA;Z>$D7Y29'C'3S\-W<#^^"'SQ/U!+ P04    
M" !4@ZU(.67V1#("  "N!P  &0   'AL+W=O95EK-H+A Z^S?+XAVE72B
M[4,%//><JXJ(OSO*>+OUD3\LO)>7
M0ID%D*7@7I>7%:UER6M/T//6?T6; \(&TB%^E;25H[%GS!\Y_S"3'_G6A\8#
M9?2D# 71CQO=4\8,DU;^TY/^US2%X_' _JUK5]L_$DGWG/TN>?N=]CVL#.&),]G]>Z>K5+P:2GRO(I_V6=;=L[5OUK O>UP0] 7!O< F
M\65!V!>$2PMP7X"= F!;Z8(X$$6R5/#6DPTQGP?::+@P))K9DQV;L/GJ**1>
MO65!'*;@9HAZ3-!A=F,,2AYB]E,,?H0Y3+3N"*!=/K0:#%9#:S686,7S!.% 
M8*>OX9@@#*8>(]N'Q=2V#[U']&]>"#M">!P&BJ9"L17"(Z$XG@J-<(<)+DI@
MF*SF#:T<0ZM)= L((B?[Z-GL8\=!O"#[>-3J&B[,?NT(K<="J_4\0>*TFCS;
M*H*.!7/9V!^29)W:B>#/&PO=V]R:W-H965T5%KM17O-)DZ"%G *9+-]^YJ?I![+['(3,#DS\]D9GYC5
M53>O[4FI+GBORKI=AZ>N.S]$4;L[J2IOO^BSJLTW!]U4>6>&S3%JSXW*]T-0
M54:4$!Y5>5&'F]7P[*G9K/2E*XM:/35!>ZFJO/F[5:6^KD,(;P^>B^.IZQ]$
MFU5TC]L7E:K;0M=!HP[K\!$>,DIZR:#X5:AK:]T'/?R+UJ_]X,=^'9*>095J
MU_4I'
M_%)VS_KZ74US2/J$.UVVPV>PN[2=KFXA85#E[^.UJ(?K=?PF)5.8/X!. ?0>
M /&' 6P*8$Y -)(-\_J:=_EFU>AKT)[S_M>&!R-O^B0F<] .V9IQN"GJC&(>/%%&DGR=@MP3QF("A!!)#
MBG$:HZ:>(&.2I,*GR[ .4D@6 ,4.4&P#I007XB-0;!6"F G*?;+L ]DL3N+@
M) @'O#B)58<32J3PXMBR1(A4+E@=[N!PA$.].-RN S&'V(OS@6P61S@X N$P
M+XZPZDC!$RF].$@&,5B].(N3.C@IPO%.>YO:34$%2[TTMDH0T\F?PT@'1B*8
MQ LCK3*QD(1Q;X=E6,ET"9)KJH!<-5VP3<&U5;!]5?KW*2"_Y#&=
MF1.2&=> !3RNJP*V56^E+=B&25G"_5V;(1V8WRQA"Y!<9P5DK=+O]&";)J-4
M"K^981T1:;Q@QX+KKH#L5?K='CC:C$#8S"IQM#\XD"6]Z#HL((N=ZR3;/ 4C
MX%W,#,MX(A8X/K@>"\ADI=_SP?;/F,@9ET4R!B"6K)#KLX",5OI='R2V?7^[
M95@F8K'@Q$!=FZ7(9J73'=.9BMKN"9 :.P:?,$-"R7DJW3_&R#JXGO.C^IDW
MQZ)N@Q?=F3/P<& ]:-TIDXU\,?OD9-Y-[H-2';K^5IC[9CRMCX-.GV\O'_&PO=V]R:W-H965T
M?^L:Y/3T&@MT=9
MI'JB3K(T_^Q55:2UN:P.@3Y5,MVU044>T#",@R+-2G\Q:^^]5(N9.M=Y5LJ7
MRM/GHDBK/\\R5Y>Y3_SKC1_9X5@W-X+%++C%[;)"ECI3I5?)_=S_0IXVC#60
M%O$SDQ?=._>:Y%^5>FLNONWF?MCD('.YK1N*U!S>Y5+F><-DE']WI/\TF\#^
M^95]TY9KTG]-M5RJ_%>VJX\FV]#W=G*?GO/ZA[I\E5T-O"'!= '<-B+N 
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M,4(&=1#(P8<4^Y "'^(WJ.WZ#83@+H\7
MBHU-V?B+:DV!L9E9*.$@A8U-@;$)'UJI%0+%0Z#-7=#]9+#U*; ^<:D'6Y\^
M;'V*K4^%@TD@R,DDV/84V)ZXI)K@:I-'JV78JBQTJ!:"2.*@@ZW*@%6I0\,8
M?F6RQ[]E__N8!:],[*QKM1"$'1STMARG]""_I]4A*[7WJFJS>VFW&GNE:FFH
MPHF9Z*/9Z-XN:9Q+^W!F.GTXYYG$;O4!U6;;W:ZJ?+.
MW#:O87MH5+X=C*HRA"B28947]6*]&IY];=8K_=:51:V^-D'[5E5Y\^M.E?IX
MNV"+TX-OQ>N^ZQ^$ZU5XMML6E:K;0M=!HW:WBT_LYDE$O610_%NH8VM=!WWR
MSUI_[V^^;&\749^#*M5+U[O(S<>[VJBR[#V9R#\FIW]B]H;V]9!LM@JW:Y6]E]TT?/ZMI#''O\$67[? _>'EK.UV=3!9!E?\<
M/XMZ^#R.WZ319.8V@,D S@9,?&C )P/N:R F ^%K$$\&\=D T@\-Y&0@?2,D
MDT%"#,*QNL/2X>ZUA\&
M>4O=8Y$SHR0T"H*29^XF0B+A$X>BRQ!S@C1K-L5)[=$LL]0C$$63(3:%*'<#ULMY/HK&L\=('3J#;*R X1>SJ^7NP
M-TXA1.8S),HP((:%=-(%-L/<;- >K0*48T '7#[_E/N_8Z[-87SAF&MC*$4"TF.!XY1#[L,A1QQ&
M,DVEQ^K"*8D&PO=V]R:W-H965TQU\R,(7Y ] [email protected] 1#X,P%, O@;@H=+1V5#7
MUUK69<'9.1#'6N\VO%-RKI.HS($8LO%QN51E0LV^ECB)B^A5)YHT:- \F!KH
M4U26 J)9$RD'7ALHM!'(2("\"$N1W";@"V$(Q06RM5&*;
M)&,9HZ8?(7D,4@!O@Q('E%@@X@4E!@C!&*K/;1!Q0,0$HNWPO$"$G9)V"+A=TC8W-%5LF3UW&8#K6Y#XG=(L;5Z
M"?3M9N6H%JVQVY.@U91(XG]L$@M$_&Z2_W^VW,8%K&92G2^&P\".,4F5"[!2&W10Y[YYT-*=U+>INN?C26@<
M2':\'.SFTV7Y#U!+ P04    " !4@ZU(\78=320"   D!P  &0   'AL+W=O
M&
M4.UKRHF:B8ZVYLM12$ZT60DZ9-JM+MO&TU8UH@62'C?)"UIO46XA#O&[
MH;VZFP-K?B?$AUW\/&R2U'[email protected]!FN-!7RIAE,LI_KZ0W31MX/Q_8O[MT
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M,U./[email protected][A1;=\":-#V/U'U!+ P04    " !4@ZU($\\2
MU_$"   2#P  &0   'AL+W=OP'782R;,OYN(S9^9@
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M8,J33(G&,K\)*^I*JU-D#F+X\0*R)Q[%^FH+$?3F?A]'8XNX3SJ4(VKY!EMPGXA8!-!'Q.0//;!!FH
M(/.>4>8_HPFS\C&()#E(DGL$B]L$"R!S$2JS !44")D^IKB=I 1)2H^@O$U 
M4J!SL%J84$) $80@I/J@,D7DH3 /]2@0WB$,JF7!:CFL@F/4>J 2X5,";4(\
M#Y0,09%#M7FPV@6L8H%1ZX%*CL@#W4(\*Y2(]Q(IH=HR5"U-014T1:CU024F
M#W0,]#U1"M12&JP6M@+*,&I9L%KH&.J9@2/^'C2#:K-@M; CT!RC-@]M
M/!0ZAOIF0+S4:0'5%L%J86.@)49M&?K;,N@8YIL!T8$8 6H9"57+8&=@%*'6
M!V'>4NS3\#0W T\138S!\8D%ST\,=@:&F: \$$\1S9)!Q[#/ LQ6%GX)A9R@-]5IO,=I9.ZMVXFIEH
MK8Z]G5:6Z]WK^O= QYWG UY7![&3OX3>-;V)7I1UF].XYFR5LM)5D=ZY?]C>
M+:C7BU9N[7"Z<.=Z6MFF"ZL.EPWTN@;7_P%02P,$%     @ 5(.M2(%X4HK;
M @  U0L  !D   !X;"]W;W)K&ULE5;1;ILP%/T5
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M47:'JA7>"Y>JE^L;KSWGDBE]Z$[Y<%0]]CBHV5[JUUB]=Z;K- /)3]NSD
M\[]02P,$%     @ 5(.M2-W3NP U @  "@<  !D   !X;"]W;W)K&ULG57)CILP&'X5Q+T!S!X1I Q5U1XJC>;0GIW$"6@ ,[83
MIF]?+\#8R--,YX(7OO];6'X7(R;/M$:(.:]=V].=6S,V;#V/'FO40;K! ^KY
MG3,F'61\22X>'0B")UG4M1[P_<3K8-.[92'W'DE9X"MKFQX]$H=>NPZ2/P^H
MQ>/.#=QYXZFYU$QL>&7A+76GID,];7#O$'3>N?M@6P6^@$C$KP:-5)L[POP!
MXV>Q^'':N;[P@%IT9(("\N&&*M2V@HDKOTRD;YJB4)_/[-]D7&[_ "FJ<4OEU3E>* J0 L!2#^9T$X%82K D\YD[F^0@;+@N#1H0,4;SO8RNC !3>31!-&" Q#SHFL"$J Z&Q>-R!U09P30F@$5A-5 8BOJ\0S@IJ
MN0^-H.%]@F@FB!1!9!!$ILE$Q5"87ID,8Y"&V7VA>"44&T*Q52C6A+X$7.@C
M#SU9"26&4&(52O1$O 7XP(JKDL\D3U>&4LU0F*P^M5P92C6A<)-^X$5F*Y7,
MB)U:8V>:2N#?U\A7&KF1)+(FR8TD(+>!JOR_XP;^RHMH9EK@S-2)IG_H\R^[2]O= MJXW>%D,\()^0G)I>NH<,.,-
M4':K,\8,<1?^AG_\-3^8ED6+SDQ,4SXGJE6K!VF\<)9[KXV=]XR_BXH0&7PTM!7;L)*RVP @3A5IL%BPCK3J2\EX@Z4:\@L0
M'2?X;$@-!2B*,M#@N@V+W,R]\B)G5TGKEKSR0%R;!O._.T)9OPUA.$Z\U9=*
MZ@E0Y.#..]<-:47-VH"3]>#'>1M&.@9"
MR4EJ":R:&]D32K62?EFN!MIC AH(Z$Z R:>$
M>"#$SQ*2@9!X!&!3,84X8(F+G+,^$!W6VP-N%)QK$:4<"*/&;7U5*82:O14)
MBG)PTT(#!AG,SL7 =?P(LW8O$LT@F%NBA1?(UB]2S2-U*QYY%9FN=.A90_>GJ
MF3?*/*-L8I1.C=;6*'.-%FDV[[+T7);NMH#)U,5B]E-,.F^R\DQ6;BKI:EY@
M[>V]]5?W'HR\$/09-+=NNP%DZQDGZRB+X!->T/>"\TNW&T#CVCV3$_)]T/SB
M[3R0OWK .:\Z?"$_,;_4K0B.3*JCSYQ3)6.2**EHH?9UI>ZP^X"24NKN4O6Y
M/=7M0+)NO*3N-V7Q#U!+ P04    " !4@ZU(OES*]8\"  "0"0  &0   'AL
M+W=O:4[$U0VT0PCG'4DKH+J]*LO?*J
M9!?9U!U]Y8&XM"WA_]:T8;=5",+[PEM]/$F]$%5E-,3MZY9VHF9=P.EA%;Z 
MYPTH-,0@?M?T)IQQH,5O&7O7DY_[51AK#;2A.ZDIB'IL$>8WV%V$
M9.T]) Q:\F&?=6>>-_LFC_NPZ0#8!\ A8,@S'8#Z /09D)A*K3)3USA_&SPK.-JP2B,KIJHAX##6;M8L" B!3[9 H8
MCL.A$PZG$FQ' (XS
ME,\+RCU!^4A0-D]0>)84CUH"8D^"_BS,FM*#;+4@S;-)2[Y&?2T'^'+&AW>!
MIP!ZG@#XL"G(5X'F3=GT(%MNAD"ZX)0#_Y2"\3$M%E"D?KWIP_5B7P5>L@FP
MN^5AAHMI6UP8R/($+]D'_E$%H[.*X@44N>]+_K OA:^B6.)+,?IDX 057SCC
M @N (?+_[LBYZ%K*CZ8!$,&.73II+Z%A=6@R7J"^*+WUM6X^S 7Z25.59W*D
MOP@_UIT(MDRJ:]CUDTZJ/1HF#3U(/&PO=V]R:W-H965T
M +YYSOM\'.!R[>9 .@T#NCG3P&C5+] 6-9-<"(?.(]
M=/K-A0M&E!Z**Y:] %);$Z,X"L,]9J3M@B*W'YG:SYR_
MF<&/^AB$I@2@4"F30'1SAQ(H-4$:_&?,?""-T>]/Z=_L:G7U9R*AY/1W6ZM&
M%QL&J(8+N5'URH?O,"XA-8$5I](^4763BK/)$B!&WEW;=K8=W)LL&6W;AF@T
M1+-AYFP;XM$0/PQVZ["KS*[K*U&DR 4?D.R)^=B[@Y8+$Z*3D;1IPFV77IG4
ML_II_LO*%V!T@5HMPE*/= G,?L5
M9K_ K#ZKTY1+3?PQ)%M!LD5 L@E9:M(5!'L_- -QM0==HHK?.N7^YWEVODM.
MD3T0#WF1]^0*/XFXMIU$9Z[TL;)GX,*Y EU$^*1WM-&WW3R@<%&FF^F^ 
M&RC>3]?9?*<6_P!02P,$%     @ 5(.M2)QDZ:HP P  E@X  !D   !X;"]W
M;W)K&ULG5?);MLP$/T501]0B9N6P#90;V@/!8(<
MVK-BT[80270E.D[_OM3FD ,FHF,#UN(W\V:&\S34["KJE^;$N?3>RJ)JYOY)
MRO-#$#2[$R^SYILX\TK].-I_QXDNV-8#$+;G;[O.15DXO*J_EA
M[G]'#UO203K$[YQ?&^W<:X-_%N*EO?BYG_MA&P,O^$ZV+C)U>.4K7A2M)\7\
M=W#ZSMD:ZN>C]VV7K@K_.6OX2A1_\KT\J6A#W]OS0W8IY).X_N!##JQUN!-%
MT_UZNTLC13F:^%Z9O?7'O.J.U_Z?:#2S&^#! -\,R.<&9# @-P,OZ;S5
M_0JJ8C?J[NN"$C(+7EM' P9WF*6)H3;,RL0P&V9M8B(;9F-B8AMFJV-0&MXP
M@DR9]TM@@2:8=D-$![1T0PT%J1MF;K'I,U4>I]*P^TT04$%&-",/2
MQST1U8GBF&D\&FRCPPBFZFN#;758DA#"F$-]& B;Z?6AH:T^&Z;'DU"$IVDB
M0!/IU7&),P:-$-_;" F(()ENA&6B)TK3, K1-%$*B%(]U=C! 0I!KNUC]KYD
M$0)!($.=%-G270^@H1\I=NI[A"$5GJ[L>@#=207%C,BTR-:(?*RRCZF@G!$U
M"NC0\HC!961W+R.4#8JFEW$Y@,:[email protected] (V/2NQ66RA%E$POXQ(E
M7\D*BA&E1@&)/:M4U[W#D H!"S8$2ZF#"P2:!:-[FP5#(6)#B)199PLVA)B&
M-'9@@CK$QE2ED8,+"O.E=^<+1QC2
M!%"#V- @L^\.PILB#X-TT1;YYXHT+;KY^S(?V7U,:\:[UE(M?/OMND'(217OL)OJNM.
MZB7Q=E'P@VQ/8W5>]Z]-_844Y_$M\/8JNO@/4$L#!!0    ( %2#K4C_J13>
M]@0  ,D:   9    >&PO=V]R:W-H965T@R;VZJO=YU_UE7=9FWWS*NWMMCN](\Z:-[*,J__RW11'>YF
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MOB$_L1/SA#'LA F[NCF+QX_%$V/Q.'+ KSL01P$YX)2LJ#47A#$SD"I%4BEGY8S+ON;C0+N
MM1@6D=7T_>Q#/3AS#Y13&Z*"1I[LU8&I Y'JY=,ZQ 
MP 02SB(/6C!.%V7+&X_<1]: QEA<>1X11H60(26,I9.$3$QF(:-"R  E19H0
MF$ 8Y"&%C&HA0V*H/)H+.^F2Z2XLGMI>&!4=II +)_>6S)8=YLLK*CO,UIUS
MO8PE7PE%!84A1?&1?!Z1VO)H:FTYY2QGUQ/.N$U% 6D41SYS!J4BY]=[5,8Y
MHH?PB$-IR&T:=K+AX0)H96%R92EW..(.8R[A>>)V[^_G"#_EX;3[
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M$$D_P).3/\&3E,X2C\S.R2V3-IU%ZJL=DA):HK;OT\VEI"G+R2E3$DKH2@-I4^[ELFUK$+K\_=]_JK_SNO7[:X)
MGJNVK&ULC93;;J,P$(9?Q>(!POF0B" U757=BY6J7NQ>.V0"J#9F
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M! 1C0!"9Q"W(I/D#2USDG/5(=%A_._^@Y%R;*&Y=
M&STT-N0TU?BCPE7NJXC F8<'D_ P#;<-PL$@M#F&4WZ<;1M$@T%D#:*)01"&
M\R+W-DNK:8W&V^VW(?$"$L].,EZ%Q!.(O_O&420+2#([RP7$:DXS31AL0](%
M))U!LE5(.JLVV89D"T@VA63>*F2J\?UX&[)?0/:S2I)5R%R3+B#NY#I1X)7I
M&@*5[-9*>YO&W;$Q/07F.G[)B[S#%?S"O&I:@ J]315A(]I",3P+ZLO?:Z7WY=EE6PRY(_[^*+?)=5__;+T]GLE\&G
M39J5__;+VZK:?O?MM^7R-MY$93_?QAD\6>?%)JK@G\7-M^6VB*-5>1O'U2;]
M=C083+_=1$GVR^]_72;?_[KZ_D6^W&WBK JB;!6\S*JDN@]>93Q"DF?!25#>
M1D5<_OK;ZOM??XO?\'?CX$V>5;OYS_/%V551,OJ?[5^^?Y^&]_V+O)RZ1<1FGP'W%4!)?P8P/,]3=E7N^[
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ME1!N =KD:SJ4+5W9HSY;%O$J@6^B):ZF@9TN3/ #/SCV@ &O<5+AAAEOE\"L8,\Q[!PP^6D9
MQ\&/>14'PT']?B)K_:[<1LOXWWX)O+.,BX_Q+[\/&LB!E.$V3U=Q4?[U+_]-
M *[NOWT*RTZ62?6L>769L)1,6)X,^H/!8 @P*0*XPKLX#$X'(?R$_PNB774+
M%_.G>/6K8#@/IS/X>7(:)&6)*$OWT%"D(*H"H"GQ9@&HJN@*?3<_&X>G@]&>
M[X!/+6];&?7Y"LXZPJV1U?H[1J8#MTBY,AYF1R0
M3-RCUT>^_S5>A(4*G5[GH^[T:MZ%J>E-EW@GWV[C@L0P/@;DI' .\&;R,0Y>
MYR4 ]$,6[0!KXM6S=@YH2X<-#O@J6^:;V$R\!Z[[email protected]_QO\A+N?>*>7E?
MP2T5,D9S[#*FRX&CK."E-&?ZJ4:L?_!#G,4H\>#[T6J39"1 50B9MD^N@7?S
M,C=1\:>8I).V=X4!-#96?X].85WDFR#7AU5_YRTQ\80 _>U3&:E)L5XIPBUO
M>(F^/99_S7FWV6CABQ@D_5A>#JKH4W.#K_0SM:X&0XF!0^)H_Q)MMK\"F-E8
MB@_J'_PA3FYN 65/HH\ LIO850FRX:,F*2[JGF/?[2GM ?WH+?_!I, >9GF=QVOJO7^
M)2*54 #8_OD2<-LO>ZEE-OG)'W>E,&6 #HBF.=!0 )4&)?R*?Y-TJR">ZRFC
M]BE?Q'#&0(^)$M,5W* H\1/]T";YW@?"WYND'@CER2+"%>"! R2] Y'H@FM-
M:E<%!F9FB$C@BDZ6&*U%,6MG'G0'!;Z,D;GQ7\\(#7%6F'&7$F3HPB]O(Y!P
M@ =DGJLL.VX3@]4&FG#=(X7]V.6H#F$4+JT\A%%7.R#%$2HA@,-K2W$"Y27+8[;5*SLK^)/<;%,RL97P5U4H +>
M6.U5="_7.>ND;-COETJE,4A8W2;%"H420,UN@Z1)%AN=H/4$ #@?DQ6V)YRU/=HI=C_
M):G-JUV!56^K@<2C;KW\X">Y!P&HBFAJC?AT ?7:PNN*N@-T5);-7X-%A*OO7Q&V63JSG>*2@I:UW;?#EKM)
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M,MMF$X&N DO'4-#K_6&W-_KC+"*'5ZNR[
MU @1X N@18J4'9@(T;6H
MVA4Q'VW[.DCS239Z*3@>HI[:60([2;(5 )QL.8*%[>/A4U@8("*A2C^XB NZ
MT4 UX;'(@J">DG?";+S)ZPC1\4^B)\I"SM]O+5(/@-&&6B0_$7Q#AI=U\&0T
M'X2SP=RR=)TPR:X,;X:Q/B;YKD0B#B+14BFNQ2$3F"WC G>,XV##8B1?#\>X
M/ GN0-#U[-(UPRGNL6>[Z@A\+$3?U]K!L N@;@=BU!!_(+WS?%>"6K)!W2[FYA\]D@.
M@R7HJZ@ !6FTR.%'M/O06N$\+EZ_.C^!(Z@8(9^RY$SGJ[YZ;;YZQ?OF\ 0=
M/ #+&,[/SIZQPGA^=0)4F31C''!Q+]B2IO%-;(E!67 55;<*5L]",0-GNS5L
M<8=R-QXBW"1X^58':,2?2#9$H&R299&OTQT <4FFGRQ.@=$KPY.Q#-#Q"PV"
MP[I1YC> $!,8 [:__N6_2PL;%5*PD*#L5XI"P*_7L(T727R3AQ;>]PFJ@4!U
M:9GD!"[R"U$#Q;'9[HLGYSNN#5PCO5PQY\ 0MSL 6%!NXV4".S7D%S28;/[-D*I%V6K"&
M5&6C(&I S$\LF@?4PMJ8W'*DA3%>&0O_$(9%?$.7%D@8<>C?[H!T #$=A\Y,
M,\PO B#M BX-X- :,JXW0M@GU&YK^\3N@B\Z4U
M(A"\6\!(8%PKYEL(5:;EBYC&0H(8P5N \O8&,6X#Q+2DJZ8+/*L^:Z%] 'US^'_Z/ OSZ^?A]J7RFZYBH6"&[B%)!L3
M71&L+DD,(!8BQFX0W'Z*%:L#"*&X W03U,R24 6H"V@B,/I-CI(("DEQ\3%9
M\@A+$'GR#;Z']S$3$4)-N4X!!4JE>@"T8X,!?&)*,($KC Q\R51@(3^F?(8P
M=*P4([XE>)$:ZT&D3VC!>-%6!@"6!B"&8T())8XRIB+(2#9G@;C0H3E*!EMH
M$UVT1DN,%K11Q(93GX4B)_+%=@4X1&J2(@@N[M#]X"6P7S* HB%4B%-"#I5-
M4I'E)4,YB+C+@]3$:7H2EHV($'RTK=<&B
M%9N0^-\PDCXBW##J,VVV 2!X2Y".D <)THH@L[W)BIN0#MC1(T(2P=&\+>+JFL.4R.39:A(IO]8\<+(>X?P9%*3
M0/',\!XZ:U',2DU8QQF?M#T5KM2*!*MD15H.Z1^1T>T4$F4-L<"++WG10)?S
MW0T0JH;9Z+_&[PCFP7-6[4:W-"C
M3?LWRF!D0FL\W]A =06E9,T:L'?[--$*=X>BQD&<)C+A)W&(4WO)&UM>- G7
MRK/G8M"9T4!,?>\-6MJ$]^=)^EC>FCP DPWS)],66_:!1X;P1
M"H:JC_5H S@/1P%01G$9Q,:R.DDRM#$5\!\>B.-MY&XV0G, '! I0;0L(K1+"1M7
M!&WC6HAI&L4-70.X(J!-3XI8['R'$QI6P>9 (>R*XQXB*$R0("&8@5>MS7 V>BVH<&!B=D7%BCA86C>(JD_!-K;DSZK,[email protected]
MK(C#KA2I)S*L9W9O0HN[RE[X5ALLO&?T=Q)<9PUZI[TS^T$7:;/9SXI 7L:+
MXNM02"T&& - Q?8B1;^@.IYU)T[>)7.OK:\\?,0I5D]/>IZ
M 285R?J>5T9LQ"739*V+"X[$ &R(V.W,HQA"Q!];ABGDI,H>@./3""&D-#!B>04<@ CYSY-MF&)@B.=Y"J<&@Q/Z$8C!_&MBM77QFM
MD3++!GG@D 0<)SRZ1Q &O&S!ZX<+R@?9R3\;ROK4OUSBU $6)*'I4H./>23<)<5%KH*.XY=#DVFKK-8R;
M8Z*!"O/QF+@#])JMZ.K'L/?\/HZ/$]3__D:*OS^V-?*#DC^CKUL2*'[(.96;
MS;,?,C%$-!)G_=FB;7)-MT+,D<+
M$/HY^!G4F3\J$5_Q7$%?%::% ['*%37R>6+:B?C08?1SH"\I^3^80+S]M$;;
MK$06!Z]?7^@@(NO5"Q[U4B=86TX"DB'J.YWHG6*8 ]'&+,].=":2@JNE7M8#
MQ1*OXFM<\S<9Q12LDV(3XN 4KI2BT,J$<9=I-P3E)JJ4:^6@UD"+CJWAM
MCA08#=RL;R)W2!^!<*%J>=AK9#O#NKF-Q EG6P@[QSU[@IO)ZJ>U(?NH[@ 3
M#B^D\]SBK- AJ.2:K*7N4;R!6.* T^*IK'?(-(6M:;L%ZNB8;+$PV6\UYHSW
MC,TARJ8JM\[_KFTO(4A@=!!;]$R\L5X4[$]FKD6>'#JZ/VA+RCZ>:,?E\0HY
MLL\)/ZQ30Y.&H!W9<+G7(#E90$(L1"&_4ML$ZN">,Y$;6)%-NI5?#\.I -TC
MY:J('4;I8U24>9P$27Q ]D;H:*.RW5SWHC[-_/>< . MQ("
MHK)F&E_:N6_>%)1:VLW>J9%],%W2P:1L1C/A5G;X2MON=V7KUGVYCG2\6CAD
MY1^OJ-E$R2H;OB]'Z\;FX?6^U]0+UEKD=RCCN@*9#MFQ_ >^%2O;-]]%0I@%
M"YB"-V0)L]9^R_HJ\D%/.CJ\6.886BAZ#6?CK;SOFIP^$*)W[$"FT%Y_&'&H
MBDEP//'*%KDEK22XRXL_T:V4-VTYOAT^&,UJD #DC;O0OV""_J$@Y\:EXP&C
M= %: KE&@I+]K*2KPS@A$Q2F26&34F3O>C+L3Z96:C_JEJG8%P U$I$1
M71%J-.@';S,CA8]T7HB]?4=@C-RD-DWY(I"=V"U(-B,Y.AO9]A5L5=
M69<^"*0<\IQO%HDQ)]A35^@1J"K1.I8 GF2)23CZFM/(1TX
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M39Y2FT&G'1'*@&-"4;'T0ITRU?#!"U!]V*B-H3%B1#0)]89+RE&P6&0=P]T\ZGB/.IZ6%I5DZ([N*$,=]2!MJT(#8H,8
MM5X!YZVN4E--YWK4*AZUBD>MXC.UBK^%.5;EQ+,'7(+6#G##)T,KHL%ECWN9
M+I6\PS?&@Q.. $%8J\\.+![T%Q0WXD]PH';4_H'/:G$!>,F:AN#I:+)/;&/+
MRM2VK" NV5088P-8]I.XJSPS_M8H!7)6.RH'30JLX5L>.JC]UC+F_5$;_O'/
ML:YYHU@"_=WM^"0661FZV!]UW\G"WN5TN[X:4O CRBC2(02H EK36:IVA9\F
MW2.W/H*;0D@2EL@XI:B0-#XKK2:U&1ZG;"!RJ>1#
MW%.H9)WZ;7.%<0D),O$J%1,Y051F=$!7>8GX+F4G4&:EA%PGS_CW_ Z#;P@S
M-'_[email protected]*97^8*9N& F:DUL%
MG(8#*AQ!E %K^QC$*%4VL"S5QIED RICPBP?*S#'*S6>LR%BMHH7:.0C%0Q9
M;^,B@G2S(<;4P)WF_7"J8>A#JB%.+0*/("$H0Z>4<$R&)0<-^A.+6+F7@(C1
M\3>AMG 5 )6GNTU\='<,/)"Q**F 7^(+,1Y\H\,UC]7[\/S9
M$4$A&)4=/<'.=?4LBS]5-KHX>@8F;8&XN-L$V8[8LV&"-JR1/*YB9')PJUG,
MJ*F(UD6UJ#L) L?!-K'K6I1Y+GKF*M#TF:8A^U8GXT_0$@U+8$%P#-VI@U298.
MUI[9\,C4UD$D#A)P#$]'\"Q78T1*23N2TAQ9KN\\GY0;?D]9SR!=)6);[BS?
MA'4J;D)SBCQ56H!V\AD"J,RO72(%:F#E8#VF\1SXR#E@!KIU80GKEZ*V#OK)
MC4I@V41_,GAIA:_I\RR%KC=C95I2A ^*@LYQV)8!^&K'$3=*]@ZM*-#^ )+WV24+^@.K'=4Q<&8((V0C@6T02-4+H>40O$Y
M"C[:1#=6%YD5U
MHLJ+P!.53'F($ G95D"0H@JR2P6W[HHN "2[-SJIQW9X!+FBR\=AB;KJPDX5
M7*@'-MI!CZK:GBYD6/:#%]TKK=;#^$F4QB5T88QU(S+ ;;S?'X.?< 2&H\N?
M#L;X53^07DRUK"G7=.\QP8ZX$1HFGLSF]+?%HO?58/9FO-CI*B%7HB497KMS
MJKW%Y57NATG:M=+-K#PU58EP>1O61&OV;>B^%I9WR,ESQ((8EH2E)8=Z*%]_
M;%G5'QCFUV9$_9\=ZMOM^3A^^-J?NRYZT75NFM=J_N:3_PC^R(M!29
M'?&-/:FHE:1Q.-["OQ%-I71V@JF3JCQ$DH'(7.I8\SIMF82AHC%V#U?K1Y4+I2KKXITU'34,30@D
M=$V[OPWR<%Z;<$OFP:3\;+!PND2$**]X2_49;O_FOPIES>_><+:[?+W>)JN>
M4VAO:F5 *=TS^6 IZ4\9"TQ!#Y2)J%B$@'F=YG< N"B]+Q-5^U_^I>7)V#3%
M"@K5P\+.L^?L7]&+!61LTRK5Z ,3(4U14\%_G<.V57#K%NW\U68 Q4O=2D!<,;W\KF=+0CU]=7HH$^%_ICWNN7Q.
M%!M>6 ( XZ*6D=1[TAN%D^%9.)R<\=^G@W!R-NM=[HJ,,G2X+!!&8\769\/3
M<3@;3?7_7[#1IZCE.I7YNL**TKW);!:>S<]ZTP$(>O-9[S6*1;<4UV&*K)>]
MR? TG Y/]?_K]CQFYCD\&L[FO?EL&D[F\QX>D^K=$E#;!N^UR6?LU=OQX1& (BWD0__Q@M99T# /7II#<>C<+Y[%2_L,@SE$]Z8P#<
M< " F W#P=@,P.:-I>Z. R $",, ,Y#L8=>>)M9.S^8>8-]P!N,.PCE 7 U+
MXD!O. M/9U,Z#3@#:?;=;,F-X)I. 5/F\!<,=S8*SZ:-1O#M:=3-5F:+RI+P
M]ES.:7]/=C9ZE?GIF/NUG.X)-#D8=8\7@30\3X  Q%8$.(6X7,ZA#DL$3*7T0&HA(P+7$TJ;@.08I^SYWU$IR]E?@/
MFVX"UK(#[%DQ%;>)4E:OI,F!%A46-B!E/$7CVVH2+--(I7N23($?I?=.M*@=
M8ZRJ;*[PD3)"J%IY5 GD8XPU6YVE\#GH8^FVTP75+=$2$UFF E5=&"4!QWUZ
M0Q6YR>7S-'D6S/KSR3@3I?O7[U_.T['IAK2QI%
MZ0^("M=5@[;B%69J;:*4>D3Z6Z
M8%!MH_JN3/H3[87,B^2&/S)@U&JDBQQK:D=$=5E(0=V**[KF;:/*$@QQ&V7,
M^$K2;$Q FC1ZNM';P;4BR-)?<_!N-5P4;QC2=LAVS6M7S2"YSI'#5*>'&0*;
M.$HR.5-S%TF/SE"%P7]H'X:-MK7< *ZV<&^ZE*#BNY2> 4X^O:B*UF1F?%F+
MDU0"TI]YP5@2:BB.9CA.YJ[0KW9#&?$8:(2@)\,P!GUE"$8\0*,J0^TM
M54S#Z.B%-"GD^"(UO&YIR14Y;F0_'F"U;*;N!E*M2Z319XIB'ZXJ1/3#
MZ'!VA9^0G0+LI:&V-!357@"WXSX.NK "467Q3G,5PX@LY[E8B$INN<[ORS.K
M#G7()\F5<&)\1[D9E'S.T;1*9[:+3(IGD6([8@S"7T9<(Z9NW8P_8>,<8_S9
M)Q$@/=!X*X7[672.=+4 2?94YR^I3=J3P:JS2I_QU1>*2NLXV%D3&@%,>S-U
M_CT:;%849GN#-N&FMYG]'7I$C@BU'>:=*:DMGJ \I$1QS\Q2F8-D,ER<,VNW
M&B
M12E;TCA62T:6XQAW&T@D)%=MV14U><=.^2TGI$K):NSL'TVL"$W%QOZX6]VP
MCN]!G\.#85JV2M]MA@!.0&V=3CLGI9#PI1';))&<]FNF;AHT(5NBX]E4,2D5(,X58[0Q)B=0Z0?E'UV%!1U99"9<]_9 @2&P_YD\ TB[@)VV^QW#5QJ\(9S>Q12NO:).H5_42QN-  D/O05
MO(*_,#[H02QAE%ES297[J)*NQ*!J1RO[S-D#H!O^611-SP&ZT1+K^[B?FN1!
M_;59!M%E"?L!AH9NZ\,?ZRWY4[3$_0UZ-8'=:3$[#@?3L_!L.E';9.\ZUX+]
M2<(=U*0P8#@".C.$O*!J\E56^'R3DL?=.%;?H_:B"9]5+P4MA?F@*5T[W
M'EWHLG=%_/ */J ?>N^1R $_^ ]D?KW?QZ7JFK@C$5I\BBJ"!7\*FQ2J-PSG
MI]AG&,W4D_YPVIOW![VW=M4-3[?PWB@HJB
M 9I]^^/3GMK3JO?7O_R?W@45HDSCU;=2K!?^HMH<\/SI$)=R.NH]0YMY?S*M
M+\2%-*P"IQJ3A7G>O/F UEF9+)7;
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M#*#H" +.Q6T2KY%\BH'Q+7DYBX9?1I-WVIJI_^94,"R0_%=Y5[@P*HZ[QA&KAQ'*Y9N 6DW*%9
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M0AMU:I58YZ>%&_P[Y[>_A^PDY9G@S,K>RUW$JY4XP6;R0Q
M[>7S5^]?G%-M94%0Y_H8>_M62??2;D&";JQ+HT_68*/VV);\ZBO$XHT.*,()
M46H^MJZ(L3N4S&X>/"Q.WM+CA.!R?G@ENQ-3D2 JGB.S9[3#)
MKZ>M9_LP%GW)L2
MC$?A;#J770I']4C'&'T^FHT:JB4GGQ$\]MDVQ/;D1G%QRU-)EB@MK]*1=HUSXC=UM$=&^F=I7FH9IW_4N
M6Q5:;P2:HVSW+JB1Y%JS,Q31IZA#<;#38#8!-?= =688-SR%:S#&;(-Q[P=)
MH2 CR K(D*3Q?XRM+X;S<# =]N"$P\ETWKOV5(;6+\/Z!\#\QC.X'F.)4])1
MMM;A.))1;W0V#:>C>6\\/0OG\T$/$:[#7M#^.B %M\L^QO-P#K#"UWE=;4B$
[email protected]!/^2)5VW89PRG3JF7#078ZZ[41=,DQQ\,/@F. E *4*&A7;1S3&*
MX$2L).CP]=F?A$KM,JL[;.N%4B";L%
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MIC@EV:JJ";(0L>8N&FBAE\1KB22;OXPVXD"U,@@ OU6>P%"@?PJ
M=]Q I&W]]HFH4VT(CJ'42[AO@=;1@N65+A_GI7Q/CI9;TAY#OQ?
M,QY#ES2&3J/,QN%P,F0O!;_D6U$/WIH.B*48JG]AXQ:)C,/967@ZG?58;U$O
M>%P'O3G!JN+O=:R>_#)>(#A]3VT4IR%L[-&D/V%;N]52A59
MZ6*Z]%3%M5\^K[_<32X9#OK!WCFI832&K^7%A@Q=NX(SK%28;S/@$;-;54H6
M%DRD6#L)@R#R35A'(2I(41O/&ST2,?31]!^&W[Q#HLJF@W#VC1^8!$A+J*RW
M.%?!/D)P\GI31=V43<5\E#553]=<2##4W=_^7*>/_X-U@6OP>!7W<$7'^-ZJ
M>MW]S7UH/.P'>SX\-VD+GU?:ETH+U82P6G^_27O%7[0 2YKEA.W:I>
M9SX_ROQ.09)*3L)YL%TE".U\Y%
MLL!,LXI*MEN5$/:LO._6-,=PV31V"V-PK1=9S,!7DU-]M KFX=GI/"CQHL<8
M1%Y),L8:-RX;/B#S%BU)07
MWBTJB@15/GLNMFL'H6E(2JB#SD4P7E4Q25@AR@5PFCMV"$>\S),JETP:;G)-
M,CN%W^,=TQ;A)V.0/88C)"(%1YY+KS'',(11?1(_B@^_?2KVEV>^L@4/-ST>
MQ&6$&KWR-8BHJ2:]CW[.ZD5_OBC]'#$[.XY^UIL@$#GE9=9J3=L4QBI9P-D_
M9>QV@V"[>"95?K&^,: E17-:/19J.1:X6!3UC:[!?2V4KH'6/;'8W2;%BH_&
MTP;::D3TDF*Y#[ZPCSF/G,Y&\OYC(?GC"G__PQ:2KS7GB#53WZ;14D[KAO_K
MLC:)^)5>[;X^'70(O^E?](,_ (CN."/C7Z+-]E?P!L@BJK>?>:HB[JV->&I.
M.?//#\Q/NKF, =00)1CNDTHL@6JG^5J G(;S,\P$'W\E6G>XXD1+H[6V&W6X
M2O7W_&UVM"Y7-
MC++V,&N%1"PGX]07\^T/Y$_2O2SR\4
MN8QQA'L"E@>#?7'*CUU '[N /O;K>>S7\_7Z]33+M)5TE=Q::T^O\A2[09;/
M.F4B^@\JY6T0R.97^;%)[email protected]=)]ZZ:U
M8$V=:_?VOOPDE1 N= DPPO[KEQ>A%$)<&N+U.^V)>2>U)P#$>BF@2="L )ST
M7I7:WKLM)KH*!N3XSDFCQRN+5Q<#?"EW(EOG5(V#I"NIL[*XYRW]H*%_KJ!_
M;H[I2A\3;0S#WD-5!->":@17(<6:![6@7[-:/C*W+I\ODL@4](4+1$9\K>&H
MG?J!43%=(BD*2ZZL\KB4NBO<]M4J?V4#!.&VSO.*,=@&#\7XKU7&!+4E.+S#
MO8M4WOY]Q9E#L8IIQ$/3&OT#(YW/.:.:$%9# WOE6D"=03)>O7*Y79=ZFOO,WY%O@J-1Z#.<2:$XT84P8R[();Q*
ME=4P&\=2(3K:C?070G0MB:IRA/S]UB+U !C-UM)[)^[]R6B.B:MS*P[Y1+HY
M,30(1'CG2DH2H1B&PDJK*"51ZEZ=H](24%1#O2"2.A)8CJ9(
MX@IO]#(I.%@,CWBW0<$N3E-:Z<7["XE :[SSXL=S>F59T5_4!KRT*E5$ :DI
M:&M;8D=S;C*U<&XIL!&@MVWR!:L+B7
MASC1(J[@9H>QXB'!#X>5;[="/
M/Y&>0&I]LBSR=8KA,TLJN(.I.*&V[+@%;Y6B 8=U$RMK1EPPX:II6%:2CR %
M"Q_*<:TH#_RJW=JAA?=]@FH@4%U:96L%+O*+KFJ.D@#7I"3'DN>XJ$J<6JY*
M),N"VQTZP4E[@)T:LB[]*HBVD'>/':@&H=2+LM6D)$T2W6YYV3&IKA8%HON0HQTW4\F)5/@C!^DGY<@OP$6L<";UJ%!ADN0CB1^I
M$;K(?&F-J"IFZQH8"%6==:!L4Q'5Y4OO3_([=';HDG;W-94>I"0457E?W+AA
MW*3V[[B3E2,RYQG\S<9'3X34_O["XVC*SR8:+D@_!
M5-NVYKL6TBG>&D*>R_/KYZ$N&<*%2;A?C39?,EV26U%R<(AX#G0^AV+!V#H+
M0P5T]3LBN!NR'-WD.1>I$\LMC; $42S?2 %+4PI+IERGE 0F*I'5RLCQ0$BX
M"H<%ELIBA3^FDFM'_DE6V/B6X45LK K34OI!H
M)94UE$E5'U$CT+-FLUB9SB5"M++82ES&:W#@%I@2E62_DOPJ7<)5PIN$(?"]
MH2Q:0=1($AH_"J=@'W-42>@'DBG.+%;E/EE1X(*/L?9VB$B[$!E'#/G.M#KB
M5/!9[R I:Z@J";EDX X5R?4?*UX8>>\0GDS<\Z8SX] 5:RV*V:D)ZSC3&LBT
M#PE6"0B#!6!":FIC*&$ZUD;Z-N1Z>/CA8A
M]1CY3D4)E]=49;V#5;[#*G$+[&%FJ&"]-9"4QXP936YR5MQ0P,_4X2JSIX5W
M*^Z-(N;(5AL4[]\HJ;:!M/F-#517T$K$U.G=/DU$/7505#F(TT0F_"1.M>IM
M)6]L$=(D7"OUGHMA!P:^).5)HZ5->'^>I"^U [B.PF3#_,GDQE9':;-D!:/O
M=,V>@E0GZY$J*EAPU"7(H-5)DH7<&O$$D5DB+U4#,NM;P4=LZBR9)B5K$NAG
MA^/ WJUHZ"2U7]5(=#&3ZE*WIK&2V3*0GLLZ;&>U GR,*'O/L?B(%0K
M&O0=CEW092Z7NO!&B$< (@46_R6RC[(1HF9TD$H3C !%5('\AWIU3
M+R,S[!&HK8VN+(7M05=/TH:ASZV([*')OP6]U,W+. :5VVK:(D=6E8M5745=
M,)DZ!#"VD[/&M'ED93U+=5$.");IS'ZYZC*3(?VCU?$#I]=Y
M8H"XVZA@!R4I4:;-&JK"-[FTKR']U+%45 FQX>U0O R&1KMNW15GDOE>FGKBG/;4"J3"5V\?A%K&=:R0WQ
MM.5RSL\42&53H@\D*."C=Y&:C(9&;HLL_F*WD@Z8>"ESMG5*.KS(-29*Z#B!
MS[2+J72MQ;-6Q)*8QJ'QH8G&C7IO05*Y+R3ZRY,>FS-H.J
M3YSJ="M%ZHD,ZYG=F]#B1K,7OM4&CY;6:7\7P776H'?::[0?=)$VN_VL"*0G
M<^T+44@M!A@#0,7V)D6_;*H5 9 T6E*61NF_:FQH0H<"E:Z M>'VR;B3JG[<
M;+,2'5>]0DB!Y>YA&E"8;L6"2X&]:ZE/+1-S'4GEPU _%G&M98[NZ9[OG5<+
M<>P$4>.9R*]7T@A <@Y1H0M97N7%JI4QG#2H+BL9D 2CK
M/H_85([IL#\!Q5)=HZQ--@FSOI&K:#MJV
MC*$A@Q/(*&3 1\Y\FVQ#Y4-1C!#=ZT0CK#!(_- )AM171FNDTG IK@Y)P-+P
MU"<(8\L+/UX_7% ^R$[^V5#6I_[EXG;01HRE2C^OJ*E7\'2[JY[I='R6JZ/,
M-.P2@<=D:9K..GG&$7.VU,8."W93DN\(Q3Q"7ZM#-+K=Z,M;$Y3*]PW7?$?E
MQJMX6R.Y)/CP;B@4V%AE J#$6;YA5Y;CY:.*W,#Z6=-K[K?;WH
M^(_'+NG58Y?T?^@NZ9V:3P=/W^-2&S'-WU\O0=+<<8:4W<.9-N7I(NR+V7IL
M)_W83OJQG72W=M*ME7U;+Z@)0+8KW*I81JZ J7YC"4/:G#0Z63_VGXD?^\]\
MP?XS#02S'! ?E!/AA121Q 5>(M_[O;*]N]V1/A""N>F.5]*>Y0TF.W86_1Y[
MR7RU7C+[I(5- ?&=,G])$\EP;E%XZW1I^K'5KN- 9.M=VALY;-T/GPG&J8P'I_;K>
M8].)QZ83/Z.F$T>W.&C5N.1V79CT#OUY>[4W2TWC[T^L[WUKT0K<7C7ML1W"
MWZX=0N<"_9V,:>=8'/N%$CNL]/>73AGTBUH)]!=2 EV=PXF".8/W@/GML1;[
M8RWVSZW%WJQ9V8;N1^C[A%)>DMQ9K7^L__2/7?^I6W66$RO=/GAE97\^94]'
M TG?8!4 Q5X^7+\(GCYIO/,NKGF&C0P7J(1]C%I#\8X(9FMR?C.IOC[7:U4<
MG[[]@1)*+B2AY$,F?A-@^8?V"9!HV#OU?TISCEH=FR]BNX8U.YBG)< Q2U6O00X-76("_(5=QXRDL2Z?\
M#,!$(I+@TW:OU >G;8"I^F_Z!]0[!QP]0FCU!] >_H<-I;^G2DGUSW7QFP>,
M2_RX_EV]:T']^94J;T:HSH88;:1LTL0FTVL(U%9=3BVQZFI=7#E,5T/[K(_M
M\FG^S>.&3P:C!M.C4E/O[%)31E?^SS.I!W;H.K!!W,FA!R)]=D#A"W((@6A!\/3X(*#^B]558G#A\3D1='V$T7;DPS#]>(5
MYHLU&)%D"UFIEXTK1A80K8O;ZM?G,E;AG7[&.I@?9H^-+\E0$+Q5#K%]W/"5
MUO$]I_+5SB;_>.WS?@RT99YCN_>$]*M5/1UTS$19BEL&2]UF>]
M""_YH^_P3.$?*Q%/I;R>.5\2KAM ]-0-%KB1_K#GHM3*^'*V%M4RIW(3KJ+Q
MZNIMZ"8:^%F2OO1UWKJX-]O$<#(2+K'M9\Z&\[R2]#&CK_IOZ.?/T,J>/YC/
M"3JMSYUS:F %R'>[VDA-.F-5'VV>(*%1#6L\65+%T1AR5:]OVT 5_P+& S':M0G'
MG[.H:RG=[I8'5F6A#[email protected]:6YNB#XI<8Y1E"\!LP#P2?'>HOQ$OO=?*X8[/+Q
MT@/(]LX/>T6'SUYI!Y"?XP@:3R[R8MNGU5[&:96V?J5\SMU?^!HROQ7C],9*
M*3\)V)+A?_Q98JDUI,3NHIG%[M7]1J5LOT4WLJK0>)!I'
M&^@X]"UI_YEK0>QMUABOXY?O[_(FT&?#(Q<"HW!P1RO:&<2D5@%\2.MXGXHV
M]"I4;;D3GT/A=C?MCJO?[K)^,!SYR1^'@G@"]E6R>(O?V
M$DHF_!ST84=NG0'^ Y)2@Z>I0 4^4Q1%??>R03''$<%8+N\8M=/(8
M+#=_J&K"8:YJ0WYNSU%H,,]ZI(\O8=%>[,T7P;1&@)%\O<^))PG1IRI@:'3J
MM1)1-$\K*EBV;:3, )I*+1C.,FER 2LHT10J@(.G:23/_:GH1GLZ GP;^6I/5<>Q=$3SXT
ML,U*'O Y5H1OS4X[;NZ7'+'7>>)N -D_JJ)P03V0-:A%K7XQ^!\QXW$G<\3 
M+0+!$2,<<>@/W?#?^.#V3Z=FT3'0@17H'#@1S=TFK$]P)@QLKAC8\,S+P.9^
M-?6H]>T1'M4RAH,#C'2N7N3W@JGWK7WR^5=-#>T4_#=M)[^MR9@-P=8?)MGZ
MFHER;$#4*_EVB+-L:DJCT\8X;4&8#558SG6B\=#GY:/LT?J/4_ET-#\6%_8G
MC6+G.E_*:.L9NR8!)SDRJ&>5J7&;]B#O<;2*%DH!,FSJW"137IEDRN>'F=5ZY>9T7*J_S;[";XXZFGF)Z;:687N5V
MBND/%'KTAE),_P;;&#WH4-[J;-<+R7;]C9WM^D9GN[Y%4X)DN^JT$]G%I=V<'$VPN=>/L#)MY^_1V,CMO!@1S@:YU,^M[D '_]3=35P=I-
M[_Z=FV=+25%=OW7OH^FKHVN&7)I4W#T1KK[3:-N>)48HL.M(G.X+;Z;Y7F*:
M[X_Q'=POG>;['FVZ5Y3F^Q#%\N>9^-O!;KH_0?.(>U/K0+C?<. 9P4E"?6&E
M8KQ42:U'#VGGJIZ[N:H/']0DY;[12;D'1ZOCY,,W6Q_I<_9X.+76L9@]EO:FJ>%S;20ON]E#OI8&W#)]!Z6Q75$8
M=U18NZ#&@WTU%][$$\MDCM54')MIMQ%R^[email protected]">%.PJ-E\G_=<&4DLP/LR[
M.F9:NJ%1@0A1&BS:'P74*=>TQ3?O8D-[^)H*F7C@9]O\IJ+J759R
MH;.P%).5\L[+STQ"&(+,3S?P)29)-\B\R I75/[<$C8[S-DTGEAYA+(:7=?%
MBWQ.=-E2VQ]TW'A"-OKJO_]W\[[_QK)%0  _6O]AW*BZG4#FXZ=+RY
M#:VQMJVS> ,9NP8H&C:TH1=HE"_[\ER[BT[C_\4T<86/1*E[>9M3M
M%KD9Z"WMXD><;!;8"(I]_[G$[&*P5D4ES[U1%R#.:EVG;62*BC,U>C@97(XK
MEMZ@?IP:A+U?_,*;KQJ30+O642N%5=2$"#\Q0?]*[*_6NVQ%A@=)AL/6L%3F
MJB7*AT>P]XV]OO;I$ 2B!RKEEI&]2*R+&861N:^KY9/_ 63
M(/;-<3 ^WTLFOD2-D5:JXJ*]Q[4RMHQ.WY9E]?W_!U!+ 0(4 Q0    ( %2#
MK4B9D_GWS $  -,:   3              "  0    !;0V]N=&5N=%]4>7!E
M&UL4$L! A0#%     @ 5(.M2$AU!>[%    *P(   L             
M ( !_0$  %]R96QS+RYR96QS4$L! A0#%     @ 5(.M2'GE>K2Q 0  &QH 
M !H              ( !ZP(  'AL+U]R96QS+W=O&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( %2#K4AK%/J71P(  'P*   -        
M      "  :H/  !X;"]S='EL97,N>&UL4$L! A0#%     @ 5(.M2$7K=$(0
M!   7@X   \              ( !'!(  'AL+W=O&PO=V]R:W-H965T&UL
M4$L! A0#%     @ 5(.M2(H&6@OA 0  : 4  !@              ( !&!T 
M 'AL+W=O0,  $H.   8              "  2\?  !X;"]W;W)K(@  >&PO=V]R:W-H965T&UL4$L! A0#%     @ 5(.M
M2('9:(ZO @  =@D  !@              ( !&PO=V]R:W-H
M965T&UL4$L! A0#%     @ 5(.M2, (_<2A 0  L0,  !@ 
M             ( !""X  'AL+W=O&UL4$L! A0#%     @ 5(.M2#>#J(FC 0  
ML0,  !D              ( !MS$  'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#%     @ 5(.M2/2C*9"B 0  L0,  !D         
M     ( !0S<  'AL+W=O&PO=V]R:W-H
M965T.'H@$  +$#   9
M              "  ?8Z  !X;"]W;W)K&UL4$L!
M A0#%     @ 5(.M2':/2INB 0  L0,  !D              ( !SSP  'AL
M+W=O&PO=V]R:W-H965T&UL4$L! A0#%     @ 5(.M
M2!Z"*IVF 0  L0,  !D              ( !AD(  'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#%     @ 5(.M2*?9S9FC 0  L0, 
M !D              ( !/T@  'AL+W=O&PO=V]R:W-H965T
MK $  +8#   9              "  ?1+  !X;"]W;W)K&UL4$L! A0#%     @ 5(.M2!V]2!=(!   T14  !D             
M ( !UTT  'AL+W=O&PO=V]R:W-H965T
M&UL4$L! A0#
M%     @ 5(.M2+XP[%&PO=V]R:W-H965T&UL4$L! A0#%     @ 5(.M2(%X4HK; @  U0L  !D 
M             ( !7V\  'AL+W=O&PO
M=V]R:W-H965T&UL4$L! A0#%     @ 5(.M2+YT!  !?!0  &0              @ $!>@  >&PO=V]R:W-H965T&UL4$L! A0#%   
M  @ 5(.M2/^I%-[V!   R1H  !D              ( !C'\  'AL+W=O



/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){	
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}
		
	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};
	
Show.toggleNext = function( link ){
	var ref = link;
	
	do{
		ref = ref.nextSibling;	
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';
			
		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};





/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em; 
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}







  3.4.0.3
  
  html
  110
  237
  1
  false
  47
  0
  false
  6
  
    
      false
      false
      R1.htm
      100000 - Document - Document and Entity Information
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DocumentDocumentAndEntityInformation
      Document and Entity Information
      Cover
      1
    
    
      false
      false
      R2.htm
      100010 - Statement - Condensed Balance Sheets
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/StatementCondensedBalanceSheets
      Condensed Balance Sheets
      Statements
      2
    
    
      false
      false
      R3.htm
      100020 - Statement - Condensed Balance Sheets (Parenthetical)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical
      Condensed Balance Sheets (Parenthetical)
      Statements
      3
    
    
      false
      false
      R4.htm
      100030 - Statement - Condensed Statements of Operations and Comprehensive Loss (Unaudited)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited
      Condensed Statements of Operations and Comprehensive Loss (Unaudited)
      Statements
      4
    
    
      false
      false
      R5.htm
      100040 - Statement - Condensed Statements of Cash Flows (Unaudited)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited
      Condensed Statements of Cash Flows (Unaudited)
      Statements
      5
    
    
      false
      false
      R6.htm
      100050 - Statement - Condensed Statements of Cash Flows (Unaudited) (Parenthetical)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnauditedParenthetical
      Condensed Statements of Cash Flows (Unaudited) (Parenthetical)
      Statements
      6
    
    
      false
      false
      R7.htm
      100060 - Disclosure - Basis of Presentation
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureBasisOfPresentation
      Basis of Presentation
      Notes
      7
    
    
      false
      false
      R8.htm
      100070 - Disclosure - Liquidity and Going Concern Uncertainty
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureLiquidityAndGoingConcernUncertainty
      Liquidity and Going Concern Uncertainty
      Notes
      8
    
    
      false
      false
      R9.htm
      100080 - Disclosure - Sales of Equity Securities
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureSalesOfEquitySecurities
      Sales of Equity Securities
      Notes
      9
    
    
      false
      false
      R10.htm
      100090 - Disclosure - Fair Value Measurement
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureFairValueMeasurement
      Fair Value Measurement
      Notes
      10
    
    
      false
      false
      R11.htm
      100100 - Disclosure - Balance Sheet Details
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureBalanceSheetDetails
      Balance Sheet Details
      Notes
      11
    
    
      false
      false
      R12.htm
      100110 - Disclosure - April 2014 Credit Facility
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureApril2014CreditFacility
      April 2014 Credit Facility
      Notes
      12
    
    
      false
      false
      R13.htm
      100120 - Disclosure - Stock-based Compensation
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureStockBasedCompensation
      Stock-based Compensation
      Notes
      13
    
    
      false
      false
      R14.htm
      100130 - Disclosure - Common Stock Warrants Outstanding
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureCommonStockWarrantsOutstanding
      Common Stock Warrants Outstanding
      Notes
      14
    
    
      false
      false
      R15.htm
      100140 - Disclosure - Net Loss per Common Share
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureNetLossPerCommonShare
      Net Loss per Common Share
      Notes
      15
    
    
      false
      false
      R16.htm
      100150 - Disclosure - Commitments and Contingencies
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureCommitmentsAndContingencies
      Commitments and Contingencies
      Notes
      16
    
    
      false
      false
      R17.htm
      100160 - Disclosure - Related Party Transactions
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureRelatedPartyTransactions
      Related Party Transactions
      Notes
      17
    
    
      false
      false
      R18.htm
      100170 - Disclosure - Subsequent Events
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureSubsequentEvents
      Subsequent Events
      Notes
      18
    
    
      false
      false
      R19.htm
      100180 - Disclosure - Basis of Presentation (Policies)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureBasisOfPresentationPolicies
      Basis of Presentation (Policies)
      Policies
      19
    
    
      false
      false
      R20.htm
      100190 - Disclosure - Balance Sheet Details (Tables)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureBalanceSheetDetailsTables
      Balance Sheet Details (Tables)
      Tables
      http://www.biocept.com/20160331/taxonomy/role/DisclosureBalanceSheetDetails
      20
    
    
      false
      false
      R21.htm
      100200 - Disclosure - Stock-based Compensation (Tables)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureStockBasedCompensationTables
      Stock-based Compensation (Tables)
      Tables
      http://www.biocept.com/20160331/taxonomy/role/DisclosureStockBasedCompensation
      21
    
    
      false
      false
      R22.htm
      100210 - Disclosure - Common Stock Warrants Outstanding (Tables)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureCommonStockWarrantsOutstandingTables
      Common Stock Warrants Outstanding (Tables)
      Tables
      http://www.biocept.com/20160331/taxonomy/role/DisclosureCommonStockWarrantsOutstanding
      22
    
    
      false
      false
      R23.htm
      100220 - Disclosure - Net Loss per Common Share (Tables)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureNetLossPerCommonShareTables
      Net Loss per Common Share (Tables)
      Tables
      http://www.biocept.com/20160331/taxonomy/role/DisclosureNetLossPerCommonShare
      23
    
    
      false
      false
      R24.htm
      100230 - Disclosure - Subsequent Events (Tables)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureSubsequentEventsTables
      Subsequent Events (Tables)
      Tables
      http://www.biocept.com/20160331/taxonomy/role/DisclosureSubsequentEvents
      24
    
    
      false
      false
      R25.htm
      100240 - Disclosure - Basis of Presentation - Additional Information (Detail)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail
      Basis of Presentation - Additional Information (Detail)
      Details
      25
    
    
      false
      false
      R26.htm
      100250 - Disclosure - Liquidity and Going Concern Uncertainty- Additional Information (Detail)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureLiquidityAndGoingConcernUncertaintyAdditionalInformationDetail
      Liquidity and Going Concern Uncertainty- Additional Information (Detail)
      Details
      26
    
    
      false
      false
      R27.htm
      100260 - Disclosure - Sales of Equity Securities - Additional Information (Detail)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureSalesOfEquitySecuritiesAdditionalInformationDetail
      Sales of Equity Securities - Additional Information (Detail)
      Details
      27
    
    
      false
      false
      R28.htm
      100270 - Disclosure - Fair Value Measurement - Other Fair Value Measurements - Additional Information (Detail)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureFairValueMeasurementOtherFairValueMeasurementsAdditionalInformationDetail
      Fair Value Measurement - Other Fair Value Measurements - Additional Information (Detail)
      Details
      28
    
    
      false
      false
      R29.htm
      100280 - Disclosure - Balance Sheet Details - Schedule of Fixed Assets and Accrued Liabilities (Detail)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfFixedAssetsAndAccruedLiabilitiesDetail
      Balance Sheet Details - Schedule of Fixed Assets and Accrued Liabilities (Detail)
      Details
      29
    
    
      false
      false
      R30.htm
      100290 - Disclosure - April 2014 Credit Facility - Additional Information (Detail)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureApril2014CreditFacilityAdditionalInformationDetail
      April 2014 Credit Facility - Additional Information (Detail)
      Details
      30
    
    
      false
      false
      R31.htm
      100300 - Disclosure - Stock-based Compensation - Additional Information (Detail)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail
      Stock-based Compensation - Additional Information (Detail)
      Details
      31
    
    
      false
      false
      R32.htm
      100310 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity for Option Awards Granted (Detail)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityForOptionAwardsGrantedDetail
      Stock-based Compensation - Summary of Stock Option Activity for Option Awards Granted (Detail)
      Details
      32
    
    
      false
      false
      R33.htm
      100320 - Disclosure - Stock-based Compensation - Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model (Detail)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedForDeterminingFairValueOfStockOptionsUnderBlackScholesPricingModelDetail
      Stock-based Compensation - Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model (Detail)
      Details
      33
    
    
      false
      false
      R34.htm
      100330 - Disclosure - Stock-based Compensation - Schedule of Performance Stock Units Vesting Percentage (Detail)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfPerformanceStockUnitsVestingPercentageDetail
      Stock-based Compensation - Schedule of Performance Stock Units Vesting Percentage (Detail)
      Details
      34
    
    
      false
      false
      R35.htm
      100340 - Disclosure - Stock-based Compensation - Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss (Detail)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureStockBasedCompensationEffectsOfStockBasedCompensationRelatedToEquityAwardsToEmployeesAndNonemployeesOnCondensedStatementOfOperationsAndComprehensiveLossDetail
      Stock-based Compensation - Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss (Detail)
      Details
      35
    
    
      false
      false
      R36.htm
      100350 - Disclosure - Common Stock Warrants Outstanding - Summary of Equity-Classified Common Stock Warrant Activity (Detail)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureCommonStockWarrantsOutstandingSummaryOfEquityClassifiedCommonStockWarrantActivityDetail
      Common Stock Warrants Outstanding - Summary of Equity-Classified Common Stock Warrant Activity (Detail)
      Details
      36
    
    
      false
      false
      R37.htm
      100360 - Disclosure - Common Stock Warrants Outstanding - Additional Information (Detail)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureCommonStockWarrantsOutstandingAdditionalInformationDetail
      Common Stock Warrants Outstanding - Additional Information (Detail)
      Details
      37
    
    
      false
      false
      R38.htm
      100370 - Disclosure - Net Loss per Common Share - Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares (Detail)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfAntiDilutiveSecuritiesExcludedFromComputationsOfDilutedWeightedAverageSharesDetail
      Net Loss per Common Share - Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares (Detail)
      Details
      38
    
    
      false
      false
      R39.htm
      100380 - Disclosure - Commitments and Contingencies - Additional Information (Detail)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail
      Commitments and Contingencies - Additional Information (Detail)
      Details
      39
    
    
      false
      false
      R40.htm
      100390 - Disclosure - Related Party Transactions - Additional Information (Detail)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail
      Related Party Transactions - Additional Information (Detail)
      Details
      40
    
    
      false
      false
      R41.htm
      100400 - Disclosure - Subsequent Events - Additional Information (Detail)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail
      Subsequent Events - Additional Information (Detail)
      Details
      41
    
    
      false
      false
      R42.htm
      100410 - Disclosure - Subsequent Events - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail)
      Sheet
      http://www.biocept.com/20160331/taxonomy/role/DisclosureSubsequentEventsAssumptionsUsedForDeterminingFairValuesOfCommonStockWarrantsDetail
      Subsequent Events - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail)
      Details
      42
    
    
      false
      false
      All Reports
      Book
      All Reports
    
  
  
    bioc-20160331.xml
    bioc-20160331.xsd
    bioc-20160331_cal.xml
    bioc-20160331_def.xml
    bioc-20160331_lab.xml
    bioc-20160331_pre.xml
  
  
  
  true
  true







begin 644 0001564590-16-019376-xbrl.zip
M4$L#!!0    ( %2#K4AB>!Y"6;X  *V;#  1    8FEO8RTR,#$V,#,S,2YX
M;6SLO6N7VS:R*/I]UIK_@./M[)6LJY9%ZNTD=XMA/[N)T]9W^:!9&0
MQ E%*GQT6_/K;Q4 DJ!:#^K5 B5D'FE))%"H=Q4*A9_^][>93QY8%'MA\/,+
MJ]EZ05C@A*X73'Y^D<8W-'8\[P6)$QJXU \#]O.+!8M?_.^__?4O/_VOFQOR
MY?/E(/@3XHL/(V]!)9RQ(R V9)LG\
M]:M7CX^/S;$7P*\>]9M1Y#:=MUK* /\M5D64?V" 9KO9:K:5QSY3YP\Z
M8>3#6^6Q_M!ZVVGUAV_?]-K]7M<>O!O>=EOO;M_WWO6LUN#NIM5J6:U.I]T?
MP)]6K]51(0_GB\B;3!/RO?,#!YE\:>)_WX9!P'R?+V^FL?;K^23\@7-CTH29@-/?)"I_0X?L'F"2KQW:3Z%6RF+-7\- -/,4B
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M#/0$>?AE):R!E8C_'"=/!H#O7^,/E09!/GSK1O?AOU[\
MK1C_IU?%:SG62R/_- ?]'[K%/& !HP3=D+\)_P/%_J=7Q;?Y@RQPE;%W/C=LHD7W]&YEU#_+HSFO[+9B$4"+;;5/CE:
MD,79!"-JU>M@W^:^YWB)@(:X'CP@ GNYGM>K%K0< ZKN8$]$.-X+8=57+QMH
M5)I8\7+*0.Y&3/O&:A^/69^#*N=;7R=3OWIHG9+Z[513O[EZ.H[Z+0R2?ABI
M;)".AY%,H47,]9+WU/%\ #979U\?PZ_3,(UIX-X&[OLPC1+&@O+#A8I['E]F
M;Q7W9(D[*+CJB#B%TCNR3]9KV?;P[)Q?7I]]8P^/N+XL2M1AHB/,=X-M.F=/XJV"K[:,&'U]H,!$1
MA_SB5_K-FZ6S)59-1['G>C1:W%.??1KSA>=L>C]E_O@+>NU)Q'?38Z$:"V2OE7!U(&.NP_ .3+F-#B<*H;I'CH)I&S$Z](X3I0^8G?FEGJ)5E:5JG3U?MG3\]
M[A91&0^G<1IXSJ@UJ)1::ATGV2:Q]=5+4% _!+QL)Z6^JDVS&ICRYN SYN?V
M98&5J]I-QLMK/R'9GS>C>!0MH#'EZR'\)]I'W5^F]26HOJ)\TLW^YS2T-3%5
MN1]X[[" PB@EQU]^]SX$6M/X))Z_W*HS^;^C[)*H5-S1_5Y)ZU.F >5'2N0G_DD
M];["\W2->E;\GOLD^"%E'")H%_N/^(>^FQ8UJ#)XFN7? E964Q^]@'T:KWGST[=Q&+GO>6= 5LH,=%H=6QYV[[1;VO+.0>>/5^+M
M,%VU#ML[0+6:)J=AY0XPZ(V]M4""/]9N'9.5]V'+C3MQ?"M-?E$(07TX^8 -
M(K&!MKQVP\CU9^2OC^'5,G*^=L/(S\+(:S)?Y:__X273+VQ.%_CA,Y^KX-&K
M\#B>GY].G].K3N-+8_H#M/?V+12]&?E\6RCU4':VCL"SYI:>];VD2:U=BY6?NY&G,_/[email protected]]
MYO,SYO/TH36,>0;&/.9= 1(!GWT:E';^E;TLK7+L/L+H +^#"5^JB
M!]7E[=>>=RL2:J*!CD#H6E3XU8GBFE3YW3[2R%TNK7@WF_OA@C$>CWV:X[FT
MN@A]:3V[Q:!K5UT3*=^'E+40:ZUIJHD<;T_+UX38)\W/7PQQ2T>U+Y^XE0XD
MUY2X.ZKMH[AT5;H0W4T]-G[WC3DIOOQI//8<5FI)-&BWLC_TY;@C]";:@(C#
MXL]SNJL79GB[-ZT!3XUO;7DT,.*;76?RC!>X&/$UXKOM)IOM&V#'O,FFQN(K
M'_EO%B=>,,EAD"[P;RD^]&E\ZS@L1H:(/T-@ZC!(V 8?6*N\+>V!!RN+W
M43B[@]5'U$EBK.?\/*71C#H,1G3P9-YL3@./Q4;KZ:KUCDU)H_B,XKM$Q7>;
M)-0+D 2?QO=IC!_HR&>?P]C#,7ZYO?W\2Q3&\:\TFGC!F\5;YO#Q.,"X?VY4
MGS:J[V2T-,K/*+]+5'[25_@$R*#XPQV-IY^"_X/W*2<5A /=B=_"7\.(?9W2
M ![Y@*T?O-E;S^5#(*RRBLS0KK"[!BY.&V%^?Q
MWP,OB;_<_UX(>:?5LZSL#_L2A7PC"DYVL*]W8U4XV(>/V6=F@DK;11\"1;3>
M>^-:)D&/L=NR'A%GJS\Y X/72LNM8W!1*/ONS8>O;V\_AG%\S3Q>'1>&S>O%
MYNJ.B
MEU@<$UE&4.HE*!\P!X$(H"(1\3Y,H]_8XUN/3H(0'G6^P@N?:^K"S88)3:]###A89)JI;^OIZ&-SPY47UL) /? B<<,;R=I0?0X?[
M+.4^FS&65U*?*94,W4Q7=;7FB0W+V[7+YA(2KN5\8;>:CNKJLN6^+T/7Q/@:
MAKXPHWL,A@;SQ6CD3&\!5/; _'".3[[[-@O5V170
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MY._Z%9NO7>0.1P)B??.]F*)N#EVMF$(#QVXE4Q19IS).KE)7;$;&I6D+
MB2C)_9^B+]YDFN2,D0G%IS1!F^5ZP:1V/+%VA3OPQ%H\&':HF^6H(3OH;S8@
M\)J%@;$9*S!Q:1KB():HB8ZH)4OHJB64Y8MZIEI[$\=@C0H8N2ZM49%%KDA[
MG(U%SJ=%OC"?8M %TRZ4)MSQFX7ZBYJV?.M%S$G"TAWP=FN0_:'O)=+5E[I;
M+K.,D)/I$/NFM?5F9/'846]&/A:#&+XXQ8:T)/?QDML[D)NW8&431M]X8<*<
M:1#ZX81?QNG4SGH.Y\,"RR6W.S+B;V&0=[NJRQYY!93MP&W;$'M8
MB>U)!.0IT6JRO7\DYKQ>U7A"RFNB#Z] ?]6-,[31":L=Y2-4C;3U+Q\YL[==
M+9>@?XG+LI;#[%$%+2=J832*#B^Z5,KP>AW*N?9A/>5'S_5HM,#F@\L)UOLI
M\\=?V$0>>:]?ALZZ4RNCDOB>Y1$^.<%D<]^8>,E^5R1U;!:-__WIU?+ Q;3
MW,)7+G[]WJ<3=1YKMWG&U(^9F*@TY-,%?>;+?B>TD3JCO=N,:ABY=ORGTXOK
MM_Z'T>@]?!.K +1W!Z \]=+8ZR87$#Z9OK/;]/_76C6Y,G8Q/3B_N(5ZOYB-
M0E^=LKO;E&\^?+H3DY9&+"9ZQX4BTT-!@A?MJO/U=I_OW>>OY,-OXB*@/RHI]^R^V4*?O[S:]JNW7CE],?Y=&48D)5O#X8#<(;K)3,9O&7T; 
M>\]GT1W\, FCTO*'NTU^/Z,^C$2^L'D88:C: %/\VO+5+"WJ$AQBDP!NU4"VHO#CFWU
M?[]_^^)O@X%MM>WA3Z]V@N5 \+?JVW95\#O=OMWOM@X"_]9QPA0>^L(@@'D3 /N!NE6A5T?*)CC JI^2*8MNXY@E
M\0I*;C$<.Z"KT^X.VX,"Q J ' 3Y5H-3&;F#?G^(X>;>D*^%<8M=V@&[PUZG
MU5?1NP!9F
M: W[P^$^L J4JU =SX)8+:#PT'K";]L@.)YAZ/4'K4&[M04 :2X^TP7:BA4L
M?SQST&O;W9( KIQ[5_B.9R(&W7;)T:H(7Y0R]Z-'1UC0X;%56N-X)F+8ZPV&
M91!73[\'E,8'#-G%4!
M:A_/$K1[@/ON%H@*[WGN)=3_R&C,/HU\;\(S>BO(V3Z>,;"LUM#NJ![\)ACV
MA?=X!L&"@&FP)[P?O0#"P/%=Q%QOA=_>/J*!Z X&8",*,%=-O1MPQ[,=5L\:
MEFQ'%> V*)?V$8.*-OAQ@Q+>-BN_S8 =SWQTK'8?M'-UP-;PY6]AX#R%\W@V
MQ!Z"?AYN%8\"C .@/IY-L2$V&MI[0_TQ#"9?631#/L[86 7T>/;%[H'R&2B1
MYJJI=P*N(EJ;;[G;ZTA2NG7M7
M^(YH6?KM(6K%*O#ENUNR9\(7^$7@=S64Q[,LG7[+ZBNBL@F"_6 ]8O:J:_>'
MK7U@5;2K"MH1PY7!L&,-VBOU>250CF=:^G:_U5(=ZK6@8$K;2V8\I1JX=S ]
M^) ,/,DR:&!-OL7>Z\#S?WZ1@&M>"6FK@1,[JZ]AN-+>^&,[VU^U7OV_7S_>
MX^XYO1'[G [,]VHON <[P2TQ?&JXY1;"C6!3$&XTS]S]1S/P32="LOJ3 >TYH,AG:_C3NQU4$Y!/0C&IKNL&<#
M+OK[@_Z%)12,NON.1@'&D1"#I[.4US:"DL4Z!A7TXUF?&ZO;A1"[VU'X8SLL
MA\!^/&MT@QN=EM7O]/:'G9-B&OHNBV+1A5&%]8AQ4 ^9NUL ^G3B70 [GK&Z
MZ8#8J9GM;8 IQ@QT_V8PCQ<&/4W0;H-C?ZB/%P8]2>KN!K2B+3[3Z%/$2\%<
MKK,_LXAO@JMP[VK!EC??"\CS??A6$\=8:3K6073($GJ[FKQG7H*H.[A-DVD8
M>?]FK@KZKI9P7>E#IR7^60GQ,@![0;JKX7L.2#_$<5J&W: 2A="^L7]L""
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MJ*Q]LK6-2^GVP18#O ^7E,K+UH"P
M,YR['6FJ&&%W6SL"^AM+5EK@X18+O)^P#3"&4O6+.GM%P'8[W5F9H;O6L!I@
M_V#8@9ZYMP_ VQ/V6XJG;3^-G^18WM#8UO00_&[$N"W;![!#.*N^\"]G>')XW_SCP70UK8F"/O8U:X]5.O -@"R
M%\0G,+@0B7?M'2"6!8U.A.6T;YGX]X<@/R2)2=/H@:E0'\G:+H5SG:*ZT-^@D 9X_==(<]3=E*C\(LQT)%\PB GB)RQBKZG%H^L!&)70$\0,K?QP%-K
M-T!%@=1_>8'[-&"SMC6:V >;]J"KFNBG\^\"WPD"2KM3/B&Y!;ZG'/ST5+D*
M\0DB0MS*+$5:6P$Z; DG"!:'MFT==PF9'BD5Q5K;6F3LQ= ]6ZT@WPC*GE"?
MP.J!$NX="6AY@CTK1U]YDEU=S0FL8:?;'0PZF]93!6U*8,UK:.('M9DG*Y:A6(#EO#:=*^2\GX@]>0
M*;/5W+2MS\A^(M'?Z([email protected] 19PBD=SO61M-XM958#)W
M""4^!/E6]:V3> _BS.Z*719U>:<(@+$!15\U^H>!>ZJEG\ )N&D/N_W2L8%C
M+AT$DY\M^QK>.G^F7L36-HE1EWD"S\#NMH8]-1*K"M_>[;RQRO%*UG;6MS
MF.\,;*NU!O/+L"A)7O6Q3,^\#Z-]!MM;:[TQ7!
M/=723V&Z;7QINS>]U\I7M_ 5[<670S)UG2<99W NM^ 
M<1]T^UN[/N^_K+7-GZUM[88ZU<]8=]N]3K=TY.KDO:NMK>V(=FER80\[_5;O
M(/B+W)#GEE-5VQH3[24/\.B@E'DNS5X9M!-$^,-^S^Y7ABRO8UT!W GB#<:WJ^@7C;MQ7E'DFA>NF <]XRV'[ =M/@_61'%+JM84A@^C>/\O4_1
M%ZR7RP**SY&G#BI_C2T5$5O//VU9T8IZ)ZNI;@?M!:%"XC7OS[UH(0R"NIH=
MKY7XW/T?28*MLZB]4I4SY5_#WP.718^1!ZP2\[\_/;#HUO=#WN#ITYR[%+_@
MJ'A'Q7OJ14^4^ EL:K\W;$'@EC5:/0;$"@:4$13^Y*_$3XBRO1'3$E$ZW;<2
M[NWSJ(PBGLB7BIL3*Q;+WV:N6*8*YMX9_+6GZ&U5R/]HAQ-K6M6D_
M<;].[MP'&2+$\3>
MJ-^V]8&J3HZR$V/WVYBIK@2. OFG\1A41S#AYUZ_,">,7 P.R][PK>Q=S)G ]9(4E97H+NJ^21.)
M(^ 2=55;/)%.MJH=PF)KV.V4@LIJ4!V\EFW-L J^VZ%+:J==ZM?T;&LYQ0%Q
MVU;/V#_?6DYQHGPP5+?N]EO+IVA" WE0  0L#GW/Y1_P  S$!B!K,2@8\54:
M8YHX?LMB)_+FV5$#42@&^OASB)=GLO@KK/*-7]X@V]:::]D?_D\_^='U'OYS
MDOSXU[_\!3_-29PL?/;SBQF-)EYP,PJ3))R];LV3'^4W23CG'W&2&R_ &UI?
MM[[[<0S3WCSR,U6O1Z HQ1>Q]V_VVL+'^<GHM[AE6ML-")!(D@(>N[>N4D7%FBV )\C[=F-# )118GM^%B"<#
M@S !8-!SG:,#$J%3'O!'(A?-%GGTDBG_+*0$'O-@U+D/;TU$SQQ_@;^S>2+>
M!:^%_ XR#Y^X.\IQ?#L#G\>AS?WP:]DZ(C@-:.KR=8)J<-%KJ(S1Q8$_F_X)- H /D$K=B F&" I0FN>6S HW]18-/
MN659R#0%#A >-T1^XIJ2XC)\GX_C!8A2(5\1XV4W+ADMQ))^R9GH-F.B0B>#
M;&;I0EYRQR>
M"?Q/.IO_^!^@OG]L6PV"5AE($PO*0%CH/2 2HG#&UY,M>356$G@&_L_%VU-'
M*?P1 K40+1)@CA: %B;Q) ?.. Q)6TCC3.'$OQ-$Q]%WD@8I33'SCN7VG >3T#
M4Q6S)OD@]%(X]P)\!B8#Q4 G'!T-3A&@ M 95D+=?Z4B+@&R 5+B&,$#GIL+
M.T'&$* "N^)X\$WJ)US#A<7.*6(W3ITI$;=DQXJ4KU<%('_(P?B:"@$*&8Q.
MI?:!&=$IXIJ;HI#@_SX=XL!P7'0V;,5@;Z$IYQ >'8[2SCR_7CX:\ 
M&+ F9YZ+4>AW+.(Z"\P;K%)@B] 9/T2@T"]2(G#D"6 \'!W_Y!I37D4AWY\K
MG@70-V^0C@J6PCO@\"**7]K#5J/?&N+?D>BJ>"-L*^=]AR8Z,%I(]DN4"C@HF$@85EO,C?E_(+P)=.(,3(#+$QC*?=<0DFN]1Y9Q%:L
M,DX4X.+,S&]8;L9)JXQDKHB6^ M7@ HN8E-X$-G1#^.XR=5',(KG/RI_[<5U
M [T\4)1<>2TU7WL6H9"BUN%"_-$W7HBVO0%ZV&ER2YX4:V^01XK*)0VD8KRC
MO@>C!A[%3[_2!;&&PSY'D8=<0H#A00R C<#U<="@1\3UZ"0 -O64= 8 .LSW.:1W7\&9XN\_>>;M
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M,_S(;[CIR?Q>WB^,( 57D6T&6B$'6U1W(X]/4T >8@&**RS)/HWD8@T,$!
M:3=*"&. ,(='E[!P\)U#H*+P%I!MWP*#/R(R0;1 E":5$<$,34' P-ESA:^'H O_9\3X6&BF*#P%$KRX"1\#=&7240QB)P,8
M%70PY1!HXKJ*\,=N;E\",F\Y=FN5 Z$SXU2); ,!QVPW_%IR=[Q"I:+N77D),WH3P+ZY8
MWM_>OVF 8>)7,%!QJ40B@K0):'J>QN"V2VK,F(=EW&?D48$30B#];Y;Y[,"V
M&'Z"B\%7C6H(+-C,0W]\$F)DB$$KBQX\1XS@0 @:SO YU/6!C(6R*<<^R&6<
M98E !%@AED*,LD 1S -&(HZP-"/YI2\$"X9F60Y+:&!4TD_@087J<8!1B;L%
M I00T2P\(]8$HX]D3D:F(>*:".X R)AXQX#UN$>@87*,5J1!,@@#Y
M^PT9P OK48ZL4>7PN(@CJ#Q'D[P#E]6#L2E>GRPM("Z)13,O0=X) XSLN$>V
M,Z!$PM?;'S[58P*X9&3'DP/"@.)F;,S!8P_43Z4;C#DL>,E),O5'W7!>Q'\P
M4DXK7#"FGM:EI<&J.A#OH$;N\ZN-FA/OA
M)#OL("U;YOL(-0 X8(F4.\IY/B;RR!M'+:>YDTD%=:8>PX2F8"*1[X$Y8X_G
M%;G(92']2$8GPDTI3XL!O2=2&U]+E(:_RY(W!M("P3%A%#(*)%#C&3B6"M2[U2
M#,+H0J7@-IV .=E7#HI4+=H,J7ZX1<,*&1P/ X5(X4B.2NZ]QU+A4;!TW&B#
MJ4T0[6Z8CB B&H5IHMBJ$HW$"?V%S//AF1,FI& 2BKP<9AZ"C'.5:!#%:;A*##JVBBS7
MY:OM$$I*!:GL->261FYY\QST"@7 B >#A&Y.#.4P1_H8R.
M^':]=&TC5WE7BI8Z[G)'P6D;TW7RN62Y;R@R//O%'1GM)!4VE4T&QBW86I,6DH\'-V0
M_J"T-DS>!IJ78R+?9-+KHG3AAJ>4$^Y]BH"-"X7R4QYR\CP@RI['CP')Z0JR
M4=&SC1N'_$M?:=$S8ME6$A?$.<7\+? 93_-PL+@=Q)SCA"L 869FY0UQ/DWF
M@I4W_C/[]K001N[CK>*Q1F')Q2:AM+N97R+Y3Z3TA3[[/A:IX-*F-A!N)NKH
M02&*,#A3.V+N J59;CJW\"*"SF9RI<1GL(J*#T%"E7Y4M-/E>W#[email protected][
M,Q@+D-XHH@:JF/]0J;8C0AEG>^(*E= 5XMQ6WLH3S"#0A^,56X1B'U1F :2B
M59# =[\S]EC(K6D$AV=8Z-*+!0YN>!9XC"EQ<3X]\N(_1!I$J')E,9A'8+Y(
M-<*J,M/%S4H^57*9AS2?,/#*/SC*_SW
M;!2=1N/G;EJ1'4S$1D6FCU4M#.#%N9CYN.$1KU8=8H<"RQ-0)3G\-(U'>3K=
M%S-DFQTR[Y4]PIG<]7B>(O7BJ=S)?.3)=TYTEDV,P.47$>5?1J60#K>$08/Y
M$()EY1AKYLU#!5%2D8V7(5.4"R')/.&HH6?')!3X=Q@M15ZEC"O?OI,:)(-4
MV(U"-*6D,9X5C)"/QRXUXVGHYR?!IYFHK:1S%*817$RTKN'?V;+$>(
MXTR9*S;CBE=R>Z 6GDGY@1&R,7+ZX@1R%+Z/C?[2U)LWLHJ(S#W!6DJNZ61B
M'8,M?)&IU8.YX.=I'.%(@9>V+4S#G1(0VP-??S]/D!^E%RM0*%HM@K;W/2UH$%<7& !)'EN9C42%*
M)7:/4B("474@2J=X(0B&$%P(_:R64)0"\3>GF+"0=4]<:R#,CPA#G+#YDOGC
M3K58#:Y126';LRM&LHUD5Y%L
M\#C![F0VM61U>!DX[[3H*#>!++'>:G>=1UC D]\\N8E7C"HE4O5KE40$;I)[
M,V%=:80EE7G@C=U8&@C4F(GS=5*Z:3PM=A=AW!#OXJ/WI_8ME@LH W?@GYJ72^J?5[
M(-.#R>)M ?;*HY&[M26\E*.1=I/DN./4Y=@C$GU$P=]E5'#?=9H\ D'Y6\JG6R&&IG?!HTEDJS+K+0*UY7-I> LLTK>SE
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MV8UNJY45]#P YX8\.\4\(=Z,FFTJ/'7G4-Y$2C;;IY+2M_I9-6?+,8&E\6*7I#BR
MF@,%ZY,S+]4K;R'=A3CY_\ASTIM\0?6DD,"S.&M4.JZVK-M%>FN!YXJS CM0
M56.(&!12HTQAB)YDQ )=5^96KCP!(M40904Y>"("A)<6W-4D_P="A!"/D?C9
ML>U5 EJD!N(0U N347<\%8*5'TN=9\V +DA%HMO T+:;P6!?PKOC.+
MYE(A=QXDB80D*IYB,;%(P(C+),0!G=*QFRAO5\V+1L(H"A\QUBL')GFEM++3
MO KB;)=4:!C.0",1:$D^XGL,"NQ3D7U"*T]]N9,!@OH'R^JZXA!/#C2
MZZY\EN9G$R&83$4E&#\:NOH8*OJ(O+.+.(_JJJ&G[!]!'L/H#ZYKY)-J/+L>
M/WC>KF &\*8>&ZL!YMC?=DCVB1"* :D_@FB9;Z*36%08\,[P!54O9M/S/C]+
M46S^,H=-ZN==2L0&8U,FSQUH8?-0>XS
MEDYV,][F(3^G)VBY69U!8,[U!*^[S.#*MCZ?^*K]?%YX1?C_C)LB"I+-DI^KMUJDD]!
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M(HBHD&4L/U2QH*ASD:\('9EM"06/=[*G 1[T^9+R.;(,B[F.1J.Y3YPM*4X S"+39 L2RYJF[(6'\9SFYEL\!!V=$RM%N5+(-,
M#UB89T/1%X$U[Y"6637ADCR;7#5V$_\EM+:'35M-#541CUV5EB!*_(0$G".J
MBC7J>0>];Z5]$4JCU/V]95Y\&G=R6^:N,U9@OV?23'%*\<$5>\15.K>QW-9+
M2X\YCMQ$%D\)L[M*X?,^&.IG-1LLFE?)(B=X&8CLTH4, ]9#1;B[B'@5#G1!
MAN4!L[2F-&Q9U:)8.^H&Y4B-")HR= (0'AZYA."YJI8KSI?&6-WOP<-N5N+%
M35K SU\F1_B;EK!OQR+66^=@%?BB"[-
M4E%R#ZU(E&&7NC'N2W''.$_BC[.[J?(,3,D0J&C".G#Z )#PWU K";7#_>P]
M _GMXL&9=E73K/*F\R$[P>IU!YA\^31^Q\E:=*HLWEJY?;Q;H_E+V3YN@Q/*
MY:X,HH]RU$YXPL+U'$.$.Y<9L5A"O2U"#\
M.I\\K,<+?9K=8'8:)@EX?=&#D]<8-?XJT>P@$JSC%.>!C!#R*7S]0D?-LO
M!Q;?[RL)JD<:RY.6\N@_.M%C/%&%ZRAL%MY9<(,>IZ2%W&8NK2+/XZ?SK W9
M4KB5+49H0F2IC.6Q%5KT^C_$W4N"K]Y1[EH1<$S/1X5 ]<>6%=RW.9>6S
M%WQ6GK'?QVWF"C.*#J=/PN82\LNKD>>"BO US\&J3-_MB32@_%'LC,] RCT1
M"HIN:3RW-L9\F2A"R_.ZKL1CQJ5"@DH*K4A4
MYV?1EO,;#5D8![*'#9SY/KFB/+&0K-@15AU(T2D4F_>O@*N!J6]+C8F?I%'$
MV@[email protected]!C."J4HLC*KDY4!)NB\O[F6KV5;!4E:$I1S*&N0*LV*=
MY4*.)Y3@W4PG\K(A2CK=&P@[LX-Y3T7+:MA2'RL@K%'-7!N7=:_"J(" 5RA$
MQ3 ;)+J8MMI7JZ\+:M%,7.[F(AS-O7CL$ 7I^J6]^RI\20[?B.DO+" ZY55Z:2 NJ#\Y-)+:Z!N,ZW02T-5+ZT@6HD]
M)#OLI\MRF4/"!HSW!*,33"\F4K?F&)85>,6!)Z4\/#_#>"%[PV83S&R"K=X$
M*SAC:9K2+E'%#:)<(V7N3#6/O/14U?3QTF:4V6XQVRUFNT6'[1;MC-]SE.=D
M?HW=T2D&'8HNZLHXB4?& K2^[)Y6D+X/'2=6(FO67XWB!+([TI/V0\@\_-%_>6B4BG6=G*+J*P:
M97E,ML"]([[EA<%^G/7U*3M_3]4Z+\Y'M/,#(9X(1$2SI4@V;%,:'M%B?G!I
M/-X+%-.+..W24E<$_/MEEY'9LG9SN+9&YO,MBV,Y# R6(B:13<@95]AU,!\"
M5'R6]SOAO?1D^P/O!_%]^(A':CBGY.Y -8F7ARPS/&#*@!M!3PX-ZB^9SAB_
M8@"/1TSRL<4I+SEU%J06(#S9DEP/A'(1CM7B?:NYYL!;. J&B;/VEA)DE9?4
MK.(3-NCY_PU%.Y*37CSHFVQ%!+Y^Q*
M&)&LQ*GGB?2.X@ZVFEU%J96%A"NMW25E:0'9<:?03V=,VDM44Y+H K"]9*O 
M"UJDS"D2#PE!:;>^R[BJ$(===1WP@TCM\B,*B7JJ0!2=9[\%8.M5]BG%8]CM
M"KSG=$:"E-OWPHJJ.$']%B60=:C O5GF^8JY.9HOP;S-#P9);K
M864 UO@+F.,Y.,I<7XGBC;S/5%&D(+/^G-:%GA$N,_8!S'K]X>&W-.O=48*\
M?-1!4-[WT%6:8<<[O#AHB51"TG>B;KQ"ISQ-.ZA7AE7WS!K+L>@,VPU&XI:(
M_/$\^R9;H699Y6V^JRS74 ['Y(H)D+"T)! $K+K!W#5/$8ET@]AQ%^JXQ$BB
M#+V4!MW#R)4C:U2E98F57:J#,-<*@G3E!@Z\LR3X:YZL?:GL*366]7YQJ"4*
M_2QC8GY#HCH)EF>
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M+#$G5H/W) I$/4HXPBX#LOD*GUS<0\<-LD79?MY!I$8=&$>\;4T0O:UM0-3+#$DN'0S;LR;[,FNAD]Y"B
MHL[; 2A& B?&TW)YT5/!3J(ADG21A /&P^497LTNCS1DE7%K6L!?Q,&@3YSK
M5NNK2ZEF+Q>^/:UV6^E?+[7(HLO]P50^Z)+T]SDNL\B1R
M%DR5K[)PQ=)?[[?V=83=2+@R7HZ[]L*C6EJ/9%O^M[B@;,0/MO[\HO6"WS8?
MSRD>;,P_SU'4Y6?J@[K_^87#DX4O,LR( 6[XD+^H2JKP57/ 7@L&_/$(='JB?@\BW %4>GI7$WB*&PEV
M3B)]]R/X" F[066!"WZ,Z/S,DG0'Z!A%WADEZ(P$:3>M:Q0:H]KJ0*4\\-55
M>IY3G6E#E2JR\TIUUI[9;RLY:=))S3#/+T4@XD%Y>R[%?6KCS&FI\391KW1.
M_)JT(NZRGEDAYMJOJG@9+7EF6@D_[P!M>-DR9;3CI5 2_>
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M4L98FH)SYG:0)8CV#H+N2W-XBK"+Q W!L6Z[P35*71E9%"/:G7KMRJS-@[7&V_U1CL
MW=_QN-I3QPYF.I%*&^D[4HM'0QYCV@SUC&D[V1DFN]%O[ULG;DR;;M)GMK7J
M0*6SITE""6.M
MZDLZ8ZUVLU;#5J/=L[0EI[%69ENM7L'81Q;'A#I..DM]?F.VR^81@QA&PQANV%;^X9M)BMYE0)H-MRT)H^Q;I=)
M/6/==K5N@WZKT>W96JA+8]WJO>>V*?9SPW3D,V(WKS/V^QHFU"=C?F,>Y3?F
M-4C =#YDMC51MHG 5VTG=;\UY!DI>^GV<]CI-:S!N;?TUEG/M3KW*L52FRV*
M#;'AR:RD(8\QBL8H&J/X/$>_AXW^V0_D&:-X"=N)IR[CK,$UZ[>.$Z40-G[T
MZ,CSO<1C=3B)A\@VUJ^VJ5-#OIJ1SY3#:$H94[RI"R5TMTZ"/'9&GDV4O#K2
MU< Z&?+I:IVTIHPY)'=NRY4%6%Z0L(C%.F_*7:6/IWOJT&3]<+7VH#$%6OS'H[&N+C!1=K129J$<72A@9T98R
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M9TS;KFV!&OWAN?>PC&F[A(TMXD,+<
M&G@0J8>]7F.P]ZV!I[Z(WMP:J.7.@KE*5VOR&*-HC*(QBH?$E UK8#<&O7WO
MU;A*LR@HDA%$W]N>7B44D)<_Y7H/>V"HA)#O% 0,Y\D6L.2$/[U*XYL)I?/7
M]^E\[K,9#$7]-]2G@.AB)+8J'\V>)Y_[\XOT_@4!6;_"".  C_/2%C7]^<<>_;74Z[?[@
MGS;\#A\L\4>[;;WX&P(JX?SK7XZ &O5&WU7BNU'2]V>-7I/#)%-&[L+9G 8+$C&'>0\0LPA0YC;HP5JW0.G[YY,YHP?T%>=B 4 -<@\C>(4YB))R(=CWYB3
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MZ>*(RPS:(',_C76L8)\?<4AA(('T@]
M"SPHUEG6H:"XJ!^'3ZD,RM/C6DF\M;S07%:Z390+@?<0O'_Q4H%&KJ6>\"OG
M9@;KO$VXC@OGJ#O*H,U G<\YV&)PA66*\4?"07HZ 5#B<1JB3DL3,) )?@%>
M,2Q?*BX$GLH)^ JEC;#XV&@2LZH H=CSVPTD)?
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M0D-0$K_U/8;/Q&#O.61QS/!WQ%&/;-85S&XJTLR_5!SK?L(=.-+AO3U)?Z(W0/DWEVN5\G>/D)4TD5
MG"V]['J*E:O"BOPOO +4V)GOQEWHE[9P^H4896;M7ZD[X5I_%3MM'ZRY7[3(
M;[_6*ER\!1\OBF1D!U$>D .(DLZY:;<;PUZ/Q%,:%?[\*A[#5B\@]W&"60;A
M6^9R"YPAR/FRT^S;Z-^( 86L4R&::'9;9,&=5/0YO3A.A2^R(JP)ER/<)OD0
M8W3*S48L9.:EU;(;G>$ =6@(!@<-9:Y==G2L'L$_P\ 9L5E]Z[ >"*B#(7A0V6LI<&=%(1^F)"W+E'C/[-@=3!IR4
M  [_G6E"!C9,A([email protected]$,8_D'208D7,];@?F<>A1=CR/@E'XH',JOHO8FV
M@ '+:G9;WR'[email protected](P&G+D(6O_U<*LI%]U6NN2^)52\6)M%V6\"L>
M^#1&\0+$<4/ZA:$Q<^\0U?K]^$:!HP<3-"!!$5
MA\?-ZIUI?>_ X01>_0""%W#._PQ!3WP9^4HUW9#% 3%)'D,,,64$)5<]QU6_
M%A(]PSC4Y9+Y!62?RSOP=9NLQ%4#O7)\CS\BOLE\1KL%:G/;6_ (?B,T4#Z(
M$MT)7Q>[G:&CD&1&DSZ ^\4C.L %N!*HM0N;L\J6YG.1$:CQ&5L:(E? Q2@%
M.-S! 94@HBZ!?F)8O;L'T<_S$-/ Q]8( O][_#
M'U/J D98D!D]?(E/I]@T0=1>I]^P>^TR3$_IL*\+-]!+-W#%1SY)5%Z&3KC%
MY"H N$ F4WD%8F^03I[0!S)FWX$[!#X4)RHPQCK!* 1K+,5:I%QYCBXF0I^4
MN9]GQ[*$7?QZ+^1NW!WDR%V[/?@7Q3R+36:1I.=[OS^_:(&M9[Z/N[O ^_EG
MN6_,/\L=:51J+,KWG^7F,0^6YS%[G?WQ(Q$;S(.6>F)>FUZ:W>Y1VLFLWL"N
M5:F06.BS(K_5''3.>_98$&"YH. .4#**O.LD"@0N[S8S]@'1G<*G.,DV_/JJB<^^3HJ#4[LH-> ,G:S/]BC_XMP*X]1[&F(I:LC
M9BBS@X+KKC8Q1F02W"'&2!4H8[\XJQ]@-Z^12+>BFD)7[PR4VCX-R"Z04+HW
MNCI/=N8@:EQ;J&-2-1H2Q:1J=*2*2=5H2!23JEGK,)\CJNDTKLS_X# P
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MHE5S6D9?\GQ5KX-72NM*
MS/,?X322ME[2GK=7KJ'$!DJ7YEQ72)Q+;B1=BWQ[&G?/,V*FM6)<<=+3V"U=R&/\
MO[I1;*D7GB&9_B3;?L.(H9CFA7^F7=TZRBVUJ_N51LXTZU6WK]-XAEYUY@:1
MR]J_,3>('+]7'9[^;0^'9R:YZ557-R$UO>IJ01[3J\[TJKM4X]5N=K7ITF3L
M5LT4H^E5IS%YC"-8-XJMSF : [:1AH.F+G'7\;L,7ABIZEP_>=VYS&KW)!\E
MQ:E+6T*3XM1]#VF7%*>YCN/0ZSC:O8;5ZFNR;6@\V[H(J4EQUH(\)L59XR)-
M$R%N27'VSMV8UZ0XZZH838I38_*=X L"0CST>$KU-&O"")
MO"#V')26%&8,QR2<)UX8P)]JZ6;@YM\_5$B#/JWU)(\L8B DR93\FT5ADZR8
M7IV=B3:22/=5@]%8#G-!Q!A3+WI"!T(?:>3&9"*NN2%N&B%!$G@^F4:,D1F,
M.05\P4+>-3YX^;>V<:^C#5//(<_'X6NLPGCQY0"$L]?9'S\2N?_14GL4:7.Q4Z]_)=V3[I/0^8/K&*D(
M&.=3%E#BVO+IU*E:_1. .AVDW3F>RXY0$G
M/U)Q-:;I7>;K@EOB 8@N67C,U[;=^2Z&Z<(HI4UEFS%(5N=+!ZK>)R!^O'XDMPTH<;)-!XZ?IZ%L9+U\)+][TQ(]][ 5DP
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M93/4C:*41@MB#P5-=5DD<%7O*(O$XY\H*3 H
M_ +R4X9I1AW^^:JTT3DV$UO\!-MFQUPPX#$\
M63T^ORY<>X!Y^03S'2Q^%'FF\N&Y_+PJ4K+#_N AYV@!5I;L*1JG[\E7X^ZG-EE6N]G7GDB_>H$W2VB<13.P!8%,(*3R-*L^93"&PY+$\^A_MYE
M0;5#CJ+Y\[^PY&I. T_?UC77JF;TK[XW=EJUT]K6WE^K !W93IN \HBTN4T2
MZ@59B3$E<1KC%[QL=1[&'J]Z_N7V]C.91&$:S7D^ZKXDR
M E0/$W7<:XN>N52^%G8+C93/&QN(I"EOA'"3-Z>($S16$\\1F*$./JFQ7UBE
MD/XJ!;,VP=?Q*&BLWXE)64GJKOYJ4TVCMDTF\60WG=;")'X-$[6"9Z>2[N=P
M++<6Y&^BIC&"6M^.4?7,Q?%(?.E6TCK[#1OKS*2Y 7P/,WEX3TL\MKJJ^YIZ
MF&_5T$)3$\ZG49GV!/]#;/>B!L:(G:;[>YI&B("6#%OY7FJ#HC=0SH@
M8@/$[&D&T3L/\^^6^R&NZGUX<(]#[3A2IQZ'/4U['/:;[8YIC*-;BPBKV5M-
MELS6:SF@Z;<0HZW$(SJ11;QK1Q:@WH]Z,>CN82KRU8>'#
MR;9>Q1=):+2>1N327>N55)QI>UAG56C:'[email protected],:WZ75X;H^OBFB87H>F
MU^'I]MU/?^ECJV203*_#VE'P6BNN=7?73VVR:E%2MM1":L^ZS8N*=W4BC_['
M?J1],B5=!Q4^&P$Z$44T/?9C; _:'OJ-VYYW;SY\?7M+?&Q]M)_X&!].5_OS
M7/&1L3^\I/C><9A&)  07(].@C!.L#T/BQ,RIP'3NJF<
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M\-+#>G&]$7J-2 Y]TW_)M=2%^=KU,F6P5QCA&WK0$?8?*<\QD;
MCQE>D\H3[ 5*'!4E$?-I(AA;WN7">37F7\SF?KA@3$@ 0I-_(=LMI0%-761,
MO)351=QBXV(8,-MTEG?KX,7BXAKQ&4 XA0=1:K @BKB%D,.S7NC&V2*8NV<'
MI-962JUU>L[5EZBK9U^BWMJ#T]=]AK-WUC.<[;5;A9=]/O-]&"EGUZ=,_0#N
M0?%1^ G%9^XP[.GL7M0&O3:DU/WL3$G]F:/N=5:3YJC[RM)T&4.<62L:%6A4
MX$6KP/-V^[#ZS=8>65.C(\4V8L6R:*,>SZ0>GW$SUV[:APK2^?2D;HU;J<
M4P]?SLFJ9^K*M%VJZ75'O6J&SY!/3_)=:0V]-E'!^D(E'BA^U&=FH6U9@-IF-1Z N+&2_D
MP[,5+H0V?CCG)R^8..BR;YAC$@5ZN&KGR\ 9NR0*'!J=BLTDC!#I*D1F#^C<
M%#"RH:ML& -S7G*UVXU6JZTMJ8P0F>T<+2GT"POPXG8>]U!WY@4>[R"+A\H/
M#'U,-D%7RV12>L8^1#3UDPUB8,UN8OMWH]H;:
MTLI(D9:[/GH?2S\;V>ZI+_MT =Q_L 2P5H==(-.6O.Z)/-.6O'*RSVJT+/O,
MY#2MR6NUQ;2J^8 VQJY^L9LU
M\J!-[34.D,H6?"Q)S;K'5>\DCDNW2C9P]ZC9YM$I>:D<5LC=4^/#,V
MJB;"8VR4YO1L]P:-X?#<%SP9&U6SS343A.':\->*/?OPTB5.-'PGIZ:.J2TC
M<;I29I>B$$,=(S[9;UTW,F0VCBXMU#&RH8=L&/NB ;G^8V!;MK[T,I*DY=:/.5?U
MS)TF3"VZYM*H10K/U*)7+GD8-H9[-R@:2Y\Y7E63,,R8M/H(E3%I-2'I
M0>& Y-[@VQ7ANF(Y\1NSF]<5XXN 5/V1U,Z(QP]O)9QC;\9(_C1,I
MNUY;7J+Q51M+W>\%>4;*7KH1;;<[C5;OW+>+K#.@:]7N58JE-EMQ&P+#\QO*
M^@6&QACJ+'7&&%Z/,=3B7%BMC*&@QY*R74FY\P:3KQ(*R,N?2\' T=;3>O[UW*^),+.=1/)(L>V'@S+ADH#Q&XM9G'@SW@@$
MIA@S+TDC@!-^:'U';DCG.S)G$:%!D,Z(FT8@:"29,OA?Q!B9 2C3F+  Q_N5
M%W:VK0:Q6U:7;VC"'[TFN>7#E7[ND83'Q&F X$P"P)B[-D#.P5
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M*^D _/P">9SY/IIXH&O^63H/_+-T2QR8F$6Y$R(]"##J.[WFT#Y536?-@_B3([_5;-OG+4/3/80_ U&L=K/3,U31C2I-VQ!%
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M:DD9$Z760K84,\%KI>"U2INJJ].,
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MFZU18=.H#,.U.T]:>2!_B.-7Z3.Q2@M0D/[7;O=TE^6D2
MFYOIJ<75A+H<<=*..GI+V[/VV#"$V$"(,[Y#I_8TVMB7/.3GH/U9>T ]LW0/5,)HQ$@
M+8FS4X?:JS!&!^773D\ODU_36)A,?DT70IC\FK:T,?DU?8EC\FL:$\?DU_2A
MA,FOZ4LD#;\K>S]-6J2=)M[D5U*8K;U('!R)V6!%RJBSN<@I=N
MY[ZW\,BO99^9H!N._&K90>-L]/I!$T(=UDSMPHBBC5Y<<=+72-$1#_(>F4[]
M7<3(V"MO3
MM5!KBIGNA3I2;JE[X:\TWHE]T[KPIK@A-=B\K+5W MS/=TP]R$ G 0!D(
M+#4*[#ZR"*C#VS:2)"2C=$&^]P(^+IU,(C:A"?N!I'/\L=WH#%N-7LLB,;]F
M% $HT0S(08.,0(S,^<5\\-!+<-M:9,XB\:)8"24)BV;X\]A[8&2!EUJ1[V/&
MR&]APHAE_]!/]/4%U6WWJ!!$"B?6'C
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MQFI\2T3#>%S?98# +"'HI-$3MLA!$K#@_W#B_&7Q1JBOSZ1FW1Z9VSK)*K_*21;^/H_OVB!96(^7N+I /+RSS)4X)]E
M$"*NQLQ##ADL@(_NTWG,7F=__$A$3-%OJ>=&M>FBW>LVAR<[T5J+C$!^96OO
MK%>VMML\Q[,YZK_ ZUC?AU%Q RMH(_7#LC75]JA0L_6UH5T]#D]*%:==
ML6YU$AF]:*ZR7D7)/+C0HOS3:$&C!2]7"]IGU8)6EPO7KF5^1DWRBK[]+Q<_
MLH8TZO'L-#A4BK8HR(C5D4
M81Y^U:;Z]T$Z&[%H>3=W[WQWO9"CL._&OWB] G K+"*NUI%$8.AY3]E4L"*F
MZDY/TG6J.0&F @]7:S6Z@[ZVI#0]"L];';F6,D>XZ*,6AX!KH.Z,I:HMZ8RE
MNAA+];PQJTYTT7TWQ(2M1=@J:N^P\G!=L'J,Z.ST>3XC:KI2IK.#(KQTB]5O
M-ZRNI2VIC!!I6EUF@BLC(X8RQM"<[ [%<]#+!$AF7T]7"LES>:LV];1-.!AA
MTI4RQC(I#1X:5J_5Z+>KM7DPGM6[!@I$@/*3*[/[I0PLB(H8RQ-"MS
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M"SZA[@/#I$#EL1=0H"['1.!ZN+7=(!&+4S_A%XR%>"=/)E%],
M:K?LUMKK/O=3F65U^X7A+7_N9V3KKXA_RB]5W:9KV]>I:ZTFD0@C'&-$1=EE
MR-:M[V<7Z,X8MI2*-]VG^R:DD8L/O/4B4$\A/(T:TG.\.<>2)]35\K6[7EF 
MNXU,ACQ^F;$B@3"TU;$;P%[*Y;KKH"E?NALH?9U5*167]FZ?!0$OCF)Q;WE]ZR":/D
MC1O!EC\O\N"N/XYJ/GL !(?@N$YO VB+Q-<^WO7+M+P%3[
M#^S-O =N5T";\QDY\8>-5J>O7DJ[[1+9GK@65."&QC"P-QNA-\/'1![C+.@2
ME"#XQ@EC8,04!MH(^86PWV? 1 K?R"N&P>QIYD//&BF[+BFEE8.; ,8$^PKA=X>%]M
M?I^X?$1@%'Q.#[D,)/7O*7@CV17'PD,"L88G_X4>)RP9(G+V" /!LU2 "_E&3B>A%0
M07>*2$J&G+J;S%U>!F0.ST" TU'%NQ#HB9#2/=OG(84X4U%1 2^3W^/A,>2W
MSK3GW>0W/(AG'4R)
M<_JL\A6GJ0/TD'_@('4%.4>$,FMF/OE!.E&=!Z")(,=AU*MIV/X#VD3I-.S8
M"Q(%.IH[@7X'\M%RJ6C%GBD,]+>&2(_T=6E^.0J2Z0<>]E !HDOIRQTW\,505PXU)'$B?Z4Y>&ZRR<
M=( ]U5%]D*O([,.-W#R1%S/7-ZF=X)*0\AI/^<=XF+X,U 7*K/,2.*_0S4V;
M^MY"H \*/@X.J5Z,"DL)1OHKNR*G88(NEYD,2]>T$O0]LO_F==#+J#X]N>>A>LAHE-@\BC>1&_R3T!1JM"^.^#^T/MCG2I,*$5U.^J;-ZH]0
MNH^9:C_ITS@ L74"-;KNZLV4X-8WFWJHT61)6,5T4]A(ID!(C)N\W8\'S*&64(XOH X&"('_F_:3$R(%PVZ>$,KT^>E-
M7V[N_UNY,I<.HA=U) _V3'D-LX<2)LZL+$['@ZMSS\GI9/#^)2C*WYP%P]@_
M!OU1RK81ZAZ)%,L,YYDVS7#$SAB8<@&U,^&U5K(PW$82I-B 079^4?:E_G5\P9^JN=/B<>%[email protected]&X8M_S"(50:MES!,"V
MN2+ !]/%$TI?D%^HR@$L4WO]K<>F]Q+;R:%9G:AU8<7V8(:A;^4\$CSAKAO=
M.0:1$EKJ;UK"+RFY,0X,FP.!0<]PJ;6@KW
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M*.F&J'B24DG:1^+A)K./7&=&E!\GA>A*WY[],6@]C:[Z6M$[KT=)L=3LMM5U/+LYJ4_ ICUAMG3Y\53<8
MD(7I>'0IJWDBK([CR73)8WFE56
MZEI?NU64+0&5F.:3\6N4@:Q:QD40TKX @7T1%0M%%(^
MO$S_QFJ*M-1U_2RNERJ%K&;'YE%"NR.85A0GQ=A)R27%%'VX^9"5E],B,5HA
M1--KTTX'SUPIT.JJDH(/>$#N;ZX!0E,J!"N?, &9L[_E$_%D[7IQJ+1?&WI)=:^W\PNLFSX6Q^.QC/[
M;V&AZ? XA::;:M%;*C2E<$(TW,)IQ3X %(.U$M\%K+(G7#>N[%0RUH1U$I0Q
M((/T_ @Y5H )<&1I)J4F>$E *R@2<;0JK0"."D]=8DW!(_%(8+I8-V59V"O%
M3GLC_ 9\&/ZZPQ=3&%\LX)!;9K\>?,73#A# L6?&-MTG-N["2AB[&.@ ,#>V
MN1*]:WB2HJFO_Y?3 ,K 3T':O^LK=WDA\_Z;!?+PD;!>>V%(!2)PO;OW5SW:
MR2N(K97,_=^LR=<7LO0#[._EK9;25R[H6P''[G,O[9]3MBVF*Z0PP/78/BV)
M16:"$@:.!GV.XR%(&7T%R/(#5KY,[email protected] F^EIHQO[]>+BMI<(
M4!ZJ)G!L>!D6U,!A*UHM8_II511P8T(K--\1:ZW#3]IRA$I-BAE@^+3'3E8&
MF&ZY&"H1DZ.TM.@AA@\^85WZD@53L"3*!@\9!.#,]R-&D3R<<->)-$/*=0F5
M!J:E)C7 &"Q""BP5VW$(!#8_#JF 4RZC8\EP'I5=Z[,-Y*EP#8J:E^NU<=S93AHU^DO0$)FNMVH7U:,8X7H;_E\<)GTK0>$"K1.7A^5>3$[0>C&7
M%=\7-S>D"B[*=J9[A!R5;V8%K,J5WL:O(&W;F/:8#) #4-76,U%'8O X'
M]35GD2T%GX>',=V90WO^[email protected]>;GX>_8J>A(-6E3H2A7R5:,8@WV&6B
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MMC:0I?]$&!?!]L',Z$=-Q_OT9?#N/0/7"_&]*Z/J[L^,/11I($MYMDI^]6F
MD\F_6'_NBUML"0$Z)V77/V3]A5R7/!+.B/.46S.:IRC_%SML )AXAMXD=/W@
M603Q A?/LRZ8 (^ ]7=0%HX5^#,7NS];B&'/(V[8RYH1H.:[S.Y+W55PYAY)
M6GA/ B9U-_CK5L25GG%F(Z0-$U/Q"=]F[11['!GW*725!+K62C]/X9-\0T5E
MJJ>3&1YFVDBI &W8^SM;-I;J,X?Q/,:FB]07!3M>J5C+.%CZK!%B_I(;LF?LS5G=P3>TEG
M&&Q$17537#K3UQY(UA7"A*N @I]?^U^Q#5$8/X1 =HG!E6]0CH8Q[HOK=FM0
MK=#@,9?7MZKI3GD')>"&T\L"WX./K&U(N-55.3Y/S>L+L2CGYATC/-Q.B+*2
MD,8@:4!&6[XF;F\@N7C)6H[1WQ;,@GG1:([1Y'7F^.# =I?H-TD[+ "RUCH#@T-!/)L=0
M!@JR=T&C;8\^VN#H'F M=.@3+##V_05>EW3Z9_W]DU?.7. H63]K(%ZR8BBK
MUE!)\U\VLR%,HWSXIK =%@4,7C.+'7@& \X8EP2_*
M8;(H1]:[D#7YHSZA@/J$'-9]FWH?'@BWD?
M1M(5)P%0_AU]Y3THV\ZJ,Q"+78;X\\*)(MILRZ4]06F?Y1T7JB3K&]5?W]K\
MCL2&IFX8)OHQG!O2Y9&D:T]BO8,.;EI9ERK3]IE.'JQ3B.M0" G;4G
M#4^EA2P5R1Y). $G6.]3@THZ39+ IA:X[-;.WD$#'/&KPS=*@'EW712IPG#XE=E32(
MRKTV&PR2D&>V R=ZE"47PXD?Z3ZRJ3Y3!_?.D19%USN46E
MJFGZYG42*&YOS730C6?:=EB[S?5)-"E-;.[)74@&?G"B5' 1/X(XJ4L'W P%
MD!D)^Z$2C37IPT:=S!Q(3R0%);4[DOR!P,1N&BBT(YQ\#&#'<6I@RSWX<<3)
MJAR.N* ^JG<.BE%*!8\^\X"BS\1+SVX:R.?(BD9;TI;1F\-5# Y@WB5&)1_R
M?WD/?T3RQIZ3!.\+P4!?A >"FDM;29;R\F(YA)12@2I'O21XE$G>S-M?P #X
MKOCOJ6,JHSI>3$I!=6C;<5B#0%>:)XTQLGCK JQ[3%=937AB'0"9O$'G&O?3
M D@9\V$"-C@!S'H$#L;X OB$-)H,3_"3CH7"F@XZ
M*FDF#FVFV = OOPVGSH*A:C05##MY N4^N.A8
M)+9CL9:!+%K"&C!BJ)1:RG"00)\U748H;*0C4)JY5:92&,%!1P\-_8(!9UW4
M5I>@U11'E,W\\W>@U"S24B_-#N-:D5+MDQELE"BXGS*3DWHP
MD?;8C)+D=2NTH;,O8:6K+UV'25OD(@\D#=I10ER: LC]>BNKP>3$OQ\\FH#@S'CEL@\X+&7-D_-!TV2:#04?
M/F\5C&41Y\0+D##:?/=;,SL>STD2 "Z'>EC,M1M7,'B=Y5(R[[@2..%?S W"
M6#FW&?0C$#<;+)F*+BI6LC?G*6%#0A2_\&7F$R_$4=MFT_@%_\[R?\IA:&:A
M&LGPCS*NLR&.GZEI*^]@Q$(L*3_FN3 L+\S(C [""HM9!XNM8"((LB0+UH98
MI($ ER0U"BQ,D_B]TDOH(;<=ZJ>(G7">Q&#IF :&=)*^&!>7Y&3 1>F70,(,9O%MT!EYA0^6C)@6O.=>,A6_^'D
MT&J@--B:#$F@IVHG)H$C?9S9,X,OFP22$YXT($&"U>!FEF7*GK*2"NQFSO?.
MAJ8P'R$^9TYL%D90J-P*.^-'>6O327(U5/
M,&N5F&N\GQ%^YL9ABA1H:=OL+.*PIQ>86WZPB3IW-,>4O,=$$M[)
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M6I#P.L)\#_D4$D93<.T;E]F"?R@*%Z-BN.O9Q5Z83*W[&/]+N*7)B,#@$)
M?Y&DS(I% JW,&_M3\@X]]X[DP2EO N5CV[.94HZS[)C>;-.I@$!EM.AG]5>V
M^)\H:;"7&[F7Q][++<(+69:#"U2-X] "[&? 7H[15I.Q3.KP( '+?5WI7JMQ
MY.BN91FBE&3]KQ[OE\VCHV@(,";,!P%E^DE>%%5BPOF*I7)%Y+V4?X?)D#S<
M$OR(^F9\R/5N//
M$G,WS,(U>=\;JU((W]3S?ZH;]MYN&O[:6$(V[C6$+:#=_T9#?J3R?X=
MS2HW^:'XGAR?#"KVR8(5 ^H!%?JK5GMF#?K3XCYS7(Y8PLZY,$'4#3D^]LXS: *
MAG;P#>^!HFOG&[9[T@L,/TSG3GOBB&\:'
M9FKZN&^(/Z/E$Q;?>R0I6LIZ2DD7DUAH^H>P"#&H\BV'LU!MNS?4)CUM.!$6
M6V=*/L*X'W://$E,2!J1(D:*F)6(&:B]X60L++;.E'S.W8?3#7/G.@X\6FS 
M"GAG,VPMMJ_5(UT(HBH+A\>,E$TK=&D#HS?6Z\8;)!6=+15)XT<43$@:$18S
M4M)(22,X6F3(IPLV$)8/QECFG)\@$OJS"("6.CJ@,=4BJ85NH;C<6\R
ME1$@P= B/A5)(T@43$@:$18S4M*LT#52]9XZE8$@P= B T%=,((^8A_4N>_:
MZ43 A:418S$A)
MPTF:\:@WG$I)(QA:1(_YM-($L!O&T)5/>\Y;;$*'EX[=$-BS4*71E:1",;%G
M5&Y5)N4=[G:L]B:U^SLVRSU%[& F$JJ$H;Z&6CQ*]$C1)K$G1=O!:ICTWMBH
MFR-L=+#TP@\BYS_T"V&=6M(E*5V2YR,(#1"$1D_7ZIIMTBMYE@0H
M VY"HT=*M]/$GI1NNTJWR5CM#4>Z$.Q22K=NQ]S*;#_;CQ]9;764E2'XK.6DZ%-#CHC94Y>?T\&HITW:#NEMDIX;
M>>Y9DJ4P(8H2V_!@4E*B1PI%*12E4#Q.Z?>T-VZ]($\*Q5,()QXZC;,#8]8O
M+"N(P6S\Z)@/CNM$#NE")1X"6TJ_SKI.)?HZACZ9#B,H9F3RIBB8$%TZ,?3H
M*7K*,'EVJ.N =)+H$U4Z"8T96237MN1*#2S'BTA 0I&#IXXGN.I1>/]RM
M/NE-)[)<0#"LB!]5D?:1*)@X5QJ1\J4+6-)'O8'>=E!)THZ,'W78PEF:SX'O
MNM)-(!9Z.N# D9)HA2X-3)WQT! 65Y**!,6,-'5$P82D$6$Q(R4-9_,8P]YH
MTG:O7TE%,JS38:/GR;3V::@A70>BRB+I?SMJJ; Z[DT&=661I**SI2)I]8B"
M"4DCPF)&2AI.TNAZ;SJN.\A84E''K!X9ZCF$U?/@>W$H=*60)"(Q,2-%$2>*
MQJ.>IK;=^T]24>>H2!H]HF!"THBPF)&29H6NP5CKJ88,]0B&%AGJZ9+1$YHN
MO-GR%PLG#!W?JVO^2!^"J$))>N*..FIXU!M*1YQH6!&?B*3U(PHF)(T(BQDI
M:#A!8_34VB,V)!%US/B1$9\FL705!]B_4%GB["C?4_R98I,9@2]M!7^0+@6Q
M\"4=HS5K&P,I
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M"->[KO\U?+,Z-TT=3@KPOX5W ,EQS&9(WZ8>?%,;?)BJ?L"5,*>=PV$@VL/]".F(8N.
M@38"JU187!4!<4N@T&Z6F33L?XVYG:J6ED)^-P[[^1P'+":K$>:;B*
M1D[2Q(L5KX]QUM]_H.80=M*WA9;^"!-,YM#$3=.2;R(E7\=8ZU!*/G'1DUTWD[:V_B*(Q,#P&FF%%C7MDC
M)4OS9%SHCI->6=&CT;MX90^,XE/GTGI/&VCXKQ )"-(KVQTBE5[93J#'V&'*
MT5D25%VG:\.(RCM=I8E1!75&?RR*W)(^U:XQ1NE3%3X'LB3A<1=4G3H;G/:%
MX8*-*QNGCCO14QHWFN(--:XQ!GU=>"3]RJ9EB9JK5M'O)=4.(;%7U:P(B9U=FG.=(7).N9%T)_QQ:=?.DY@W
M<>JJM#"!OVT>.(FN#%W_-=$U75A\2P)=UO74*7=,()
MC!SIA!,%$U)5$Q@YT@DG,G:D$T[8I+A66N)WPC-W97H6<5UB_PA7SPB<7?M'
M\FWI!%W)GMN_^^89TF+KL:2"(J=F^J>>I'7U@X:-^ 9ZRP@M*?GDJY
M)0IZI/[7-8RM]<*3*!,?9=LGC$B,"9[X)]O5;<+<6KNZ3V9@S=->=765QA9Z
MUX.$=M-^:5+LZN,D;IXA08/8=0!$^=&PJ&0NGSK.7SG B!O Y/5F'X
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ME:].-*=/G_FNZW^E-ZPP]V9UU!HX[!4.]'<&*6$2R:1 JH(NM5][
M5-_!$76^ NF?8F:%23GTS@DM/_8B)0#C'G:%MM+?L0.@A^56D$E6P73N-G3R
M:5\M'D5RZOQ.Z^N#?[()"MI(7+KJF:K^:@T+JXN(Y*+J?LE$_Q8*E;SPXOL4]
M^)8$"%[LP9][&N8+>(_P*X;,S4>R.5M#/]=LC01&F*41S4E(8!L(&I:Q$2H+
M\UGQ+2L.E ?$F^)[-*,"4VY,[SE3;\<_A8IIS1WR1!"O^+00I+8S<_">A_\C
MF(H#6WEX5MX1BRP>2+!*[3!#Q281"1:.!U?#)9O><.G#<<%GOW,">*(?A#W%
M#Q034+=8.%%$2+*-RG>#+>5$H1+Z+E%L)[0"@MONX9)8TLA!TD3TXZ.9\\VT
MGI RKI60ZB6]"T9G&1PPW5N)MPD%\GU=N!Z5:8TGAUG
MO(NI:Q ;?"5^R);9X_%YX<;*T?72T2O8_$/@R!CXL?2\*E2R0Z1HGXI*6"N)
M:I+&X9NA59CU<);1/&$:(6Q&W;3:J(X#H*\372D[@,$SC92+KKD?6F1I1G\L
M/)(^.9ZSB!>*%]. KS]33,LB84@CR\O Q\_$[BD/CNLFS5\Q5DBSO43-E)0$
M)RQFF#"3^5VX6\T0%DUG2D!=*SX[1T$5D"?B8<^:6> O:$)88%I1R#K)+.GYRL(/
ML!&JZ<$O1'$PV.\LSMS,M!TWID(=V\%$S\H,A+U'6[RBI5XM)"IUY^Z(<6E\
M'E6,#X5%TYD2D#0^Q<7-1;Z^-5=F"L;G3R&K9K7\8.EC'S/ET3?=NOY1J2B+
M*J*DI7G4N9!U190DH&Z(J&;GQ1PY5;X3<@N%E$O[&C"G*>V#\-I<+@/_B=BP
M;Q16CX[%(&-:>*7 >F&51/JS),S.&%_-85!*OP.CLA+5G?U,24&MMC*1>+ 1
MDYT0B?=^Q&?P[)32?0S%W0U'2]%[['VY^RU4OIKAP9KJ#?=IJH<]]=*KT[F:^$>^Q5Y1.[U]
MV^8)ASF1VN:-!&V;-^X; ]EK1;2N UI_5(R5T^XH(-OF"8^B[I9N2DXG.9TP
M9)2VS0-=4K(W@? BV9MD;Y*][8TEVBUOI<,EG:)67T2^Y'H"H4MTKI=C<;*3
M7I=9H>RDM]G%*(H?7+;/$R@UJAV-KPIIR/9YLGW>X4*YAY\HI^8$DFR?USD,
MGFL2K^CJ^J%%5B>RE-:Z$LE$>+'0(WXE22*?9);07KFTDH#:S0T
M%F)5/V\^!H16:DA323"D25.I4^BJ+9$D 75#(G4ZJZL38NH#]GQ!662FC5]F
M?APH'BS!=LQ'SP\C[/A"PDA9FAX1ND^9[/C2=4-+=GSIC#$F.[YTV$(KDX>R
MXTO=CB]"I #*CB^=33*KFB8H.[X]W8/B[MT
MX:JWWW^G*#_'X>M'TUQR3WL/]IK_3,@="9X<>.(<3LTE-H?AF[![#A58X/UX51F+U&<>Q?7EW_"2= FQBOZ"1#^.D+F?WRZHI^JPX&
MQGCR)W:LAC\T]L$PM%=O<=/)GK__KLN]6^[G).E& _A06).694!"=-#2#C9D
M-B,XW9$Z<0%HKUDW'HMO>Q,0UXS@R\A/1U"87\W #ND7"RFVL!U64XMRZF'Z^Q/EE-WF4W*- MLMZ.$-NZK-3QSDD>R4%7%U%O)'EMBCT<,&.I]?5]":H]/
MBM8L1#+(DR!1]*E*!BDR@Q2RS.?83L7V(KVR.&]C$\IE+_$T,ZPY?I!TQ]((VBK^E321I0\H5*5!&*I:>QXX*9=8@D-O4+%A@20B
M48E(QH#:QH"D#5%I0PJ8=M%E&#U5-81%E20B&2BF2LIYNVCZ0-,6A#2IB6)JJFMXQ.V?ZZ4R&FHN8#P@B[[ME>4J1UAZBD2!,?I<:X9PS:CE])D2:#6J> 
M(3K"(3/:^,[,M'NSXG.=(<1TF,BZS4[[)1M"WZD+/7TRZHUTZ;@4#"TR--9Y
M\TS*J(X0CY11@N/3&$UZTVG;0X2DC.I8<$T:8;@W_+5BS[XO=[]UIE6?I#@Q
M,;-+4HC$CJ0;$3$CBZS:QH"D#5%I0\H4B1U)-S($U0$,':JAA'0HB,KL9,[[
M,=$U[@U;G^PM:4@&CD[-U)&T(09M2/DB +K^:Z)KNKCXDI0D9.A'UE4=N=.$
MS$47G!J%<.')7/3**0_3WK1VHI$CK"$KW,N>D
M7!.-!-L,<)79>+8?/[A$T?OG9^.QPBM:9/7ZP0P)3B=?H&U'4_X$=J3L.K8\
MA^.S%I:BSP4Y(F9/78@:QJ"GCMJ>+K))@&YDNV=)EL*$XDH,P_8%9?<,0RD,
M1:8Z*0S/1Q@*41?6*6'(\+'&; LQUZXQ^6-D O"RJVSGJ0:$<@#Y)P\ O24(
M_)/;."DXO(=U7L(U?[W]_CM%^?G!\2WN
M'?"HA>_=H;WX;S. W43AA14Y3T[T?(\XR.Y6'/N75]=_PE'2)H-78%5Z"( O
M9/;+JROZK3H8&./)G[H*F]14C7TP#.W56]QGLLWOO]L!B:-2)*K'1^*%$L8+
M6. SCE\F?\< I->6:X:A,W.8I0VP3#J
M*@1V9BN?:)ZJH?44!)KBA(H9PO6 V:_AF]5Y*03=&C_@(%D.NHUT^1V'+L9&
M\1PDW.V75RK@GK@N\B_@A-G?"6>D?R<\UX(7DR#CL E[!*[DFLN0O$D__*0D
MKAR53PL3IEIT,.I/]4,EK'7<0CDX\-6^H;>;8R.Z?=("4C2C/QA)K(B&E;XN
MD2(>4@R9Z]PN B:2*$3#R1BI0B)%**2 IM5RD:U$2I'XD+4R:%>CN0DHT%^U
MFO(S[(^*+4'.T\J,WB9CR<2F(]$U$RL(]N(PJ!%
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M6YX]O;7=6)'O'7!D3)ZZ[#/Z8T,([#)GF23#+C'673 FT7-T].S=W/X8
M/'4Y]X.&);^:WC)"2TI^A>R@T1J^_B4(HO9KIG9B2!&&+Q94^DHJ:K"0MV$\
MC7:VE=5(;!76*@KR4QHOK@+QB1ZCHX>51)4MS"6K\.5$JR#..Q.
MUT*A,2:[%XJ(N;7NA9_,P)JGK0M'8COV9>O"TPW=R-:%S;NZI$^%0)YL/-@]MB@;#PJ-G@)_
MIB0HD3%6Z,^4 DRV#3S ^)44&V(-MN3]F#]&)@ ON\IVGFI * >0?^YR5LO7
MG*SFYQ\?'-]ZXG7M8
MSZ4+O[[]_CM%^3D.7S^:YI)[P(47.;;CQG /N2-6'#B10\+WWRPWMHE]'?@+
M>,4RCLS(\;V;V7LS\. \AKO:9/A*L6!S\-,7,OOE
MU17]5AT,C/'D3W1%PA\:^V 8VJNWN,%D?]]_MP.\-7T#P-<8P/&.W/V<*#/?
M=?VOZ()=^A&LRC%=]UE)0:R$&8R5N0E_/Q#B*20!MS(#>"L1/,5: 3U4_!F[
M'RY@ZR7V:Y/->U=".O53\3G7+ZR4/F-) L>W0V4)%^",++NGF"'^\JQ\]6/7
MAGB60"\[.^$
M\=*_$Y;.!HUE##QAO<#Q7',9DC?IAY\4QJ''*E^%(TQ/TM&P/SU8?5 G]*ML
M -ZHU0%XAD$UYG(=Z@2'VUW[P6J>'7 C_H^ $ 7D630/%0)K%S9S'HP=.>)=
MV%*4A,4)E_K4E1'O0O!%.1BT )-92%^(9!K)!247/%TNV/IX9+5&7HQDDS0_
MHOZHUH8YI&2/K>-@7RK:PB1/FY(DTSP;5.^1)"K52I'5RH,G>![4I2A2\.\V
M(#,2!.B'3X(M.]$
M254'V)V45)U%G914)R.ICFNSBH07T:,ATFQ=F:TT6TSY-M2$194D(D&SRZ1Q)6E$8D8*FH--I&H#7]) DG$]
M43'$JJ@*@WK".APD,8F*&2F9N'+9GC92>V.C6M&LI"-1Z4B&F$3!A*01B1DI
M:_;OBB>#1**1D@P2"6 #K2)$PGH2) F)BADIC;ATA?&D-QC535B05"0&%^-1]6ZJLK CVATU/XD#5'[!+1M"?G+I/M:)X)!1IB4;1)[4K8U&L0:
M#7K&5!#IMA5[4L )'MDJ,_+.>'K&O1^9;K[]=58'14-@7!V4J)[B*J6_]JP,.B1\O%,T2OE
M8^/R<3"=],:3:C7+Q^D#V041*4=<-3GBZG!#JO)#L*Y-)_C==&/RP8-[PX^.
M^>"X],G_&Z-AB(][@A\1$_3)^8E:_,2KT3E/O")AY " B*V8CX\!>82/RB,6
MTBDV?IP!F)%GQ 1[C?Q#ZTVGX]YH-%;,,/0MA][XU8GF=&955H(7^F!Y?,0A+A8Y"](/; W%^:C@V@
M4RQSZ:#YCZ_%/_EG.6$(V+?0&Q!&80^>9=/GKW89AW"XE$O7M/YZ#6?4=V%%
MN#]Z1I2%;Q-WM:'5.##8;KQ@,>5V!FVU, -K6&L&UL&]TN-A7QN=29H=G0VH
M+ /'(BU'X#9G//:UHK#S:5:C+M5^U-55#P9_<&9DH[H@1Z95\N2=!\"2@7UWY880)P%]("':+-;_P['=PC>LO%[#1>Q]_SV[C4W;'Y2F[PS1E=TA3
M=A6;6 Z@+:3)D+'GL+M^^],)_8&NC7^[>_?JK3Y5Q^KTYQ\/LO9\[O)G$GWP
M+']!/OIAR&]K4G5;FI[?UNOAQGV]UD932BTK'.?>SV'L(LT _C6 'SY@LB@)
MHTO8'E#^!SA\#R#7/9)?\[1DS*=S'Y-\TOOO'('W EM^.I
M*N".=8W?\?KJN8W=1',2?/:]-3!P=,YO5=N6&K_#"H?\"KCZM!J[T-01[FA%
M5'NLD$-/X;W8T\R)D*T #X8C$[C/M^8S_OURA\;6':;%#)6WFFRT_OJJ[^\Z
M('_'Q+.>;V:W)'!\V[&2)_%['.Q6L)$MJMH>-J\A?R3O2;"XF55&.[^!X6X;
MB.:!'S_.E4_FLZ(# E>';LLR+8/B-[-53=BTF0^?KS?LYD]6G -\K3\<)3NJNK0:NWG_;>DP
M-8J1&+^[,H7BY>[>(D&\5O4=U[R^ %X+RDJ.;DW'_N!=L7JCBR?3<:FNZU^2
M#V$8$V[5NEJF%-C$^0@*B/L>]>>5-G 1PAI(\OCKV+,_?KQ*I']"%7>@;1/D
M/.__CN%.K),#DP2VESV#M;ND92(IN5^ MD-O6FD2H"_J5>6T9HQRRE-E:-0"
MX1VK">, 6:9RB ?(=8I*R4@?309P[+$&I/@A=&S'#)[O3"SH_.B"QK_T@O8,'2ID:U,IV
MQWF;9/MN-LOJ#TF1X\V,.[3\YLOT(V[S5,V)WC^AN?J\S)V/M9^;/BIMU^&-I6KI:IBT*#KZRPY>S7H^FZ^EJ
MF>(J.#@K:9N&VJ:VJ:MENK2(\$5]5WNM#IO3=W<3K!7W#:W!8H5Q-,=,J
M^ FK*V8B 70SFS2F^FY*'3V,-S,*9Q9.\*DBG$CQ=>M *[,.A($63ZZWX^&[
M]'A5V6P5X/R.T2B@]"_P]E5'%1Y,%6P"P<"D_;$-2L6[SNMX="',DGH7TP-'
MG\9 ^YE\I3_E(%7!4+A"'R8)EF80/7\V%V1E=^(>$UONR@^6Z-,G;N3R%@)(
MF/3#M(KA.%'7M-QJ6]H7#!5,AGLG0EQ_\&@Q5@SF*W=Y_V[B5GPDJM44/GW.P35 ##)2:.==M,$%"IH[C7.
MP$ZHK[OQ[,C@=R\$<04=^I#H+=1[]2%WT+-5O"HTJKR&WE'8'L!L=-M8KI&;N%;0L6[ -]86V[ANW-!THQRN)-%
M225\8<'J6R*^:Q!^>SO(%-+M[]F/'_&KW!*SK2XI]#[email protected]\2OZVYF;H"
M/[V:@:%4".BU8[DE+'*DCXWI>M!PTV+6^",+K(=@8F?( X+ '&(OS"W\( '<
M=9Y8NIHB H5?T\K0W $YB*SESTKA"K@5?O8]CAJV,KL*DG-79E=U&3P]>E9 
MX+!G 3(43GEIQ*_:.(2@U":Y\&>5)6TX&+@[3 I,*X>YA6\7BC4D_*;CL;:.
M#2Y^9LAS; 9N*65#_'ZJN!M2'\"=13RPY/V[?E:C2J!4(&HNAU7JU$E
MWBD4E [J:=UH"!IE"MR!\GHRWT[&B/.9/.K.N5$9"ZMA>>YNVAEE:F3[,'M[
M:ZB?=C0E:WNHC3(5M7U85##V:!KUOH[](O_FH(7)#*E/"&MU])]FQ=/+='/JT5Z>E^
M#J":^ZY]Y7LAB'8LYKL/3$Q4 N#P#'=0IE$WL6W01-147]MQF5688IGV6IO\
M7YH0S'39C_FI_6$)\UL'$#ON"31^]]UX@4<<9SN8CSD(E&FF#9];/;?%91P0
MW%66VU5U]7F-//GR9L8N^SEXI5A76/O:(5ZI
M]YMR 0<'40>/GY$65Q6";G[*R.!GE=;$-KRX2%B52)Y4XW(J'
M%9+ WI&'Z(,')EQ,2^9VJTA8JQ6KL'>C4(Q4V%9]76Q8(6WK0%#8'+<8J$8=
MS6H]6)"UI]U?4-8>'*CY@_A\65< /E<,A:]5@6[7. HZ:2!_&6;!=0O!$[&L_
MN(XCD)PIZGDH'*J&H&CS6RNX:N^H@4CSL,G4I0:2BJND^6=R9C!5@=CV#&XW
MG08U/%3"?\W"'&TZ'8]&X\-E4'TRK3D8O\'SA6>CTX*V)Z%%*SQ4MBM6E?NH
M#+6)-IRLZ&;S FHL=+0EYKN#1 ))H0XGX]T7>AT'\$0@=,P%=+[AI_#%.K>%
M>*L#5(-[]!'7H6?3ZVNLE
M.54'Z' \GDPG*].T? UUU[M5#:D,6NS9D=F6%=>;HN$C)B^@(^7#8AGX3U1M
M?GD,MN4S[0!;;3#2!JMCL/G]==:Y=5)K99C676W@@-"O'V&HML3K@,U"FO"U=<).TMFD">:RA:L-(&Y\06E!\QN^9FQG#"K[A^<^"/ONFE7]YX).^[QO>EKWMQY\VW
MF1_8UXZ'[N9<0'^@#O1)\@&+1RH=P0EM55D<)BS2_
MQN[O7]*W,7RMB.Q0@"O.BLLBP#N A&_$#_L"O<^,W8C6J:QW/-=+VU/OS[VV
MI\>]@$-9/K?.R\?BO15O'M?G_D]L/R*P-D"B0K* ^)#8M-$UMSR.Y\AR"6X"
M.KXFRV'+:I:N3-<%@_8YS3E(+N2]RZ7=M!N4?CL7#&R%9IIH,00:X&R//4%3
M !G^&2!V\%H^1XA[8YJ&[:>K.0
M_1W8.\'YA>FDYWL?ORH#>&DK]"+!L[%N;SI0QZK6'*RJ;N9XA[.TQ?DNL-)!
M:X1_.G.N6+.0E!NL)0$:I2W-ZW&ST2!?TM7\^IL%$$CW&:$Y]6&!S"CM9%X+
M0&!^C =Z
'D9\-
M@C'<22Q5!>765*--PF0K3+6^,=@!ILUMKV&X%DBSJL#=DIZ[!W!U.KVUK3VV
MS0"V=<[?'9Y&?R@\ SB6\-K6RK\.=%\T?1-)>#UL7\M#4VOY0A:FX]%NS5X4
MF%84FRYF%FH\ G9K)?+V=OK'&G2%V%&SD-Y] 3H/TJW#$UZ 5/LT>M<<6&LL
M7RCX[=9LY>WMY ]-_:0/3@F"AZ'UK2;8"\!./VF3!N%Z4()O1HA^@/[Q?+%W_F1":Y6.+1K31N]V#[/;::D/7^V0SV"L&@
MKH"]-CR:92[<7-?\:W+,HD*XZ*AP/\B&&SKO6>;#11C&"_;23R2:^_9O82ZT
M63H490^HYAGWI6M:?[V^L^:^2T)E":HHCH!8^#9Q&SC,Y9L]($0W&1';9K9L
M=2WN[U&HO8V#@HLQF7EFS:OTGTX5;_G"(R]-RE0DUV_.;JX=05LGO^H!O[76DG0L \ J)=%OF
ML=0$N#%M#>![R\ R@EJW$.I-O-ERI-_>#O\8?M*:,".V[J4-F%7(M]OY5+Z]
M'?VA3]L"6=-\^W??A<=@PN"Z#-I:UKTKK4X/+H3RFSEDNL*:+5R:9%PZ"J@:XW86;EDX_ZC;>-]-TA2C[
MH,&T&X%8^DY'HT+96$>/QF:64$7:-Y@RM/_1J*,IT_^@/];Q'EEE96%]3>GD
MJ@[email protected]! #9&A+K+JU=N+ L0OM-A;1Z+@087CI8]'OA ;SA ZK('[QK,&U-
MEUO_G?,-E[^/&:ZM%[DTC>0CGZ,*WHS3.T=?R!/Q8D)K+M.87HB=)6X!E@O3
M(O!$"T<++):FYV"*T$&.4A/!!8&.4@6WS0D=I8LH,AT/@70SNXM#_ -#.[=^
MZ. S?KVXN*7:Y"'2\R^=WQ*+/HPO&PL:&#]-Z.GO'#U,%?]8)'::$+]TL
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M8&T+JN/AL6%WL!R-"K #
M@B=F8,TO//L=>2*N3^?/)HO<]R3JZH"WK(X#S8,E*30'S7IGTS!@>\>&YL&B
M\!6@^2OQ2  &CV=?V O'?8G,_B+H'NBH<-IP$WZL4%YL)J6AD!9DV^.C<&Q
M^>:X^3*1^GQN,AKIQR;+V)]IW!W
MX;T?L?**]'>TJS_[T1\$5FGYCQY.).'8,E\..VYN"KL^&(]RU:1'V<
M[-=^D'R%U_$M(\;'*-9_>ZO_,1Q!06])O&M]]8WTA;F
M#>S@(*"HH% W0F*' \5JA'OZL(W]EKF-3W=MVEO:*7KGE91OH$H_^.FNHTMJ
M;6!+IW9Z6SKR?87->_\V#JPYZ)/<(RG!\^Z<:17=+WX(R=\Q'CXL75]W2*S]
MS)^^(<[OKI!!-)BJ(YR^N?M6*BA!N5[++T\[[Y295M$*#P6-X@[4ZA8=:=ON
M-C*L['Z0A<\O].-I%1UQ#T@8*Y!@;]A"AE2PPC4'L!_YCT0'X@#M8)K
MMRI%4*Q1P9-/?^\"$'?Q]Q8"D0/=RVE2^QS)
MJ3;2C8Y!BXUI=K6]G?(#-0*FG]3(-D)$OOZ9FBO8&+3KJ^K
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MF.XGV,V:W7&4&VD'.\-:=
M;EA\?F<4 -2K2W4+/ L:O[TJ \@.=V;'KPU.2RI:*W=4TY;X[*%ATI_S9I:*
M&IZA:U6&A.TKU)IUS9>P+]Q^^FXP@I-#OA4>>RJ,VC$4QJ/!<.6(&;:C;&K'
M4#:/%474='UX;$55.X:B>K#S6*;DYD_D+DHNJ&%,I%\\TO\D(O_]; :; @;\
M+I>8.="J9#_4V3KW(QBZ9O",?0/6?2]W<^*"MO68U/C@;A)7S>9X)7YZK0Y>
M8WO,RCOF$U\S:SL]D5N!I%?Q'HL)I&QL:L5=[RDA]"H>8I$@5<5W,YV,AF.C
M!0&A'RH]I%%H'C?)A'ZW-G]\H!\J<^1X@"K,/WG1U(^;6+ZS!JP?*JFD!=IL
M1__5JV2HM ?!Y"FEG0Q?>N$ZI##K59);N@A_835LO4HF3!
M)5^[==[=6H)E&58^8#&LZ=[&#ZYCW8"N&^1J!@9ZURP@#L:OAYN[,V)Q][83
M6PB;2D*29D 7R4BC:[9217 .UL!9"2ZQZA
M/@F<9%9P0(U.V%15 :DG<*P#E#5B9W6::4)'>J;7(WE&)XRHG0_D"_(N@09?
M:I4P4'9RRV;9#(Q.&%4["_+I=#P:I2'3;>"H8'L:6U)F=NA)P@]S+K'\TN^+
MBY,Y>A?R*8"<___CM(7#?_G]02P,$
M%     @ 5(.M2(R3+=@\%0  L-4  !$   !B:6]C+3(P,38P,S,Q+GAS9.T]
M77/;NH[O.[/_03)LXG;<^_3&4:B;U+0 $"! $09#Z\H_GN>\\4JF8X%_W#O?[>P[E
MKO 8GW[="U6/*)>QO7_\]N__]N5OO9YS=S=T!F[ 'NF0*=<7*I3TW?WU+\X_
M3^^NG'MW1N?$&0HWG%,>.#UG%@2+DX.#IZ>G_0GCA+N,^/M2>ONNF!\XO5Y"
M]TQ2$@ +SI $U-%_3ISW_?!Q_[YX.+X_/CP_ZO9[U^OW_8__#AZ-.O\/'PN/\AR[E8+"6;S@+GG?N+
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MY+*\B?AABC#SY\_'^BG*4.AE.!MJCB*GY9(
M3I_=63D2/LGU+ D"R1["@%X(.1_2"0E]T%_(_PJ)SR:,>N#P?(KN*@>0>1P0
M.:7!#9E3M2 N;3JRRKH .NSPX)_75Y&CW(,1[SA?V'PA9.!$0_]*N-H1UG0X
M?NLENNWA3^ A0=;]9P7<\E(^JPSC8 L6$L5OQ,+*:C9B(1ELV/;'JE;+1V?[
M]M8](3;Z&04^/&XD<-&3;L.#X#?;LI&=,AJQHFF4.K #Z@//G26[GS1ER4S0(;<)+U
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M@F-I*^ZZ+RJ7^C8#U5KXU+LW]N4!>19GCCL _Z,1>)VS/RSQ]NE'PCTG(N=DZ+7S_QM[\V=2[A
M3'"/N20?;=-ZEK7;FLJVY
MG!$UN_#%TP:648)J,H(/38T :3N:>*?M%]5V\]F@#1V3'7S5!-A*OA3/I]5B'X"D)^**IH":S=#I]M=#7%?LK9&#W2YA_OPG&
MIS!67"KY=_PW((P'RU+]-<$SZ?-309\I53TY:[I.3-C)4.XTW$+#]\2G,-+.
MH6>#Y3UU0\DP?5"JU2I8DR9_+6A24\*1&=%R5L0ZY;50W@5A\@?Q0WI-"7['
MJ:M4"^(RGU7,>E6P)KT=%O2F*6$%W G-B34P[1XE#](2'6*:Z$XZ+BYX+HK
M?R=2$ESXA0%66F$U;:D"#2@F11X5%!D1C/3I)"2=#,U.HRTT>D,#S)_=4ADK
M:@:KZ%)%ED.:]/>AH#^@$Z7L%E2FRD1:G=Y:CD06Z)R(SL'R "R?IT>6^CQCF+Q":;*@N487)DBKLYSERJQ$MBDP6(.)B;E
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MH*60B,$+(KS0IZ/)!7NFWD IJOWIFDRJ+*-7
[email protected]+!TXT[4NI[=XO:=# .=+>VP]*.M3]J C,E2BDG#ZH*1SL'L-J@I
MS1"VCFE:4S&8Q%&+Y&-G$"]O$/?A?$[D=K+[#(U _]"V5B$.3,;:O  /_=Z*20>YU,:9X3,;I*\9-" @MXYFMQ?SZ\0,.YKCSJ!WZ#_3
MX/J62CU#8?2-H-^!>FS5@,L>2;'2-[\R$\1DN8KO3
M?#@Q(\Z*D\[,=F=FYY,)=?%08?GCN'AI+**L4#1_P;?YPA=+2G&U=R,X3;Z.
M>/' HND0IU>Z=%J*24+!!)EBX.*/"'1""]!,Y*
MZ !FR0G/AJ>]NZ&VZWWZ-&R-='CF$Z7T[:!%M"2&K!DC+]66R;C+2U7KJP%R
MP7+$46_%4BF!51C=6>+.+;'MHGUS:B9K*NY'-+&F;A7_PD4GJQAQP ,V9'Z(
MM[6OMH;.GUT_]&"Q(\4<)X\PZ@68FS4L]7ZG>#4Y]0:/,-%,J29:-^/_?"Y,
MEEG;^=VD?5>8^VQK$)'9-E%/ZUV.
M%O@&,_A0LK]1*//KM/^BVF^4X<4+FHIQ($,@1>(&D^\'%0+>AXN%SZB\B-[3Q*QV2#F1]6\_95Q7ZA 3JBGK(ZE?#G?^O&!R&2DK
M5:09,"M:HHR?8[>5$TO4P: AW.+1.])/$MJ3T5[ZZ)'*@>\+O6R.]ZUUM06^
M"C"-G=*Y:#?$K!G=)B>7D3!CQUHDE;>-)I#V&4-%\D[>;R'10P%6! H:TY)P35E!
MO\Q9.(_71TDG;H)I3:^83'% ITR=D04+B'\FY.*:SA^H3$2O>AH[4OW2WA-/
MS E[Z;FU/I!N<&!QE4]28_H]-W)BT+\C8 M%&^ZEK7.((M
M5+OJ^Q**XWAK.G;W3HDY)_57I@YI@6IC'ZS7QZ4RK&6_S'"69(TS5? \BW(C4$X((G)0/9)'=4>?0_L" #(?UEO,,Q
MF.,[O5=9PHV0K1GHA@6M0;P+J3?,W:6.!H =YL:"-NR?.@(_?18QS(_9!=PU
MX1#9Z VO6^A)=<6X3O.ILM5>#;!E,^4JEJGC?YQ-7+1"V4!<+SB9P7/IA@^Z
MTUY&\/&3&,]$J
 MQ?B!!&+>7YI5P^:]$&P[9,QD MF*1QRN4BY-[5U=E:
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M2L/D?&RW939= +%&4%.$M59@@?D*Z@=^?1G&.I3-RTO)
M#8B\%0NX)L\85]V$J,K1))J*7S7KA&F(\@]Z?"1\/;BN(MO!L_E@27:U!EJFS;XUF
M7[16.*D0\_M#^.&VC$IC<<^*?RS-]_\[]*8(42]J->A;D7OT/!'2BTXCT,*V<-53V]:&^4D0
MJ['NDD$5)2''3R(O61L,VZ2]!V= @."(T[4]X>(#6WDO**3D@6V\7PG"$Z]=
MZ/N*A[;)<$.#; [D5$@IGC"/-UJK9[IG KN83\\$A]0_L6HGVYH_]PV+0NAXNW.9&TZ<%VJE#Y1@L-*@<2G0)IZ
M^I(]^. &>+#R J0D?L;4[MDS6EK>%%^&MFTF&TL9%]"KZ/K+^+@D3N*W8#MS
MXE+@R<6T]GQ!.(-E?;M.W#UYV_IQ$. )1+WU.+D/%7Y!,K=",?1:WP:#6[VL
MOB9RROCIK1L+.Z)I6X]=HG?#G^(#
MG7BNXX8^#1F9<@',N&-]M2&G_B9]]U+4;>O%G2[J\ (97)S ^)M0AF?O<7GW
M(NO'JJ8L6S;F;ZU3\;5U<6EA]D["=-)NCF#;%FAZ&U">4="0%FI=I.0PP"J_
ML#&^;3U1H41]TJ&5VDLQ;).VK"(A.=Q1(5?)<:%MJ>0&_NO?Y;:!./GC(UL0
MV&E7O(Z!%)S#=C3^3_2(=@5;]4=,P;;>J.!W3<0[BL%2=!F7IAL2_XI-J,&%
M-J9B=4UJ3)F6"52"8AM\F18C,\[9<92Y<']:E#;
MY"OQ$'FI:@!LDV5 IY2<,A%0=\:%+Z9ZE\LMG""I [)-IAO!81:+"MGS@I0]
ML8W[>\*'C$[%&?'91$C.2/D])68XVR2[HVS^$$JE?X:%N@XFO5L2P-?<,;P&
M@-84FYCJ[JYH]C*2H3[WC5Z/ G;V/B4S7"[DA.>O&VZFFY":<75'\:X.?2,T
M+"ST%0QI;6$#2&O4:3I+&E==1$-,Q5ME^#).2=U R%4)E1DP*S/C ?A8^S=XS&$F/=L,UBZ379U +UP25"IC@UC=I9
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M/UXOTH@T:GK9/C]K'_[+M"]M>$O M 6$M
M_8" 1KMA-]I+Q1X=]XGO:LC_=U&W;;MG'Q^VS3_!KZ]0^7M:A];/[2ZRRU6^(/UU*"/)]
M-+7^:3U1PJ%D,';(M&%U?-_JBRK3/^7RC*\06/Z]]3-^XE";VLW!+B7_5YL;KX"#JX#ET[X5X-;&!9EXSZJ(\&
M5JS 13@=HZL:Q\'8%XK'GXT8&ES57C!UZ\+D=CNI_],S@E+@0O>QYD+.UWYO
M15U1!XW#V 'G59NB8'.U;G-5%6E1H3.AA ;31.93" +%6+BAQ$.$(^_:\44/
M/(T0"ODV.'V0\5U2QJJ99NJ[CN]&?MQI M9*430)$0CTY@*$POO&%VL!>OC4
M78$Z:R7VC('#7V+W@ EGZ#ACT=9)$_DAGW\BC')2MULS+_EI]O'W1X;&#O9N
M)V/1=(=X#^$(L0[GT/1-Q!CHM6H=7S@P9?,/?><%^?%$)R^NJ1=2C[Q",Y1-
MOR EW5?K:5:RX[HT(B'O(Q?A5^?%1]!J"8,7R]$,XL;A(^AC\=?MGQ$T[T.K
MO!/>.(Q-80'\YO@14D$C*5 SK$=&QXB%TT<8AB&H(U09BQ&JZ%#%^QBQNR2$)4.I/L^MJG]V9A'R[K'S@GT<8E1J(.4+J6AQ
M>72F8D7885E9EZ!9\2X:(&C)ZXMP*!XY7RAQU=4OEJ/JNST2(H9X.#.&FDK;
M).B>QB@9/B,6B.EH/ALI36.9]0\SC97S!0EAVI>27::1 \P??10ZT-_>K<.(
MF&]A-H@"L0="'HPL[*JYD(PTW1.B!VX+O>[XC[ [Z9&93]S0(*#D*:3N#Z7)
M44*:[A&2MJ4>9&_4U:QLW-2(^AYB7,3 X51%W:S:%5@7AT&\]X#=""4A^"V"
MV ,I1:J%8JJ;K5A>N7(2A"EJ8^.S8M1Y*=T4N%F!63'P
MW 1\"M>LN$RNG[>=?J3HS8K)Y-!G'UVEF,V*PM9.&.GZ_V0 -"OVR@=8? "=
MXC4KXLH^V5X9O5(L@A2_64'85OS%G) %[".S@K&ML%?Y.RE,L\*OK3"E*%8I
M^I)AV&5SC?>FB8K)*%-L[[!6.&1E (OZ)[ROE7XD2P'J5D.T7&
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MH%NFQ7L8=$JP5\)B4XD315$@S=JBF$J;
MD 2ZN6$LQ99X#\ZW'8=N?3M[VFZ?.%OL.,?(:RVG?O3! 4NBCYNT?FA*22Y'])@?J3$FM:
MK#/+5+_6+R.ONNV&4:^$ 
M(RXY2M_9*U<$'*QT'YTA0_]IVGC=.9W=&R6@E+4K[5^/'#+DX"64A9@XH"_%_E8U;
M*,:T7+FN(3>-0[IGVG'_C#!#N30ZM:$H+U7[B6O5P$_+?>U?0IC^"53L,D&15PQ[V>OI5U@D>V3A%?'%
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M4Z3Z%(JI\-F)F3W5]<^5H?LV==&BN&ZW%XQA[DE8Z(C6$$$_LB
M624NOJ:#\ UVCM**R4K2;-V[B!$J].N8>W2?K_PWN2]]GLY0&Q
M;9(J?XRK!(8"(=6\X?;D^"+4#@+,Q>O&Y=]QRQ-4#8QK2B"$W^$9NG4!U:C]
MS4F>.RZO]X:$RMS&83N]^[GUF<&$J'4W)!@4QHJG<,B7\
MV^)\4V^WD=K.R5Q7/]M]FOI$D*H=]I=X,)8<)IG2H'+)*5.98.I6*$@QFLKS
MDC>";*[8U#>*U-VA*)UO*E-+W0KY9S*F\K%*V*#H7&WGYXRRCHXOFT*)%[#Y
MK_\#4$L#!!0    ( %2#K4C!XH&UL[5WK;^,XDO]^P/T/N5[@L(M#.L]./S!S!^?5ET,ZSB7NF=U/
M T6B;6%DT2O)Z?;]]4=2LBC;>E11HD0Y'BQZD]@J5I7((JM8]:M?_NOGS#MX
M)4'H4O_7=R?OC]\=$-^FCNM/?GVW" ^MT';==__UG__Z+[_\V^'AP=/3]<' 
MCMQ7CD[,O)Q=?SAB'%V<7IV?G_W%\_.7X.$/@MUB(@\Q_C,#[L_?'[\\R
M7WNT[#^M"3FXN\Y\[>/GD^OSXX^?KR\OSCY>?#C]=/-Y\.'X9G![<7-Q61Y
M\.\'S]0/V3=G<\M?OC\8>-[!$W\D/'@B(0E>B?,^H>BM=,A>C!_^^BZCOY\O
M@?>>!I.CT^/CLZ/5%]_%W_SR,W37OOWC;/7=DZ._?[M_MJ=D9AVZ?ABQER"?
MXF3RGCOY_/GSD?@T_2H;WHG2[V:Y^7 4?\B^&KI?0C'4/;7%"P6(<%#X#?[;
MX>IKA_Q/;"X,74='/QB!79 /?)$Q@>"W2_1ZL[G'Q11_
MFP9D7,C(BGM._P.G_!?+\]X=)(2_/]UMR^SZT9'CSHZ2[QR)!X[T,<3&(CZ?
MWH<.&5L++\*QE_-X.\S2F>7ZRKPF3^MD50QQ.".S%Q(@^5Q_5".34T8BL!+/D'DD3/WJ
MT2/!T?JS&ZR 24763^K3V3*F^1PQ@GS7N:*^PZ0D3OJ7<#B^LL+IK4=_A-]]
M:^&X$7$>K8!]-"61:UM>E;!/;(0_&AEA7<6)Z&Q9NK[+S277R-HWR<^(L-&<
MU?-%&X^@O7YX?#XY/$
M>O\E^?,?5];E&[$ 1WOGV(@B(<[F('FCT#Q(]6JZSKC^/[RXT
M6/W1LUZ()PXL2)I'1<)M3P'^ES]N5V>8KPLKL/R(D#N?'8+XELIT&P66'86/
M 9FYB]FCM;1>Y#(JXUN9="'[S;R;._^5A!&?)L_4==&"[B=\!H@E]F"YQ@E?.[%?!I
M%7(RQ/G*?^9G[5O+#7ZSO 5\HE83TCPM,SIAEFH8"&/FB+$?2? \9=8+92T@
MY+#:3HCRAX6B^'H=T>_,_ 8_ F9C@U#\O-*ET"(!&;E:Y+%BR!'X9-RB/V2N
M(W-FJ%C.PSG?P$+,*Z@_AJ;WDB@L'J[IM[)!'"M"AEYFZ@JB7#$NA4\C"*D6
MIDP-8]30:.AIQ$WT<)RLKV$@O'EFUMU@B7P% $JZS6D^!\QE<$.V&;LV23\,
MDT_#$Y2!51L ^TY6^Z,D-J*K@T5F=L;?$G\2
MR%W1XYJGS!.9)RH83 *2N!8+9M2"N15$RP=K1JX3[QT^3XVH%=@K
M@DGL[MF(7
M(>.(BBU81$-$E.N+S5Q;\C.Z\02A7]^%9,)_D)][E+F%O[Z+@K5MNED]Y ;(
M2O6R/@5IUK3B$2,$_F2QXN;%3.02F@I\ #*&I@M<\O4L=?.ZO#J >6BKLZ<>>"]N0
M/YTJY.Q#SQ4""9&DTIZ?]5Q:M0A6*O^''MN[^K%(J8;>FSS%\'*J@8L>VT'4
MO4 J\<>^&[KJ:YU4UD]]-W,M7,^EROK<8YNH<&Z[$52YD%])S^Q!?Z7'
MIU&D8I^ /;U?CM:37AK) 9)9J??N/QV^!_YW_&S']L$\<
MQXUYNO/'-)B)=,5KPCZ$I0,U/5@7F4&-R8"\]HA/SL/QO3MC4XS3&5&Q\?QF
M!2Y?2D]L@CX3-MG8B(C;&C1=['U-X0#9(U-]=M>I:8Y7KXSW+;,1,M*1V=HP
MX6L ,;3.%R^>:]]ZU(J^L<4P6\R$OFYIL-K'X0H'D$)?X4TF 9FP>;4B(8(B
M\"N\@L?1;*2KD]OD.S^QWH-7MCSC\_LEB<]VR$F*)ZR/=0U,JV=2)4$P3FXM
M'K;R#D2,2*QJ9$Z ^@"Z1&F<=04KD#$L7P,:ALE0*_+A#Q*MBYP?JIVLQ\1F&S I/+&ANE3)I?&95#D&^
M=;G"][D-R#\7Q+>7PW&\WER;'?R3ZTK8?*LQ0L/"_"]S:B(2>,MD@,&,7_8T
M)4@1=IX0@)&]D&'12,P]!/%#_CE_%,2_\DEC\E'#/CK.N
MASL=0TAAV;M>D-_=:.KZ0Y_\@]$#,[/]H/+!2UCN#:'NF&OT$A'')R'BJ .G
MJ'DF/Y"(^=IT1NXIC/^"![7G27'7D#@W5N S%84#VU[,%KRTQ[EFGJOMHM85
MA)KNS"@KG#(/F/_?#7.(7RV/%\D,HBNVCRX93^#L5"1!W2E)BY=0;"W1S2O[
M!YYE6$&@7;9'C%%\VETAD1;R"/4*T 7[V%3!0A+XO'+BC9]XJDD4^SQI$!.9
M,UM-2+=6F0T8CD4PA&?5#,:R,7O#:3[;"(G9V9AQ2KJ,35
M^&;2(-(:0TAIUAX_ET5+CLY!?38JWE[E$FAA9NIAO+W\^(WA0[1]+2>$]B?#
MN1N0)%)\N_"=^_LK;#U."0F05D-BOY_0UR.'N%RAY_P'SNIY1H_L3W_<^!&3
M&/[&-Y\!S\ZV&&J8G7OFQGLQ?>BLRGT,.X=&/^AH2A>AY3O,Z[NEBR BQ+\*
MB.-&MY;-PRQ+Y)S"D-3M':\-BK<^W8"=UL-TRT^@*K9RGT1Z7/27.@A]<
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MV*.JEGU9AE&YN#EKO_!:KRNQ(?("%GAE_ENQN%OK^<+(2FJUN#PR/526
MWAOI,=73 23M5RK R VMG@(V*Y6,*.!.[H9"RPL!4*:<[9"F5:SY3
M;9SMD"V%5?9*T8WT"6JL#ER9=JJ'_16M+ )U'MRL6L6LPA5)I783+S".GL$ -HGE?[3#EG%
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MTR5^ 2M1$#766U&>D.S@;""[!CE3>4VAW!=?)%NJWX*AV8[;CT9NTVUL4
MWS:.XC5YB>[\, H6?-"ZAX%%1\XQ$:_&3)>7B/^FLDZN\>6?UM@Y;O&T@4K*=]
MMX6Z[-O$MYA#>$L#8ENARI&C@$)+C'_WPSFQ14]SA?E31*2-OB-:!6AO3URQ
MH+P7KA- .T71:><>
M3@Q\CT'?KR#0%N ^3 X*5/;NPNICIBRM7%<] M,O-RUEHE9O $: T(/PS'1I
MP1 =5&.@RG2HZ#$3T( /B[:/^* AU#
M$[#]=I:# 2) 4V/0=K;Z\AD@+P.>LC)_EB+L9I#2A:X.V
MU0L US8>"5X?O+29, H*]R0J\-+=;=:Z9GM>^X9S(_:G9OL@Z:B00(/0RM9X-++'&#&ZTI;AYY
M2?I27N.;K)54*!0*N5[_(84UW>&N)ZLADE:OSB2==W@  VBZ#;X.!
M-6,2T]Y(^':PW"J%@!*QO-^RI^\\4YDI4,EC!5$8SVXGB9 2A.:82?^ZWQ'GGS^).8&=F-I1$
MQA1 H*A29"-; ZHOVRV$VE12,[email protected]$9^=&7C4A!:X'
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MT!ZH9_MDV)**,@.W#>"D1V]4RQ3:?9BHYA#QMC97
M3#UN=&O97&7+YF*#Z@-T&P14X+O-9E9WW R2,.(Y S?C,;'Y36KV1A'NR" )
M8T-G)C0M+FJ?3:)L4LXE#0+Z@V?.#?V-MRZS<\#LJA%OHR/:^DT.:K)[M/9BD/,^L+1;6*2L-<8QI..
M:1$:E,90T_PFLCOZ/?4G(Q+,.&?ABC6,^@'$]DW^]DW^P(!YNIO\Z6Y.NV_R
MIZG)WSVU_)7-'/H(Y90]K=LTK5EZ_%+/?[Y5IM'Y"#E/H_LY)G#4HQ\4V\!Q
M^TG5P?%S+.?)?9,\T)[2<9.\]>!1W.1CGAZ0V;D1/Q$Q)-L(EY1A>:'#:RVF
M1Y7@K:'95ILC(]V^01LL=D.+XTHF-&;3(F/>,NT0+D//,BT]2YZ:VF,#
M$!\NE'&[O9S1N:NE<7M:?J4@1>Q!ER/4M,WK(03.C+:MC720.S,:2@T=C ,DT48CLX!%Q^1#]:2G7",Q
MV.+4-=G6R^C]"3<#RA(2>](_I_Z4+\P03370Y3&K:0T4Y>_*ED$[-+]!"=2R
M>8[1.%1H^U8[]5VVV-FM_;YVJQVC3WBX%0*H@9%]=HP.5J.G04XMDA35:'1L
MW"M6JR*3;8:,QHK&J0+1E:/+QI^Z)CN\0E,V(P+;.LU5QG$K5RLD#G=>F6,O
MRF:;*S)6IM]MC3&>;15 P>T!^#J:B+C)Y5)^)7$C!C^LP,E6TR]F<4$[;P9C
M1P(*$/)/@E9TT\D5ZH/XK6Y[$$=R'(RI 
M*.3G?+MZH-$_2/1$;#KQW?]C\HKMFDF3_(E_#U4KVC9G?56T6')ITS(#]+O.
MD.ZL<=4UR"2+>8Q#D'(S"H>+*(PLG\.:Q^X)1JOM\-.&4E^JA7C9%&*;=PXR
M.YI:B6QA"D#-MOS ]4/7%G;P-S''T'KN@L5=4WUF=AFM_S4^334JE<(ENSMQ
M[GQ\<7.K;/56Q?%"-4N_FSSU5KEQCUBSE+O)DZG*S67W:T!#7)6;CN%[I;*-
MUBMJ^$N=L6:JJO-\TF\DFE+G>ZAP--/!@JE'K^'*@QWY+O7YT0;F].KDP
M=>ZM[9(#WUG%0D:4_RES\BLX&[:YX&LP:;CZ,R)TI]X2)OJCOA;#!L6#FZJN
M+/!HJP?)_(%-5=-ZAZ[!@FV# 8^NM1.,*AR\)^IZM5R/;X',L16'L"ZTMLV#
M;CBCN"&I IS1^H-[U*6BU.JW@KK45+,FYK.[_(PDK@2^^VX4/CU_5]!I.2'=
M$$A3EXS9L3KN[3HR/..'1!>76=A>7%-I"U/%&)IRPQ
M12 1H7!$=6/!*D^DUE=.4ZRVQBAVLJX_IQTZ<$JCUK6P1T+A/#0[:M9DN
M8F\[!U*G_YD9K6W$J08U1+7,D-V'L6I^#=,B:]0CJ*M<\YLC6!_!K'"R&2)9
M=3)YP=9.E4Y,O8*LTKJ$-TZ_$C2FP\H"V!K./_!3_=Z?U%&'12<@4]")B@Q1
M$ !Y2*>;34'Q%ZFI[DJYS+!#!?&U5$'G'1;\@M9:>82Q3-*JT*B$=3"Z]%2T+ADLU@'M*[K)5J;C]D-IZZY8E#Y+J4X?%T;H@J3X970NJ"$GUR>@3
M1)50ZQ?H4BBCZ[8U!6VTI4^D:OW<[WVA4[5F:^1^2SPKHU%K-.I=4TV#5*S1
MIV+#)G15J4VJU?/]44M_39C4]MY?:*:@48+H[8\/&DMM)0;=WOAJ+!>7.'#[
MV:P7]4#"S+U5EUCEF-8(IH=4O=$ OSNB^A61.-\0\IN#_$Q5>\I6+W=@)U*47C0@(EQ32(2S!@?_B05>#C.
MKM3OO.ODI6?9?S[;4S9(R/&MV=>_48=X30*EZN7-2)!532(;FEI?MJ)^HSP7
MA8,00_%<6V7'5!R;,AEX$YIV<&P 7& KMQI]JWP=\DX-_%U>4E^-6,3KS/1+G9E6$AWJ<8V+/11&3C(4@LT]
M%$:OH##V!9;[ LM]@>6^P!*5NVQ&=66SN*5BC>[7U@O%YKEDLF/W&\JPZR"2(/7\AJ+_;42U9#_KMZI8W8%766-J]LV*
M/&D^DD T3/-M(HO_^-U]W HZ:9#7X,5)O:%-O!=1E,C0&+WX)^$Y;@6;[9/8
M0GB^G %L9/Z.SQ1.6PP_'-_21?! ?ER[UL2G; Q[Q$9ZM'SB,9?JFMC"+@G8
MC^70)QDHD%MWS)% D.AKNH;'JB%Q+-(;NH"9JXEK#R8!6?F3S0O?[*!8D0<1
M6V8^'X>IW?79HG0MCQ=#W]+@EBUIRZLM8)TAT&\P]J)N+N]&UX-[&H9W?OT7
MA*&I..6>R"OQ%Z0);L$$][##>]CA/>QP3=CA/4CI&T?^+)@ _#CGD?@X7N@
MWVA 1&ZW3T3/='=V[7K"L,?K,3GE^),;M@E':AMX%QS6.3P^+T+^"[]8>:2A
MRX?Z.A@\BD*P;U8P*."^
MHNP'6Y3^-*N%A@?7O$4E?CQ^*UU[L 6X[V88;8M-[(Z_]MB^T42M3)%]QX0.
M.B;LDZ3V25+[)*E]DE1'$-;&)TIU#<]L=M:5UCT="<_\YF'BU\ZB4BT=IB3 
M0.+SCM[;8N5ANW>8+@0R'AC)#)&K>LWG.W14JS/=DPP\D&J:C[88T1"BKG8T
MAN5ZTNL -'NZB/&:T &A_ORJ>6O0DR35D"F_-SX2K@I;[#FRC1A3*SB,D9'
MFC,U/'$K3YQ\J\$+&QG3J!0.($7=R0O$\_@EAN]\LX(_";<^R=#X[*-J6IJ%
M^4I\-E,\QL# X?B*(=_F>?A352(@0?V%,X1M;%/&QC4[H7MTSM>%LE @^M[M-6]VFKNW@5MD];W:>M[F[:JD&:@EZAG;SUR_E2
MA\2$3!U@TB_$/ZL6.R@;+3\;FC/KB
M,/.[%8CFNYD&@\^+V>JJ5R:ZF9BVZO
M&W4)AX7MX92'XY2%(+Z;WV@>_D3X$N)Y^TG)Q\+R[MTQ*'+4R#!82(X-P@(*
M^Y$$8B$6\,*6HQL0>!^E.D.T(DZ, JY9H'20%D2Z"\.%7GE6([0@S%H/8GT2
MK0V#QO0JG<;7BR &L!4=K.L9@ER2Z'9KW"K&KS!+Z)8&8M3Z*T1]@(8TOSUV
M7<7G4=1]-[[&2<((X\:#N:\SX&,%.G]1G9U?\15X! =UW
M."M?9&/X$'LS5T&HBQF/OGHKH]*% $KW9%64VKX# TI&8:]A]R^L %.9@I==
M?VZD8(:(5MK+GEPQE6\7M' 7Z\F]4$.+?NVN,*R3,>GW9D(ZT=
M,DTU\MGHDU,SYA0<%U]IY00.;M/IU=' <=R8G3M?],02%XS-7PX!QC'Y^J>,
M_5J1Q&2"B56UK!5!S*7411ABK=WI]E(ZJ1V=J!X W7V,[7R\&YPD-J*/B\">
M6F%V8@B["(JNJ%!5:/!1,F/OF&%RF1]MBPIT^)Q"$6V Y>1E\H!%J"#0+ML\T5*AMJ282/OLHP/2123VH>A]*'H?BM80BBY:
M<#T*0E>8G7)I>Q:"KMXBBL7=V7"TP@&D)_"Z]7502,21;AB#R;SE4U86(@W\R%TA/3\3>\%X
M=0FS>;:W<(@3(Y'/YHL8YXL)+[Y+G([email protected]&)-G?'7;8RJ?;$UU_4SAATH
MP\/QC17PF&NXBE /9G3A1^NOI@(/H)D!T=FHVSLBLJE@"84NW#M\;*"$3 LH
M-/J%Z$8$;)"CA$B-4%Y02H
M@<_3S,BZH9;J,:D4]VUNS+8CQ(UK*Q>VIYF)L_OQ9TV+/"]]>MN &1:U+@/+
MJ+;EV\&W1B)@U+E%<35A#1 6'I?).%!1T2.M7;+Y,SJH3LHP^]R&_$29I
MCG\BQ3SMN9@@_U"*VYT!-FBK*G'UC;B!@FU5U5&/*I'S&KUV>+\ VK.:DMH0
MF17O5 J,04DHM"?7BCJ]AH8BW/(N#KQW:+Z22AH[/%I!M,QTE0R;2V"N,4*W
MUT(JC".#A*L&S/%*"Y-VG_P**2 V\^SA2;$ 2II#',-H2H(86@L3I5A[3#.+
M]\0*B;@DCM\9>[VHM.G\Y[5W]A#F9GE-YKS+,BI(MODH-HB=]C$6DH=/$O&.
M6;9OU(^FX D*(85E3Y!*6W_QUR&:!K-?;)($5&#,51/2'1\,B#4O6LEV/;;K(J]YJ0OH-I=@N. QX-/ =CHTA,&[5I@> 
M7 L7PNT+U9U(ETN5E0 BAUT5#QSU->E*C5P'>8]BAQ^0";$N71H1>^I3CTZ8
MK\Y<#"0G%50TO^:5XX;?4S:?U-X 2[K)^!6U_70+5J%IEEME.!N*N%QF/\$N
M?0S5UA))8$S5R!=!#=#->]T.1:J_S?ONTCC TN6F9Z#>TUO*PE!9(51MU?5 $'S_ *%Z[0=
M,. @C\T(E$*8Y<8XM! UK <8C.C, K+A^O1@B!:J[0 F7$/!@3,I?'>).>V;
MB6H@B#/33S4- T&<&;W9-PH$ >^PU/5V#W8,@3<^J0H^=.BR-*N"6B@(%SLW
M$P"7L%+ZWC@OH$D N$Z7L+M&XZ"HO/CB! <)(VMT3C;Z?5?GI?0$0!W?FQAGS(RJ.[[]9@E0
M-$ &-Z@!=M>IJ:+B9+#RUD#"5C4)TN(B\;'5!] E2N.LJ\!]2*?D:T#3CBDK
M\DI],'%$6TRDW>1#-8=VFX[J%(DC U_YS_P <6NY 0[NNIJ0;OW&[;97-9LK
MSQ:<;PVC@]7O:.H&\:XO"+!3RX(7_M[Y5]3WB3@#_.Y&T^%X3 +,U$;3[29%
M6;SZ)C.4-PEVD/U^Q\\/EO>X>/%<&_/B%(CN&R6\Q9J&72IK$^-H38EMZM:C5O2-N=.SQ4PX8;P#!UYR-ZXT>N2O8]FG3;HF*G3P&!?>7BOG(1R+QBY>*4>.,G,G'#
M*([2I9!NV,K%2D*ZM6KQ!20.@ _6C/V8N:!0F!T :BU,$]=QK6"9849EHA00
M:7F6HVMUU(<@]@8*WL],*!_1,LW+\X7/3<^@;SA?^-SH#+IF\X6[*P]J?"(7.%0R
M4Z[##"K0-"YW*Y(GJ1H^@%3\?>H#C"UPIF4T
MNMH6_FY!=T!2:J/A@<%2PR_H4LG-KJI$!0.0958G9[LQU17+JT[.C=Z:4&\^
MD[(@Q=L-@XU)1C_OO15#9/:D4E_LS#RNV2;YY*+W4UXA3T]*OS.S'YB F4K^
ML?=[N%IBK51 [W=R6 IT*O"GWML\8.:ZE'@G;=MV%4$JL-F5H7!'#%4((J4W
M^VH&.\&KJW:DY$970S 3DU
MM;\<<39>F._[G_\/4$L#!!0    ( %2#K4B8*\HHGF(  $&'!0 5    8FEO
M8RTR,#$V,#,S,5]L86(N>&UL[;UK  "*0U.[__S_GY^CAX0HM5GGTBJ^B;!63;)_BWSU^
M_#WZ7Q7=N\^?/W^]CI(@645!_'6:
MAE^OR/8=.C^7D"]3'.24*G05Y!BQ__<7](?W'[X[?__'\P]_>/KPS5\^?/>7
M;RC)WWWSW1^^^?:_O7__E_?O*P!^XJM"E?]' 7S]S=?OO_ZF\K'[8/6/8(/1
M[57E8W_Z_L/5M^__]/W5Q7??_.F[/_[AS]??+_[X_GIQ\]WU=Q_>__GR_/W[
M]Q_>?_OM-W_Z,_WQPW?OOZU23G:'--J\Y.AWJ]\SDM'#U_#_79$DP7&,#^A?
MT2-),OK)[2Y(#E^C11RC!_A*AAYPAM-7''XM(,:2AU122?;7KRK\^_*(W@OS\^W':B^_X=?.)=@C=4R<*[X!G'E%R _9>7%*_;
MOQ>G:>UK0,+W0,*'[X"$?VF#EA]VU'2R:+N+*4/>C:'R$\[M$MH$:)'6>YQ&
M)+Q.++.V':QUNA_S(+7,ZR[ %FE_HGX/VZ7Z&*1->DD>Q);I/0)IAUX#9
M YB6*BC#M:,:H<#$0'_U'T502V-C&C4S58E*W%_/H27Z8B/:;/191)PEI6@H
M1B2LN((3_2*Q_F=32!8\I$3^1%>AZACKW]'VA]6OVW>#!3TN57[OGV%*\ C@#^7QK5SEG1RP _
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M)$;TF.BM=.).P2C(1>U*^W&_V\413F]X[6&R4 GGE^I!N!H<,W?6 ])!%9O AM("W:R;B(I<
MB ZS/)5!W&!_B0E15'*KF<06;I-7BHJD!XI81_?KWS/B40,BB((82U8\5
MT\0]IN9CPU!A9
M80?I)?H!FG?P]]$7R -S20P>_BB)!6BPRI/)5 X;8X(,4S\A9[$
M-5D$Q*U/WTN/,2YZS)= 61$'5.><5-',EV&421MR!<24Z>WPG*@YH*JZ]IDU
M?4 <1)E-/K(^KG.]Q;T;O#)P6I1659:6BC3?R(T;E-YT4NKH-GH706R/@PPO
MG^-HP\JZ3'S*$"3#J\T^H.X"QTIM&BX.BOU*--TUM)+$B!X3O95.<>/,4"&&
M"U603;KYWD4)SI;KRQ2'D/Y8U"3V,.*843K8 4;P2PO,I3$051X
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MH.0L/Y@]G^Z&8OAHN@N@@TLX:*,A!VD"%QV+U6J_W<(L18LN\I&90I'%[].+FHG%JLG%=;G\)H,P[1&GO1*89I#.*6)3M'&8,$88?W'-I$1L!3O5X90$,@?6LRCHH"Z+*) _Y'E=9SKJ;R3ZBDU?W9/ER+8Q,5\TK
M7S3F<0'#C4)#[7W:X4*FUN9C/I->7OC"TXJRPL,> 7NB:_\,0Q44-9$KBC8F
M[,&C,!:]P* 7D.%^UP/310C!T3$7'98("W<];VBA(BBBQ3Q?A1(WY '^NX)+
M^O))#.0'G. TB"D)BW ;)6R:)CD/X#P^L" UOI@V)6I=$)T$%]?Q"+
MRH"MQ.6%:2B(AJASS$LQR*(9CH;90H%H4C-H'F_&G' MG;"<]8LY.M?.?1!H
M97S/<=;B,=;Q\742W5WN,&P.YYGQVJBXIHL\YGL0@;J6*39B*'ZDRUJ",
MY//WG,\)WD#IVIV\/!0=783NS]ZZJ(OI9( M'C"XHU?.E $W\V?<:K2"E>K7
MS+;.$H);+SUK4-+"7=+# S\X&5>9>-O*Q&EC#BNQANW-S-6YD)Q0A*$56;B(
M**:*)"8L1H(0_X:RG_<8V5-:EL4!ZP*O28KYYYZ"+SB[_D+#&Y*&41*DA]L<
M;UD'2?I-NJZ8,8OO*7JAB$,R1A1%.:'(T<'XF=$CK!CE0-'\I55N->NH/,NA
MO-ZF%A5Q8''41T I*DE%):V($RO]%",7U>A%C&!4IQA)DB?T:)0VX48O<(+7
M>F_B.T&,T($C:&X.2M+VY5%I?@_0+8DCZ^W@D4=<;[4:BJ0X_0LTT\2N.#=+
M^S:^:!8>56'8W]%@\GP,WNA?@^WNWQ!%M$OQ"V4Q7)+&+1G)26/35L:37N;X
MPN2XY._4^=V?<;1YH@ TUA8R5EPGI!EQ72F0P(XX>BA1/'[D,G6&6I4S%T$6K5S8O #L5*P,AWUK
M9V!/P0KKPC,PP0H#3T501L;7*M$I[>XJBO?TMZ/>9&J#MBG2+BSVK4]@\M#^
M!H4X;('];#P=@0U;H< _UWM/V?I,MOTP"6^[81@)J@N<@QD0U<"S&F+.&EL.
MBH2H\LI#]@N#*#KN%8U?I@[\FLO4#O Z %CA^5L-V/J9WJ/78P,PAPSNUNCI
MHJGF\L2F,D:="Q!6^"V@O$E&KO 
M8AE[A@Z% B^DR2*)&:4<]==SZ+JNW(@F)SM;5'2HT'U*5AB'[.+R/CBP020W
M)+V6HS;+8>_*JJ0#4E^EU*$[42V)GA>H[P0!:$W2UO&D\^F8@6")(8MU=>XR
MR%Z@O_K5/J5 J"^,2*AS7%( HJ]7??"<:!(@9.W_4TD_',,&U-T@+;>BEGV68/PHZ!/#Y4G7)24)$1VV
M.5:I3SAG:IV2URC$X<7AQPR'MTGQ5&:QRJ-7/H2\I<3'Z/F*)8RFU\X6D#OH
M8E(J,BM2*I\JE13-6[1J5T^(&Y&4=N(F-^'3B];F$K^3W[LTO!/O6 ,9X!W0G20T*T@X[V!*NCF
M'<@^+!ZBP30_11&W2(%U AJ0@A=IU8ZR\T8"U5ORC^JW>1)8X@,_52[FH7TQ
M;I(6XLH,AY=D"Z7DVDZI"X)9HJ(5F(/^2]"(^_P9$+%J58EIUNQ$ORB(&I>\
M8[O,#,E[4PPCQ;LY[D3+^:S._QDEH24D8@ISC"@@F
M?Z'6V.6*V%@,E36<": ,U?1%E2("^]8D<<.4/O[3[]D#!S P"GL?LX,%NWE;
MO="5P(299-:SK(&0B3FO3T*@?5%7>3J4N2EQUTFVKBWV^2D?!G@I9/73*:B(SDN>I
M2*^SY@ @2Z*IP'1Z,/;+3MI$TFL@1VSRCOT:!_N62'HB4[A/,91U7.$U3FGD
M+SO4)2%K>[3(,IR/M!$U#):DIX+,A54)O$4/V\JQ:;6GE"0Y"AAROZQ.2_J]
MYJC.^-.1M((!2[E+,HJF"Y ]Y9W#%JURGSA@O \.]J+% ICE8$3 =7 7*2./
M'70]]'V<@3/GH@:H)U8#>! 
M<8G$.\/IDM>0[;0RSW/9#%@0D]5=MZPF.UOQM*4PY4]X9,:P#9ZU4+\)VIT1
M11W9W+E/79W"&CA\M7/.<\'T'\7$G8A "H4D,YF0#":M;42M "W)J@6VB_(0
M$5[#2YL%VQ#!R0PP4V^-]:K'E.'
M:EBOI(K R:4(_?I+ +SBT^W>LWCH">+ZJ'#)7L?UNOI@;9>>;7?V<5>>TR,4?3XFB^NU
M,=K4$DWD[N/Z@B#/XWI3/1GV&$8B.7F=4/$@;;KA25Q?Z1YTFV5[2B9>KB]9
M4U#V$$@KG!\&9A8/#L&U(\E7G#Z3VNO^7:U_5"100S0OVZ8"]EFC>67Y$6U^
M^BPK&;)+ ?'4BA00--CA GIL$Y!S2_HY2%-Z7+C^@M-5I#F^OA_.:)DT0=K?
M&.M-U[! U#0:])D3,N]96$5F'8;3SDA/Y=-J+@(5*G"9/A&>NLM?3=ODH9TJ
M5EM/OU-94ZN$BL51S&7>H0PGICEP/	.7&Y9B6=5_A9Z_S0 <#(5EIA.4G>
M510KV^]V<8332E5S_A*E(=H%D!OJU[:IG%F_F(@2"[T12=TJ2@RPM?.R8D R
MN?K?10FF_[ED;X1-3: !9#3/:_!B(SJ;MJUQ0#Y:F!^H%?@KBO:7E
M\4;GCSD]Z51O/MK4$P4YNL";*(&Y&1 D\I6?TCJODU!EE==P#NQ:GYMF9' $
M90VW@U@VW+Y-UB3=\JYX)LW454&:]J+Y$4=7Q=7A$?D+%@,D8!9)J_[YL8KJ
MWL::6#Z_DVKE,!OC@#T?C.C.Y
MYD[XG(UL\5/P!6=&>GK\;=/W4 U ]K6509_Y-5H7K\DP*[SB:Z&SK',W@Z^J
MMUWSYHK;=W'1EST169%H\Y"TU= ;="2KJ
M]]ALPJ0#$:)#0%U
M,T\,L%84#)$4I8 9.BA1U///%U.6&M%CI*[Z<-4#/<7A$_DQ"7'Z.8U@&V(_
M+U]QNHACPD8A+',-/"#
M^PIQ_!^(O,+EN*0/$4X@VC#5#BF):$UI1*] Y'PZ;5>5B'W)Z=I&!5G%63/H
MF:9O50&EK]7#4)VH; 5M?;/>\,U\;N>J(3>BR4GMW9D#*W086G^T:#%#A$.N
MO^H;MA%P@SW< (^;;5TH6^DR62N5=J>YX>0(;SGC5C]&!EXPC?RQ/:\*>;'OD(_#.?'(#T_Q>
MN3CQ"_?LO5_N4@5-S]PJ"%WME4"XP8PXAPT#TM?((9A.=$\BE<[4LR.1LL"(
M%A-U]6:Y7F.X6+HD&>O)3](0BJ]$=V'14SB3S8TO>4=IWEB8?AH2#]$Z @]=
MB8UE:HO!5%:\"2C1UUSG1#E1?4DU/8)E?$(%HQLJG':J[<+A6P7];#Q3]3A7
MO,AC&.:SHNG4ETRK$;IV+(H3@_B'?<#V$7R;9/N40TW857%&:=Q&^ZU&1VYC
MT/J6IH_%B>D49*""#E00@@I*D"!%]NR4H3[H-
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M?7M]#!9?BYD:A
M[Y:GJXT;"UVN47$Q\$20Q%[K6H4X =,<'MMK]WA?H/LTJC)+_#7[H'6Z-$-@
M=B@RP65?JR5&M .45=V>]: Z2M+$"I=/3:KR+,QJ=DO31^9**'S?$T*@F/%UL;OE'TKW:UU1I.":W;>
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M)A0PL@8VND<2AY](_C>:EO2OYJ:TYKBY7NP9VHJZG[!Z9;0QAE$-[N=N$
M[;3AQ3X7ND^W#JTK$F68AHTQU<"[.ZAZ-0936X+$E)4G("UYE!+5$56L2*)%
M%&_I72GJ20QML5I!;12TMR-QM(JPT0"[/BA&XND&:+=HI4"#))Z!YH=3F8^"
M7(@ZNQR7\"_339!$_V2%8G3?R"@-(?O'19!%V7)-=Y!,%I)=[#-HL9]=X6R5
M1BQ)1*/^XP4\X2_Y1:PY(,TQ(4:J[)0F^YL)HXKUWJW0-:2Y*(*O2P9T.J@@6C$J#8LW[V+?MU'=/\]4!0_$)9)
MH6J8)C_"_^9!E.2'2E]C+4\T#KY^4:HA*B<5P@4M+#NV(3R5QLA!^Y*>^9H< Q7R4Q8-Y3N]K.] L]*%23
M&G@GBJG!">U6CJ);M/EY69)ER=;@EU%4DE-Z@U,E\:)*HM$Y930JMS;2CM5%(R,*]IQ;0)6@DU#] 2TPT?T^
MOI^NQ(W<(KIH^,7Q!Z3RL5/1QF2?9WF0A%&R&75@TH=L/.Y#'8G321_LW57Q
MC(>4A/AQQ#(6-1G';==UMO T[BX*GB&2BI%/YJ=>6ZRXK%D/@==!FE :BB811L%K
M#Q"S>I\N>/:5[A/.T1W)^!2U:F.#6>N !H5"E)GEHP!D[97 4G8$F5[_0>01
M[\ZR2$)XXD@IPLEJ]%ZJ"=BP%[T&#NM.36!FEZTUW/[MMF92)J,X[3CR4Z+(
MR)OK0G:GNHZ##:G 05.!O5?5W@W!A+4G(T-M_S/UAB(R%_?0$.")QGH9=0C0
M]LID#QF&93B&H1^LY>D+/)/#L*$J.D_V!F6!$5T..MX!NH@8Z?ZUP%K5OTD<
M?[<^^JB$BBY?FZ.G(;=A%S*GIW_.:M^*H^JBG
M%S8X:1/RUU&O>2=:C;!FH534G$M\!G9L9X/\A#]7/%E*$@(]
M4EB2:_16J0_;R"'KHG%QOE^Q+L$5[UPC8\Z=U%C 9"R'3TB8TC+QYVXAFN^X
MEI]$5QX!CS91#:#C'[email protected]?]-/9M6EF#;$VHU3IZ"M.(^0H#-SO>D3+T+>IF%7!B") X)QQLF*XY
MMI&R-T7L(J.ZW0;I 6R*8W]]$*T^H#QLGG
MI)6CQ5M4'U'4WEI4-28K5<8C+R+>?##-K7(0 A7>SB++]EO^.[L>90QF:PID
M3H2#![@E*O0CJ!)XEBM,/[*-H)BS,B>JZ8WD1+"+.%C]XYPNE$ #-9C?"]_[
M2$(<^^:-+"C>@&<:*]LWHV0#'DN0QW>OAEH5)**J=FK[KZY.K 6S[G%*M7W+
MPKPJAW#&$B0XA-'
MG+Y&<"QNBX9A-NQ*-""#*8";)/HGW8G8=&CV\G=D'&>=B)&[K65Z[!O;]7J-
M8<"7C-S.6XX+LAHO)[+SK3A1PB_$ GEVZ1-)2* ?6B
M^X#-$++E*:IY*LP<]IC 0!F-\]APU=IZ(!#$^! -ZHO[. #4Y'=G[6J';G(?
M?EG,TBUP:%0S*P+2U[HAF$Y43.QJE?'"4K?F4REE*1$MSODJ$>'5A21*;.7[
M^?Z2H'5UAK!GPST(LFC,(KWE!YX
M_K**]R$.;ZAY0CBQESV4K?12<(%]9.!GBQ"WR0&@\OQ*D%F=QB$)Y9/&*Z2R
MZ _GBU=Z'-F(J-&3LX=U16P]=-B5\YM2NA;G526P5=UN&NK&
MSB8>M+PH*HMN$TI:5JG]^/_WU %'0.TK_2/+-@'AYE=JHU&-*YTRPSKKI1GS
M2:W[HA?5E"%(&MW6P]8GG+*G,TK3O;X
M!YR(I!SD0,"3/> ,4XUY623A%?U,3'9P9'HB\/?B:\J'1?N(]8\RMFEP7XT*:@$ZTH(3R^206I+)<:EL1">I9]J@0PWW'6F=X1I[)]*SK6>"_A
M3,%,SZA^=9RNY9 Z*^32@#=^)0"^QH ^A1)/"?
M/W,"Z"]*"N;SD/HR)6;LU,OZJM.$X83#:%(
MT&>&!9$$HP/%,Y\>=+*;]+)$5ZJLL>PGDC34I1*,*LM9!92^Y(>A.M$%WDDX
MH?Y<^@DD_417[2Y#ALD\;/JK&"
M5BBJ\I! 7#>1#3(X.<%_X/KQ-8A-&YD-03)K,-H+U&Y#48J#=Q*%'RK8/&EN
MIB@IHL<\76]Y%U%(5)L/%/#'( DVHAL %65V%R7X-L=;]4A1$9J^%U0"[,3C
M%9A9=F1;XD8[0#Z?1].3'-%GI*XJE3=]?4A8HMN@%DX!YI@:N$'PSFO?XGY%
M0SE0X4,)G+ITCTO?%-E\ I)L+5I8KE'I+V#OJ1" & 7H%T:#A1JGB=;9&XE;DT1J08
MYE#A*[(-HL17W+3"9@_H-*7*#]YVJ7&6,9WSN4F>.P["HX.DS>7HA^XP&
M)M3CWU"B?VCQR] O':1R[3;TLX0M &R5>%K%)S,H+[-GV,KSZ>D->WX4X
M@AWO6_@!/,BWE8V._NKO=W@3Q-=0^Z0_N+C5CH#X0!D4XG=#<5-TP=$C@0X#P#%&4,Q;8#$N$
M*/+*/^[7B\_;63\Z0'&]B+B3?G1'_Z][ 6Y>A(%)-GN2,)N5#2S2 . 
MS)[-],%TL)&(=YD%FEE?22D)AF@QRUK/.B:ZE_]$B3>^\3IN9_/(\*ORU%G68"PV*68VI!F&J8#2#PB&H3H)
MRRZK'32*^IQ 8IXO.M,0&-%DH;_":)MJ3?&XY;@9G$I9
M@W7#MLJ7S(9GRN\[>,(#H&>=7GK$4-*YM7S/GGRM7
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M.Y'UQ.*'CTMQ%T3M4ZJ\KF
MHF_6>5_?+-]7%%<70_$=*WW/X'0G$=2/28I7) UQV-I89OD<1QMVE*^.(U=O
MM64%C5%@, *C?>T=[EL4%-Z0=]R:,YBSH1/$HB1.4_ZQ%+VD ]6UH"A:*DE!
M@A;$B$&+3DWPO.^07&>_;,*U:6=$&(F+G*.]()6B;9XY\HFY=K98>HLZ]K@S;RY9I89E%I)M@Y
M=VU3*9.1?#X=B0J3!=Q@BSH[L]GM\WU*5AB'&71M9X=<,7KE^@M.5U&&L^4^
MS_* 8DXVRC?1>D#U;T!UX#NYH98$\.D /.\A!B8B+(E I*1BOFMK(P$38T;K
MML23DWX$1&B+)8'?I]$*R]E6RKJG#E!?[U1A.]&Y8E8@+K$7RH9V@!]5ZC>&.@GE==07L^/J(,4\U2(YG.A&!B^^U'HQO
M:I?"T:RF%A[I"OY^3X^_JYN8!/G'*(%7.W?1-LIO2"J!JY]9%4 9G%0'H;HY
MGS*T: UXS]"68T8QH&9S6*7*S'@L59<2EMA*Q6 S:16\CSL GPGR2>"^N
MMYLI0C-0)17 ;K2)!^JL [O$#?M4!-A9AA$J]&?>JO2D2/29:DVM?@K2"/:^
M!^H#RQG:XQ6L"ZY%56M',8/2O0I"4 H[8%:0XJ'^#8A[4!/[>'X*J=/J)45;
MWK1(%5!1KZJ]63[+Q$(ECVIZ$S?]LN/&BME85%Y&)G"C CE:CE_AM+G)6GNH
M2MY')LS32 "=QO*$\(K45G6)$BUB>.&Z%#U.L3(WR3QC01YG\DZ3 2:B
M1B4IXKK)^?3:#]%&B/!/Q^FDMV52PW&K'%Y\[R.JT5]+74SH^TATW298XN*\TCM,F
MRI?4VN>(],BNDC1IR97XOB09P
MLKBV*#8OK%@4]5L,*Y+M ]TLRN5)7EUP7W)_)C$N+T,X5'^84"A1S3G8NT\ 9)@_NA+_1)**/EUA&G&D.)21QR7)-.2O!$M?
M&Q3 .M$-BO>\XF!0*#"7$?\*<,^G+#JR([K,U%6DVV25XB##Q?D2DJ@\P)70
MU35)#9B^*JG =:)+$G'UM,_RZN(@(U5J1FW2$B#19NB8K0C4LTT@W1[4AOWAOQXH 8PKX)WI-U>U&0$='@G)_RB$U%X>817Y3#6F^3
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M?TRR'5Y%ZPB'!@VYNX$8IDLZX+E3[C-4039OOFI(($2943XR/Z[SOF7<
MK;Z2MWS9B,U'1"LKPRF&^J? [MA6&!V"QLHN:D1T!6&2%J,N[DR!>MX+@=@%GLU@;+09#,JD'**;]W_3-G
M)@N5>T5!E-CD&]MC;8X[REE3M+R^_VK/7O^Q!RJ\[O\3_LS^I)G$5H-HF'%5
M >[@@5*]6/8,)7L((*&D)ZL^#9DW#:XE2F+&5>_%5F3.P9[$RUZ.5+S"%X_E
M$,7+_S[-@!J&5;GE7-NWS%A? +##WE>#+5/^8MZ6:!%WR4
M:LHZ19B^AI;$51O7@$K#[)7ENI+P<=VD)Q)(F^UY)K&LMM7?)E$>00?^ZH, 
M'J-TV9<@$&'$RFB]$4+#FCY'"_8H]#-BW/F%C
M501!V7R!/56:TSGHJP *8/1GX)XCVW&
MHDV -F.:.FS[QMOVGDN$H*^ VL,(M$-^PP%H&R]]E]5P^,FP3AU]&K^O'0!@
MF$%R]I*VH]\1VX2HR:SV[!TM#5A)BG)RQC>K+".K*,CI'V  *KJ]7YZA9[R)
MD@3$1G?$^8"M;[(J4GWB=7/1'.BR*V3PNF5$/5\@)B\UVU4^'^JM
M(W)"__XJND<4S2.RXP3#R;&C>L#)I"=\@IJ>RO+9/Q 0@0HJD"!CFK,#'U^7
MW9"T^F#T^LL.)YG627T(DEEHV O4Q7RXLNL ^,Q9XW8UT1 ];GDK!AF6"U2L
M#U?M';; 9CYFTEEKDU8-JAT*/20Z;J'W:BR]DW4,J9WG&^U".D_<7JT@+HBO
M;@G(F*T;'D8J3;@\'^)<>,(6FFIR9((C9R!%:MWTNZBTV$=];KP
M=@EM[@L0L<B:9@I==D)](=5JQ^+M*R&0#R[BF]MH()Q@0
MF@7Q\7D!=+%H<4\/"[61O?)3?LP--5>5MD&BAA(Z2;7HOE:#H,&'@6M*$P.,SG
M :WH";$F'^.A>(LM! PU7,IJW ]DQ("\%GA.U/#I!:. X4(IWE& [ 2>PV^+
M5O'B[[S7*_R)*V:AD@&EF3_59$GD1;:+4BSC8P_F[?4)^&CJ7B?C=?6K H 5
M.3S13V H
M->R%[5[_Q-8L->V5$0!;L:# "ZU3$VB+NBDPUV"XG_C^-D[:VLI;.D:>9D?F[$
M=49P2MCC$LZ(9OJ$3[\JDB8PN4[2A*[,&>'^^-8^#TN/\S]=4Y--2!-O--$]E(?=Z60!;>+7B;5IK):#KKGCB
M!H^;Z@/.K]AFZ"*&4OZ"Z#-#W 61'^
ML7BF?P]6Z@/:](#JIT9UX#O)=#<;* $)XNFA)$+\\Q=)QRP]?LQ%3(Q9?0KB
M%*9F0XQ.=LB"!XLLPWFV2,*[*'B.8C:O^B,.LCT\&T@>8(8U%(/3#WPB22K_
M>1%DD?XP/(M(C=RN-?SV=]J*8G#B6'%DA3PDZ4/+!!44LD]5:42,2!^&\]G7
M,.),DF]!F^(I%BA
M>CER6#V:I5Q>N-M3W;_^=1_M6"O@)'PDZ_PS/2#]D)),J\IU"))106$_4%>5
MA PKPA(M>\>2"<1H YAGK2!4E!G18Z/C*=/W*=GA-#_<4Z$#!04UGW"NJ@N7ME+JT QFX'0"=!%X9S Q3QRX9]GG34Q+!6BSBPO)1 WF5\W
M!89IFE/3/DTBR-/"D,;H"_R4:1M #Q"S<+,+GH,=0J)BZD_6:[A#]\(*AB5#
ME#GFHQ3BI@#8X$Z!I]T"/ MR&W==?1&NYRN)&XLH/1$(12*Y2\LJ>5NK[I3XH1B;1#="^1A6X4%1!-J='4A *4>>5EP*(F[ROXIE0_\6]
M*J,CY.<7;>WOAF%VZ]P!SL6I+8$+8T^BT4%1$%4>><*\@6W2;TE+BABS'0^#XPAJ46G1#=/)F0R*!A&.O0WAX%35<;,RP8HL$N
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MZ%A)%P0C.;0#L;NAW1+''-I]09)]-L9S-P&,878=ECO5
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MO'4#S*Q#'O>?:X$@[PX-AH-]G-]%VRCG_DU9S;J^;M9Y
MZ!B2NY91(<=%HP2*3&Q6\^G(@!B( I-&2!ZJT./_;Q]N@$DCU: ;UBB=Z +K
M7D'6@!G]ET#MG[X,"J]%>?JYZ?@I?YM/,RG9Z8=C]N:F!Z3=5S>P?T$[7+Y_
M25PS]ZC3DA#18=L,*J7==*T'B#5E ^9QS$"/93-@+L)C_<)1
M&O9@6WY9DS04SXCO[BX_8IBYH'QPZ_JZ_EFM'9*3XQE'Q0YFT"V?(IOO(#; 
M?Z+ ';]X774H@M$W):/1+QQ7:T@Y-^EQ.]7T_[KI-FG-_G.4OSS('-P]3B,2
M/GTFFI:G W)L'^\^Z.X2*%'9S9M-BB\SLSM& LH_DWDS*)HB;6_$/LQ<_\57
M-7H*&OT-!VDVVM:G7D51VU%O)0^(48$9<=0(ECG.*3RN0(B!-+EE@026:\0NEF->GGAC=LK0V6DSRE.$QMRQ&9\3&%EJQ$?X=L^::Y
M.-WN=P6_9MW2NEG=M)+1&Y0CMK9:"<4QUDK<;#15"D=:R1T)$GDPU-]/.KYM
M<*W?!LC-!3[%5!8,S;JY]/.>#+/&*S[7NXNE68Z><+I%C-]C SJ'9,M<"9!9
M9$@T=A^':46301D#@.PEK=P-LNC()GHSD4)-5D/Y1 L3(R:0RU#BO49.7HH2(]H<]%DZPG(D-@3H$. 3VR)@+$W*>&.5QH8(W7"M[4Q=*":\CBS:A  -B!,A
MTG*^!12#@AZ(+_JY?2)"'3!,37'Z\"*AJJ8E;%!67NTI6P45+Q3"/49!CK9!
M3I>7'WQ=5[';R1<6]V726R"RN1$XK?BOW4D41]C.^OZ36=> -96X8<>S(#B7
MA?55&;%KEZN6JGH?"8];:&9(1(1A@6:W%>M'G.\H5[FL>NJX(&E*/M/-*ELFC8JY)/PY2-,@R=5'&)H!UT\=FN!QDL&%LVYQ
MS(5("CT7M,"QM_DH%'KD?A8$S9?L':4#9+0,'-?!7\9!1@_0 NP4&%&49O#G/"8IG
M+[:TI07$,M]/5^)B>V*T0- FI;Y,$4.#.$'PIY(DQ&E"%P?Y^:SX@OF\KS9V
M7'_91>G!YI'O%:?/Y$C)(9,Y48>@Y_R66A04\%V23,\SM7S9L!-- XY][R'!
MHQ7 G[?O3Q?'R2!'?.)N-9 LN'O9Q5V_ Z[FS4(]VFK$5Z>WO+A<63T]7]( 
M@\R;!V1HE"\)F6$U53;]7J-5WGTJMF@P1"PN9FIXK"OM@42&OXG^VIF
M+:4DS.[PM*7:=(9ZG#T5"=:<:%E(6T_TEJ+MSE$YLHG2'.,$IH]!>0+$AQ"H4DR:M>UZ
M0/7O4W3@.[E'@<<#N:" _L!)8/.@Z6$WDD2@':5BOFL3(]$28Q:?@ABKSHC:
MPC>(XT,%0C;8;W3-_?0+$UX!]%)B1A*UYB+=S%5@T2==GFZPU?BB6:O^*@P'
M?;!9Y KP9QV,T,IATLL%7[@9-QDY9?;P^*.^50P ,I)$+TS[ED%!^[$EJ F%:#'*5P$(
M8R@QB0V"X4(/Z!'].*U%#,:B7:'HG4F# !O8W(3<@X@=!&<*4?; 7=^='TT)
M+"J1SJE-468GK3 :)S)S7?'+LQ1ESO#7;/$:1#%<:=^0] <(?'CCEORW,=
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M'[/K+SA=19GFO80!=#-=T48TA>QE.W)!TC:-\#ZG+*5/Z?>AGV1]:*!FI1M]S-4KP)J !0Z=;N(30
M$YK?O5MS$NA/&)K4G7:0T:=8%H.,3K&]$25R%614*.V^"'@K9\+KI,O\ZB?"
M:WY [LGTO,E,Q!"35'-E_>SSLCVE5:2.)$ FD1LB&&%IPAU_S_DR0V-XE)4\?#6O2;5?_9TLP#5G82
MVX.'^X#?#O]T/+O>5< I.? 9/;7_+OFT?>_)^=?.GA2M6?G)?*Q-LB9NYJ%-
MH8,Y'NI>]A1NRQSHJ)4N,H:2_FWHHX9K'>@YTWGM]B8UH_;Q7G4U::[-9#X;T8U[3O=8A%OS>^VW 1YXWFU:9M'P37)G-7[GNHE
MKBLUMNF1C?3@-Z2R]KURZ^6PKE]^JTF=YFVI:<[QA"Z;O6:JWW?3S\-R>;8E
MEP<,/5+I[R])DJ?!*M\',4R#_Z =77A"M;D3]V(!#EJ>"VLH4*(*3@1(492@
MO^$@52S:F#TX\4)0G6&+%]2-#6@\6H3-4.=9[3[EV<55=K?]?3B)K45?@'^8
M<@\Q(F\6 S&@=.9=P:4_BC)
MHM5/0;R?J\JH2<3<91MU>AS,F9?PT2L@@#)HV8^)>.0[G6J8FY*@-LF]16UR
M6O93JB>C^"1+;R^&)5\WGT$2<)D8Z'SLIUJ4R::^ZC8I8#5C=!DSI=7)(QNV]UJV06
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M/UI6H&+^[%2N*ZTWJD.NHQL=G%7HL
MY^FUJ^@U"G$2@IN>T:FU$>.#7A[39=_%%9G.4*#A0<@;M ?VMC
MME]7/WU^8+IG!@I43)NI'R3(X78;1VN,?AQ/U[1I10BF[(J4YLT#X;+#%+IKE7%>2!>
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M=0[]W,LAIYY^D>O^(?%XI[-G/X8I)LHN3A<
MX15#]_02I?EAF>#1OMXA!?I&YXP8)_Z^I)8%\2@K*48[03("FM$&B$9;1C6\
M,Y!T4S<0_$1
M1?$>E@=%;?GAABXZ65'HUW3WR\U. G-0:!RR34^L
MT],$DNE6=4^1SWLGB9(,;B1:Z^(;*SU"(NJR>%S"#W"'
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MP-KQ?VS;+]V>N5])^(0977+5X16 >ZPB"+X#E
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M&Y;?6],GX$W=;4+/M"S,RI;Y"VPE0=+:>4;;
MJTU"T[0M>33)UV<,>>W3Z+\-$<3F*JBC8901C+]
M#:A=U46.:@$E:G*^DP\3]J)]M,S5<-)_&:;/'\#*C>QWQ13B]^*W[PAZ1I'WKG.%K(\4^4C
M"NT[T">2![&(-64W4LC=6
M9AO)46L:\!M57$NI5C7772RJ.<0>+;O-XFTXZ]=["%
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M7C^L04>&Q("C?LLK;HAJT2ZJ:A0ZFI82D"-!*5
M$FS[QB70,MNJ(_;+O/1D28SXZKO!.R_[.^7W/JH)V3CO2%" QXZ7WPA*65:!$G9EI@=:L
M9X)Q@KZ83;[(LOV6W_\!)?!T2=3:[5/\0$E7L;7I:-%_UCX!64Y:*W"%.39N
M%%2N,IX/O-!,?&XGKC("=I6QAI'MHIZA7 +"8@W0,4HL D'CC_G:+4RIQ61J
MM7CG=L.\WNYBOT0JW+^L327@1"UM!QG:/ZM\AU_.)Y'_#^0->D4T"
M)>/L\;:H#-#9;RUKND[]1
MH!N"^!5\[H,7?K2#,K\4N97(V3WK9PSM)'!X'D"'DPV-FTKJT*[U5#=;J
MZ8!P441<(1U)VE%)/'IH8:SB"*68'G"7ZY_9T3C/EBEO^W/+N@A<[=,HV:B_
M7-:%:#!)1Q6XFR%)@!VJ)SX+_(C:>,K[)/&^"RAD-(@=;<8!2=IB)68<[CRC
M=Z7=(%(X!D9UF2%NHKW^@M-5E*F]!!J)P"!!9HC+3=:+G0#:U) U.%\QW6U1
M7"RIFC&+-58IB!6!Z.IRAZE0!QVE=IUG*TAKWK,%^N3N$W,://>??:(=<*"=
M3':];-<5)S%DK&.MK!N)L)&GX#G6NJ#N@V)6%]H)T$$E+O.&
MRS42V- RY:J'?F$8YZW('98/46>;E[*(#<7@TDOKESDUOCC&X[HJ8"J@!4QM/YY
M\&.!#7GQ!@^]%9#FPGK*WJ6/HM=3
M!>D9NL";*$G@&'@1Q- ?VCL[&NC.I,97CT4V:$T#S0<\3.6V]\Z5^G?;V377
MPZ5T2"T0N
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MSKUJ.Z*?F@7.L#0N9(BNR0)*ZK;!_%=M%;O"#$6C;7:
M8$6,D]<+?VZ>$5))&5J5I*&8TN9=%;&NL@Q4%FN)Z#05@^)X)L4&(,V^P(DJ
M2-$33K?H=U&"#CA(L]];ODF:=-D*MTM'OK"=*4"3H<,CVRU)V/VD1"_<+51'
MUL=WJ+LW+: &.JL!WXWK8@2(?A*%^\(E#2BJS\V9T4F9")@8,UK[DH!:T;].^!/J7^7BSFO]&Q9PC_X-,/H4G$F]8?> )SEKBM)XQYM\G7%M
MB;P&IMCC*KB;0Y4LKM"Q60Y+DE1/*.XDZ7B=O9*LCGX9D*2;MK*K%QSN8[Q<
M+Y(\"J-X#RUN'_%JGT9YA*F6K^)]B,,;ZI3@J?Z>>]'E^CI((9+*Y(%7^X&2
M;C
M8?'DRN7&=\FY*.(\RERK[O2J'B!F\NZ"Y^JA#90= HY9[7E0$D290SYR71I,
M,8BG2#OP[7S".575!>H/IVK[]IBW%A5 ;UF_>YA^_+3EB"=>,;B9-Q,*K#9/
MJB,/<4__B--4-(J4L:WZ@UT%(/I'TSYX3O(*!<+&,6:^](&27(@ROWR40=5?
ME )H/5[U/;'V8S%QX#8ZX'A./TH.V 047GC0::F1RA#O4A&9B(="Z"C[*G2RV?R
M5&1]J<8YR78P]F3@/$OIO1D,9BZ[&>:G&(:-851:LZ4^0#/0ZX%@\/ZL"YB;
MAX8M11@S/AP<% 51XY)W;&_M!FDS2'-,?VQ NIL9K^.NU^],^C7:PVDV>M02
M>ON:/%A.L&Z6$Y#V4L(YU =CMN- SHOM$>FCYD^X%_WT6L0TU!GUC&6=K7$GC^I2N34-<*R)^&D
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M#<.RF<.]BN?ND-6$([YZ\Q)UA.W+07&>')\B"-$EVU+4;/K.QQD>+%),8-]1>$M
MU_!P#%/5@M\HF_4P('VM&8+IQ*@94A1(K"BD:,&)KBJ(Y[-I97D1+1[J]M)=
MTJ,EY5>R8>"S!PKH^LL.)QFT]/](DOQ%67%40.FKSC!4)\I3H$4QPXM24"',
M,;.Y4UO /9_^: B.:+*R4X(4<
M93K'@R0BTY!BFLWN2*D&=CJ_5Q-7%U)@0X .Q'-I82%3;22]UMZ^B_B^)"&=
M9(!C_O!>IF<;NVHY88V);Z841^=)F_X/0VH:&%
MDT%.L*704"QB" Q+U5BZ=+GF-RG9IR8>XX*Y:584UQ9#XW:!
M#WYD&.&'JZ[%*#9=C@-^#EALV/^(H\+U>DVA1J\8_)NR@:L!,V@ K #733-F
MB9B>!OG_RJ,4EKC95CMC4]2_5LZZ92JD#-*B[4(3M
MIBBF?$"\$]@]5"]M>1(CWNJJV=-+E/(;@K-OC,I?^N&88/A=^[*W8XY?^='E=N@5+K5_Z\NP(XF>_H!* A!0@)8=*W42--P$4:S-(3M
M #8^41E5\*%"/O=M\IG05'889I5<1:]1B)/P03''I@_3HJB.P;NP'XX%A0(-
M.D0X/BKVG]^0>N0W:$]=C#P!60U9EY">1(P>6B(-MU9VF^SV>78592LH"C$V
MK#8PX^1S#-&^^4CH**7@SY\)E4#9^-0C4^H14IOU=+'.3X$V
M];)L=TSO1NGETZVLTDCE[IU/'10+584=%E'#A^R:O_X OD!6\8$$ ;($NW]_L7QT=$WL<(W%9'N?^C!-Z?O3]^?Y;[M4?+_KNU1$=W
MU[E?^_3EY/K\^-.7Z\N+LT\7'T\_WWR9?#R^F=Q>W%R<''^^>G=\?'QR?'Y^
M]NDS_>/)Q?%YGG.RV7IXN0J._M7^MXCEHZ?W[/^OB>LBQT';H_]]]$QF.YV_='$\F*?^$=/R$?>*YJ_3R@Z*89TI5S_MU]R^/U\\9SWQ%M^.#T^
M/ON0_N(O\6_^ROX.^/6?>[__XRSZ[9,O7[Y\B/XU^U4?E_TB)7ORX;^^W3_;
M*[2VWF&728W-!O#QKW[TPWMB1XLJP-=1Y6^PO[U+?^T=^Q&5AW=4$G[Z\U\H
M9$='?_&(@Y[0XHC]]_O376&X%TQLM DB>6.+*'&5IO'"IM]_%<
MV1"_KCRT^.T7]LV[])?9./]2]KO!=D/WAX_IO]!9?Y!D);!^$I>LMS%/ZM4PUXH5RXQ"[,.MDJ$A2?&2_7Y+7#W.$V5CG[ \,D?-WQR>)G/P+_=&?
M,76Z"=?$?0Z(_??GE44G.0V#2-]1'5@$Q&'22[STAX[U@IS??A&E]$$]Z[?8
M0=X5E<(E\;8P7G<^5AY=/[email protected]]#EG?CSID6%^6P^GL-&%[1D3S+
MN:/2^_,_$1#%O8\U,/B$EMBGH[C!@[46QK#\6Z7LS3R+2?;S=OU"'%&^=CY2
MRE"J.&+!>40>)O-;^C-?E+D: AH991+>@LW4!"E3\324[^X2W[CP\9B6O^=O<).9D?26PVSW
M]\?TJK.APNE12K_]A3)LF&D;,<]F]H@>@Y-+^/(:ID/^(]H)<-%/WF
M&T-H9S]PB#Z-$)%:799!=7(V0D4:3B8.UI<1K%*P"M9&!M?IQQ$N4FHY9A"=
MC]2V#ZGS4Z2E4U;=QCM:HU(N"M>-=R8#Z.*KSG1U8
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MR 9YP?:17EXC3P8U'3?,!GM (&SKZ72"KHPX%S_4CC7:T!O1S<\-5#D.\+5!D(WP:V1D(IFCNYZ.]B/<7[%K$?T/
MVUNOEA-=E((KR_.V]/"#WW/%"':Y=664>@4![7?VQ/TW7=RF\=R/Q,?0$!08
MO3Y.>Z,!(%4]:_GAIW*LX
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M A8[(.$#F::,F,)I:Y[L PKN7*JQ(Q4+F*WIY N,3_M+M&">"CC#_DW/^GB4^.(6EK>]HZ>CU&P OV2
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ME@$0"?@8>**WL?IZM0E[Q+\?1P@W4=Y!PMOCCRM'!CH_D!X, ?EGG&
MN+'^".F7? E@D]@$CJJQ?@R-J%:'MO ,?6,M9,!NKXYVXEGFQGHZ&L/%:H#:
MW:4:BK89@%(6K\A3RDUJPI6/.67E1F\=\D-I+&XUT4,,NRWAMJ-@+N2S-&!P
MT>S]KSN*CI'B=N=3:&L(MCKLX^O0HULT[A0+;N]=3T1W! :K%18)F^6DLB;9
MJQQ,TLARY'\Z^-@Y-71R/4TKWA-4MWBL3-0UBO_;?G95=/6']49[WB.OF!X>
ME]OO5.G?N5FYOHD=X->X@EB);P<8!]QJ).UQ)!MKFQQT]_GR7BOT8LTZSD"T%.(+J^-T#SR!CXF!&^)EU7TE6A38&!C?6T^EP$BPSD27W4SF5ZUXI0.R@-9A4++"B$?L!AE6X]X,N5+OP2+H%
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MH$DIU0A2R_AC$8+VEP&%]S'PB-W5KLL>$UO6K"NA13H=A"7W9]Y M_%"&\[>"%^%IX&:.QQ*.',J@6SS!_'
MDP35G78'IX%5 UEPT_)D.(//,-4(BCGR.;3J3B[CH=U[!^(IA,8>4!HPW'L=
MY"F&XX$CK"?W7XYY*J*QURO5,):&%?#DN=%#(^/M:A6JPL%7?Z4ZD'Q:15Y<
M<#@43UXT]K12'*M6N)^*!^3Q[$=UY]G!&5?ZH&X;\,G3*M6?@V:I$'!0,<_$
M'-K1*!OQG5SWS@'9:'=OZU@!:<),.[#1M["]$G
MP!5Y4KP9L<&.L&Y0O2\FSG%D#?:#Z4.V;=HE;QBMWO/S1DTU6 (O;R8]VKJU
M .[E=_-.TLI-V4VT6)1O+S 5OS3YGZ.HW*:*4;QQ#T�C$4K@R1X6=N2 RT
M\ 81JA:2 :LE;.KATR";L,@P<2_ U%
MNQD2NBY.$YKBD_5;_AI:S*^"T)WKAQ[S83'3GNTZ_]%#:QRN 3F7TJ2U)[LQ
M7S,3DV?BS!/<0L]>L1C 9VH1I1X16*Z;,%'HZDP75#6Q1U#6)X"%D5'%-L]B
M0;(. TD0R!43"#>(8T'H;SN6[^,%1O,9R7DC4Q=E1%-X,3O@! I.X@E,&J5_
M97^^IDK@UL*>VEEF%!--?4B93:/QDZ+)H*TA0@Y<*6XF&C6FI[M
MUQGY3M6O]X,>K?18C/Z<8AFA*-;7NA5YZ#3X"$P8]^A/7Y$W<1P2;>=I9"/X
MD"5H/X:F=4D BX=3O2H[Q*%3R-'+B6Y$-'&0"#,L0JH#D6FAC!2-!A8CIJ*G
MBV1_3;TG5D&9JG7L;8%+($!)MSHMYR!^,'KT,'N>2Q5)\J_^"4C!R@T 3K_.
M'A-38C.2&A8YZ8XE1GA]@%2[2NYD#ORHKP-D(5E58P-2!0 2I$C8P!%/ 3 %/%K#: ,A\C^E')9ZBBK\?:P
M:^6X'D#1#'7BM_>.,8":&(+&BKG64M'A3
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MXQ7<:=Y%V?!1+]__)R@#+F"^MA]*M4$3Y>\GS)Z5X6H[4
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MMCQ/K&:]W
MY =Q-SN;2<<2P;6_HH%T^RX)6:7?'2^'ZXCG^FXE14,W(/
M0.7%-<]NTFUYJQ8@#
M#"%!0KVU !>>X[XB!R!OEO.C-%E 2D4(4.I;,]2QV-6U;>(&>(Z=D H7XK66
M;G[:3DCG>4NEF1UB8>K(4Y)8H6/T,2.C@XP,'0MGEO[:"^F2J)]ZRD@U\ +#.^HP2_U5&A#]!6Y2>0/N]6SD_")
M,D WP6KBSJ_I[SAD$S5*).S?L\^$+SSJ!QYCZKH)#5._03;G.()H5P%B8,S#%ZH/;QUB!=^PB]?A.L+KEGAI
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MU>@E0'/61@QNBS53U)ZA&MQ1V5HC]JP'DDN>&3YS%7"_L,>W5\M)W(?!U?T'-U2GI(VPN)S$B0(E?W\
M=?V;Y5K+),F-ZAO_?J]!**1]60VU;I\COJ'U"Q+2)PT$NF5[1AF])FLJR"U8
MSQ/IGOW)3PS2.94DP&D#*^0LGM 2,[]G'&N;)/F("X,@(=VH6E$<*W-X/%AK
M^L=<;1X)Z1"@UH&84!5A>=L<,S*"4D%$,_O?K)_,VP/7*3L?ZCY/+7>)X$P6
M/NN"1>C"YSZ"ZH2&
M]\$:H)X0^ K@;["'$N?>;>C.[^^O@$)11T((51_9[Y?D]<,<80;H.?L#8_4\
MAR/]T9\W+)9@*[[B^]\H9>>>7G2@%
M"+G%+B? )820U'U_*'9K 6_O\N\[91JZIX'J0LL$ ]0.#4ML4AZ!Y#Z33B _+<:S54)3JI4!Y"J5GL:
M$8G3L]-TLK>S"TL-H^+V.S4)JSK[D919KAD6)\9I[TK3G@A<,#@NYZ;AHN)4
M:[@M%G?8N4GHP2[>I-$_P 7MBVF")N9:*>D25>D#RL Z-:YZ@XI=F7/F%7?@
MA4E(5?L[=Z'8%YL+T\2FSC]-*IWE')#/I@&BY'2K?@TI[JO/)B$G_J!$8 ]@
M&69GQEYW :^*1/@EE.-FW#U8U2XM?=PN[-$3HW 3C0VHAVEO8WXT[A@0CP&I
MAFIO'UX-DI@\9C!,T]#@#\,LH:!S _7ARCM.HS3A.(DD *7(GYCV-M5-E
MK3(_,E1/S'0KRLFC9"81!W,\183!K,LORP ]'4^5PIX'IQUR),=SIX!D?6)J
M!MO9>'GC.QJ6H9QA>&[F>[(C%;[\> Q-G<]0'&*
M#,$+XR)G.D$PK4G"<1Q/EQ*OPT[QF0RM3^,YDCN+!:H'9$R&,\ZT'WZRTA;#KTC+.+@.#Y-
M=>4/Y0?HN^2A!.>:LX2X,DP,FGAKLQJ>WBN:TX/F-F1-H5/]"4H<@A/77>\J
M:8V31+2DXT8M;" SJZ'Q$N)8CJ3D;C8\9LB-?6
M:R3175D%<'VZ9AH2Q4"3-EC3Q>_$"=?H#X27JP#-)]3>H#^&58(4)=
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M;%"6K@ROAEA-HU/FH141R[[67=\X=DA)U#*W(?9$7NL2[_L.ORC[TZ*O;3V*NC+?LV/?77^#;+S ]%X+EY]J(ET=*2D+TD=)D0#X3L%T07(?N"+>AE4EIOP[
MT'M% QGMK=$VNS?O*_;\B+R-Y05;N0LQ@*AV*Z\X++AK0.GWNJ_U]*)I4Y[@
M&F7W2\V,SG# =.Z=.\>O>!Y:#BMM\821$U"X0X40F4YN/C)-*':_[+_L;UF3"2&,#>XK 1%5TKB?!M!-
MHEX5U4'4I$,'T&M"]L@BU8>LP=TF)/=FN=5D<*<)(7.32!G(O"2^<9FZ\G<0
M(GAY,KBAA^36K+C\#JE'1:G?@ BY-K@\&7M -GN'2J#:]6!QG,8CL=%/.8#N
M%/JJZ)M71$#"WR]31=]8:P*X,2O;Q!C9SD*B3=9)N8\_%,$WJ3'T+G
M"=5]SSX:>T]I['M6$UO#X3&NSE<+E4M22+D;O\[X-QG48D#S.RU(QBJK%2+=03?Y*
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MI &_=4MTD.93]XFY()C/D/[" W&]]*^7EH_]?64G4-]0\K1M8
ML6N +X>QP29ZO#@M<\(-KC.L%V_%&=/'IQV\IVM_,[BT'":#SRN$@MAG[?-R
M&;?X)YIG:S&Q;8]"EUL2J=<"A2/V_4Z@8BIZG2+[PU[1O8)<4,^<&B*:?3K1
MHXN2.311TMZ5.U8#3\P,HO_%@<0<:HAH9C\!CD6#^.QHPKY/=Y>\*%41ZF8:
ME\2E:KK%3M@ET W;OUMVI-3D^=ZCT)G86%XKU;-'03/C=^R>@OS@T=HR:UJ"
M\2H*W2"^K^%D>J4)$-,\G4>/;!"]+3[2COXU"=>A
MPW*3KQ&U3FR<1 A0JR4RKJEUL"9>@/\9_;R25^#2*1JSKQ7^ZA$?].[41$G[
M(VOT'A&U8KAC@"[I]O?!LZ@EHWL*L<_EGJ45)I8KG/]*&IJ9CT9DH>-WZXU'
M7N/0'##[=52@#W2LKGE(3X%,$*E0/I-%\(->0X49$Z6D^W$U]%S,8N=8-RW\
MD_T)#FX-$JH]'@0RASM8O1TW^Z\I>4F)Q#3>\3!9M:(!^W21J<6,0"6".R&-S<@$;34BIAVXS]!8
M7[DL;#6' F],9>R##Q0U47. -R8R]H%15N#J3#P.F[%5#F1AJS;L>2>>\4S8
MBYFHNT3D33Z,M?_:
MX+7[6)S!9:XOH.5V+ T-X"U11JU?5MB])"B$=TL9%7\>LJ98(([;>  (V6;Y
M-C+JSX ]DU=[4.2$[62R0S2J(Y:MAB3\6 0E#7X>;R[$+/@XW$X*R1B^Q^<*=E\3SR ]63WCJ
M[JPZK^ IS*X<<>WAF72MBY5U@()2_!@<*E#>2FF#O6W:?$0T5*"9DNXH$KFV
M4( 0$[D!^IAV5NTJ*S5Z93D.O1-L=QEL#0!D*)E4.\__"^9(I
MQ:B\:ESA4EA A6BU8+ E3ZW8H&4D5<8D^*LCH3ODJP2:_#F=[PT&"@(#T54A)'09_5CH$N==*_$HH:8_/"D[
MT>^)NYPA;\TX\U/6@+%)3<1Z$*Q[F6I,#82TAZ1F283P\CDE'VMFESVB!%L6
MW$!Z2W59[A+!F2Q\
MU@6+T,7/?00^4(CEILIEZ@+ J?M:MVHJJ$3X5B__OE.FP5742KZ&+O4S-:TL
M:G;,?A#@,I=\*3LX7,9*OM2ME),1O[O^!MEX@=%FSI$B@
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MP@:)XN050XR]\8/%K>R#ZF!=7CC$6$L+)GEUX=L\L7OI#RH*U+M6= Z,2H#U=R27&I ;4ZWRZ#44*+KK4$IFIF98::^
MXM8K\E[(VT*M\!1;S*_E0!E;H0$F7')9U1F,7XRMW .#L3F7/H7L]'@\(6_DEQO)S\L;YYO,QBNXTY_]""FDHKFM\1;H*@>-9-?X6#V3GC1
MG7]))85L$7I&WBMF7>W*IO1 W%>ZN=$\XMZ?D:A)*_]W=D _D.!O*'A"-EFZ
M^)]TOI%Y0V>3_(C]'JCB0]>R1C8)S[8-$TZ'/2==#X%_@\5*72.+GD=$?S.Q=>HJ13MMXL
MQ/%&/2Q\=WEZL^!^C6_*!P7N+D^'"FXIN^!^9%J&?U.0_8&8$Y6:I*_(LY9(
MKHIB;ZP=*M1E=])O*%B1^7=?PC33P<*AFE[3] 8?/8^PJ(VBZ0*Z]NKDXE!E
MKW!*LLX:B2]D1MB/2!PY^;0G_PUC#Q=N#KT&U0/?BAPA7]
M-'ELZ=20+!_X4&'*(A@BKBO5P@X[ NG%-C+"^D!M
MGX=#!6__H4\G3+G1M'> _BE9WK#XX5B%L2J;9RA5&!6Q1PU%#S.C,7HC^>[B
MP']Z_BZ!:3TAW2415Q@MZ#W##MDK_W2QP#;R)(K-UI'1/(49#APZY!VUF%[Q
M/+2Q7W4\
M1O\SHY-C714=RY4K4:AG?,V@\:&!(KKS(;2HX>P'F:U(Z-,+U&R%O0"A[!66
M!3"Q4"8*!+#4(8RH[EKMTH+4L0BDPT$EH/B=]D*S*S0/F5*4WV;@HH<*!]5=
MI30+!YLN\AQ&AR!CV@_\/1_F?H-8D8JF+4?JM=B4&I2(%@D90.E&]9N85*FC
M 91W+-7;)8 ,J(!CQ9E+I.R# 11QU+HA=RS$ =1[+#>FB>XK B\P9FQZB=:[
M'1&ZO7*4C\.JH.HR8^5@6=NCUYC9034R'L
M2GDVN,@YTJ,"E5&@E57]C"R7*5'5[[.QJ:*25?T^&VL/-@%2?$SF@(R:1T;S
MJ(@[R-;@B[&U[!4&@Z@ OS$VAB_)<$V?7IVL]L(W4E.O&*SV.YG"GJ@V9'0
M\; YD"7:K4_!2VV.N^A EJBD1 M?I=%-TXTIK:1X$2_ :FPTH"'+EM;\XBLV
M^N$Z\DU#JN'Q\KSC70FT/[email protected],]Z0#F-]*DJ@\B+-XT()+51W98"SI3GM
M8&EZJI_]'*[7EK>=+G+J8\(JB;/&6,1+?A!)>72G1'.%Q;7;#GZ8E;>E9W78
MI;9R1L".A^X)L8! ^O,KXD:)4J'EL&9TI^#DV:[9._#J9LU//H)3[;0:FDJN
M^\X8;_TFMS/50CL?I;GE6CG]T\''3D?[1Z]OVQ/Y0A;/4-L;&:^>"A'8H-8L!"=%^C5)2G
M0[$_WE2]US<"6HE=U"5LINBPX>KK=\.H[5NTRMWM69 /&$;>7OY9OX] DL+SB Q[[#6Z2ZU3A1'@XT
MKD:+".+C4V-C'S6LA(09F@%]9FQ4U>&)?.D-B%?N4;<27^*5<*.PNOFX%I!+
M/"].HSRP-SX2;MQQ152XJ+*%^J3)DAH72H_[EA=A&8VN_K2>X!I]46Z(#7Z-
M5#[W#:!*Q0&N$/#9FY>O,#97Z  7"1P&PBM:C,MT:"?2KM&G(35_-/KTQPWR
M#'%-II_1RW<@L;C9(EZ,3KK.%E JK)UG^W=@'?:4N)++WV'56^BI?XTH<^L(
MDBS+IY"$X7]W*2Z7CF7__=E>T4%\IJ3HKW\C<^0HS&O1S-MAIKWHFO2!/FO7
M)9+]3EAU'[K)8!+B ]KI3NJIL'Y+0#=A:7A(W
M2K1_M1SZR=\PUTVSD9Z[,UW[%T51>OBJXY,?=(?@N+4N91X2'H8X\$H;7I
MP8G(UVBLE0??/YJGU@ A<\Y[^0]L9Z!\1U"]!VB
MXFWUCFV>=;IAIHM;$GH/Z,]6U#@^%(?%)9#$6'M7^2VQ/EAY*;Z'J)Z]V4.B4
M)P'5.RX;A\*.7:JEL.6P)N6WQ+NE.LYR6D^PS1#@%8R=*#>7=[/KR3WQ_3NW
M_0)!:$J*W!-Z16Z(5' K3%#WVU5]'WO >U8](PPP*]T@RZP
MC3SX)&K):)["# ?,$+ESY^RR'EK.'SA81<\KS.A=XO"8N&A$P+
M3+KKJ4(?3RL(0+=U;M=%2IMNN[0A!+-:J @P!0C7J&Q,=Y.-XB28G'?
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M2X[!DKV%+.WHHP$$3):K;B6%+.H.I %$7VJU),HZ/>[;2@,(Z=2J#@IVBKX]A>#!/;
M'IW&''MC0Q<;Y+KE$\8 @J;K 91ZS^*H&7M0:;4NB\^;1?/RW$0T2]^!2P#9
M,S#-+:=??;V3B#?@>(W7/9D-61%Y4MR9%R;"6A^T4P=14[01#]PW]FB5#>[*
MP5H;F\8A-/><[(%^/#E[0>\K;
MO5DLD!WX24G@O7]. D/H)2"ZN4=X^?1OR;.M3PW7!^*B]*]3]XJX<_HQLU'I
MA_&9F;B5Z7TB>DQ:TXFNZ._0RP(S/11F A_:9 XSM_A@4-(\HS[>33ZP($.0X[.7?G7^SO+\CILR3M8 '[S;3TCR9K\BE
M6\>A#$SFK&X["[V+WM!D9R1(4'\Z)Z)FPHJR<4TOZ [9,$&1GI00.=VIG=3>
MIDK4O :0IB)R
M?VV&:S_*T-BW>3&_!:EUK7"8C'V%!\,DY$(;0+5G,'""#E5>D]G8%W4P=,W>
M=8[:>*_I/0YAK"8.BT,0?2#D '?0G$5[8 &=XIJXD;'\A\40#/(=LY_#]=KR
MMM-%_)Q\Y5B^CQTD\E1384]
M+KHZ)I8-T4#=+!E.Y\/]0[GW0$(_>2_N"  @L)!\!YBM*250SU
M._,Z].(6$YB(RQF$)+B#.SO%8JG,$[HE7C1J^TTO/X BY/?';@M\&46#)+^?
MR>S? 62G(/4!;(SO \-
MDV@@U(>T@^,@ZJAT(^4LZ#C6?P\D0/P2)1/!($RR3W<&=-Y$;+4&$&0@(/)$
M>'L.((I 3-.11H4\@+" ^K.,5!ZQ WC+A^VZ)M.)/\D;V^M:T YM [email protected]
M'+6)KAI45WC!FP(/>I4:P!L?$#SY.[2.5Z')L2=PBNMJ(MQ
M>,/X09UGO'R*\A"16!O>N&\+0"5>5EZO0?G1_*;/F!;^>)Z5/EH[*AYK,CP_
M#\O<5HQG\IJ7H?G%V'M=IRIT]W@Z47]??L/'4]LX@0Q5]<6'Z= OY+!"<2;S
M.8XG<^=&/>6C8#WUP38"XQQV.$W=!%J]]"4"&FG+;:L7OE)*?3P/I"=II-?V
MM^))ZY>#Y@' [>JI)66Y>6(S\AAZ]LKR\X(1:6BAUQL9JA(=86LD]HXJ-NSZ
MV([JK(G+%(BH I:3Q62>/G4LUQ =GX<%'S##%Q_](V1^?5C/V08"W;+-CN=L]IT,(#.^E4^Y
MU,_6:=B'=J?Q PI845XZN62OL6W&DY0G;H#31G[/R [I/#&BYX/MA',TCQM<
MKC=AS!X%+OI=--_QP<=[5\K9W!M_?3NINY^XYN*!E.&Y*,/3Q8WEL4<;/WTL
MFZQ)Z((NY(H&U%U3L1V74NY&=6."TP/W#21Q;V,3A3Z<7G"'8RV9/J8 =3K6
M$&GQ1A!7-&LA&$*TH SR"HG V6K2"7=HT"FZHET
MLS6BH:4W=>'KKK+.\F-+9YSM$^FL2&_+TZA%I5XU(^M.BMRU2R3>)JII])HB
MTS2STN*Y:A9M "\6FG9864+=] 4#H@!/''4G*I$Z-0?SOM&
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M@"A:8'[G,??Z+0MP&]TQ!!^B3ESK#I-7:*@6P^=&I([J;HVC8>,WH\H)2O,N_UQUI$'L/MM=H
M0WP,,N_V/H7>-Z8;Q*;J+J.9^T\HZ[%%3YMO5-VNA 54A!24O8C49.FAZ!V3
M+4?4[);^Q4:@*UPS(=UAE!ZRIHLG9#DW/GN7??0(Q2O8@L(B*VG H[3P^B6D
MIU%D8I#8)4458BUGG8$"@5B,ESM56EF!] JG1R5Z]@")3]BET^ E:(NL2DP#9*YYO3"!E>_NU]V>/;!=U39U_T
M% Z L PM
MCQC=*:>+>[S&\5QF)+I8_FYYF%WIGZB@\BQWX4@;,%UP7<>J 7(UB16P6Z0F
M6U0VU[6@4/H\K0G 3PI@\SWY 71-13GK,B4_^:7UJT>R[NXI^6(K:%$) 1'M
M,/)]EP_9H/=].K(B$ONLOK(_,\/GUL(>K)=>,R'=^,:)EFG)JM3S(9P@(48'
MBN]LA;W89H@(4(LI9$?XG7M%7!=%%L0?.%A-%_1HAX@VF&X_.071TJM,*=@E
MV$.ZRIU+CS^6COKB8!NR_SAJHYFP5 ,4-!>"'$"8)M4,>*7;"39?0_K=@4(P9.J5A20LO(
M9QP?$<([J_9S,%+1,77K$"OXAEV\#M?1)>R6>&!#1H14MSE?^QX=>-+7?6=I
M@M^LGPPT>'[*SH>ZLP(L=PG(02K]K L6P?DF_*,Q$RD>;H8#%H)R1Z_5KW@>
M6@Z[B$3>4Q:!LL*;&;EQ RR3I@0FW?54H>)306!,+1Y3BP69ETPM7B%G\826
MF&4JL01 DXG(GRB#B#-$+(C!;)'C$S]4IP]F(C*OJMV%XH]$?EB;-^<
M,M=Z#HX=/S\'9+S.5;[99'&YIT-1+/N/7@3P0,?Q&HH168U7U1LKQV@H%F2-
M3 D]CG/$S&U!)XJ8>-1#AIJY53M$4(/&M7#8QNTIF8=][
MMOLB)W3JZXA]_[N/YK?$NT:4K35VJ:+/# N_<&E/]ZZ:6BC*&#BXDBGM9Z8W
M;#CC(<!Y"6;X 
M *V;#  1              "  0    !B:6]C+3(P,38P,S,Q+GAM;%!+ 0(4
M Q0    ( %2#K4B,DRW8/!4  +#5   1              "  8B^  !B:6]C
M+3(P,38P,S,Q+GAS9%!+ 0(4 Q0    ( %2#K4BHO%JDP0H  "6-   5    
M          "  ?/3  !B:6]C+3(P,38P,S,Q7V-A;"YX;6Q02P$"% ,4    
M" !4@ZU(P>*'#Y G  #&UL4$L! A0#%     @ 5(.M2)@KRBB>8@  08<% !4     
M         ( !J@8! &)I;V,M,C Q-C S,S%?;&%B+GAM;%!+ 0(4 Q0    (
M %2#K4B[];PCOCX  $*:!  5              "  7MI 0!B:6]C+3(P,38P
A,S,Q7W!R92YX;6Q02P4&      8 !@"* 0  ;*@!    
 
end